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Chronic kidney disease (CKD) is a common health problem with a high prevalence in 
the elderly and is associated with high mortality rates and co-morbidity. CKD 
guidelines recommend that diagnosis and staging of CKD be based on estimated 
glomerular filtration rate (eGFR). Estimating GFR requires estimating equations using 
the variables gender, race and age and body surface area based on serum creatinine 
levels. The commonly recommended and used equations are the Modification of 
Diet in Renal Disease (MDRD) study and the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equations but these have not yet been validated in elderly 
people, who are at significant risk of developing CKD. The numbers of patients with 
progressive CKD is reportedly low with only a small proportion of patients reaching 
end-stage renal disease (ESRD). This study set out to find out why there is such a 
disproportion in the high prevalence of CKD and the low incidence of ESRD patients. 
Many patients die before they reach ESRD but prevalence studies have shown that 
mortality rates alone do not account for these numbers. I hypothesised that the 
methods used to estimate GFR underestimate renal function in elderly people 
causing an overestimate in CKD prevalence. This study firstly set out to assess the 
accuracy of the MDRD and CKD-EPI equations in an elderly Caucasian population 
against measured GFR across a wide range of renal function. The study 
demonstrated both equations perform fairly accurately in the elderly population 
with a tendency to slightly over-estimate GFR.  This study has validated the use of 
these estimating equations in an elderly Caucasian population disproving my first 
hypothesis.  
 
If the CKD prevalence data is a fair estimate and only a small proportion progress 
then the answer may lie in how CKD progresses. There are several known factors 
that influence CKD progression including GFR and albuminuria category, cause of 
renal disease and hypertension. Some of these risk factors are modifiable and need 
to be identified and managed in order to impact on long term outcomes including 
death, cardiovascular events and disease progression. Acute kidney injury (AKI) is 
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also rising in incidence and is complicated by high mortality rates, increased risk of 
cardiovascular events and more recently CKD progression. Little is known about the 
impact of more minor episodes occurring in the community on renal outcome.  
The second part of this study examined the relationship of multiple episodes of 
community AKI with CKD progression in a population of patients with CKD stage 3-5 
referred to renal services. In this observational study, patterns of CKD progression 
were assessed and multiple AKI events were recorded. This study demonstrated a 
clear relation between multiple AKI events and CKD progression however only low 
eGFR at referral, diabetes and albuminuria were independent risk factors associated 
with disease progression. During the study it emerged that there were two patterns 
of CKD progression. In comparison to the more commonly assumed linear decline, 
the more common pattern was a stepwise progressive pattern characterised by 
accelerated rates of decline followed by a period of stability. Multiple AKI events 
were significantly more common in the stepwise progressive group suggesting AKI 
may have an important role as a promoter of CKD progression. This study suggests 
that community AKI is a modifiable risk factor that needs identifying at early stages 
in order to minimise risk of poor outcomes including CKD progression.  
4 
 
    Contents 
 
Title Page          1 
Abstract          2 
Contents          4 
List of Figures          6 
List of Tables          8 
Abbreviations          10 
Acknowledgements         12 
Declaration          13 
Publications and Presentations arising from work in this thesis   14 
Chapter 1 Introduction  W Chronic Kidney Disease and Acute Kidney Injury 16 
1.1 Chronic Kidney Disease  - Background   16 
1.2 Definition and Staging of CKD     17 
1.3 Risk Factors for CKD and Progression    20 
1.4 CKD Outcomes      27 
1.5 Acute Kidney Injury  W Background    31 
1.6 Definition and Staging of AKI     32 
1.7 Risk Factors for AKI      35 
1.8 AKI Outcomes       38 
Chapter 2 Measuring Renal Function      42 
2.1 Serum Creatinine Measurement     43 
2.2 Measuring Glomerular Filtration Rate (GFR)   44 
2.3 Estimating GFR Equations      47 
Chapter 3 CKD Progression and the Interaction of CKD and AKI  57 
  3.1  CKD Progression      57 
  3.2 Albuminuria and Proteinuria     58 





Chapter 4 Validating Estimating GFR Equations in the Elderly   72 
  4.1 Hypothesis       73 
  4.2 Aim        73 
4.3 Methods       73 
  4.4 Results        80 
        
 
Chapter 5 Validating Estimating GFR Equations in the Elderly   101 
  5.1 Discussion       101 
  5.2 Limitations       112 
  5.3 Conclusion       119 
 
Chapter 6 Multiple AKI Episodes and CKD Progression    120 
  6.1 Hypothesis       121 
  6.2 Aim        121 
  6.3 Methods       121 
  6.4 Results        128 
 
Chapter 7 Multiple AKI Episodes and CKD Progression 
  7.1 Discussion       141 
  7.2 Limitations       153 
  7.3 Conclusion       157 
Chapter 8 Concluding Discussion      159 
 
References          164 
 









    List of Figures 
   
Chapter 3  
Figure 3.1 Relationship Between Acute Kidney Injury, Acute Kidney 64 
Disease and Chronic Kidney Disease 
Figure 3.2  The Clinical Natural History of Acute Kidney Injury  68 
Figure 3.3  The Effect of Acute Kidney Injury on Chronic Kidney  69 
Disease Progression     
  
Chapter 4 
Figure 4.1  Accuracy of Estimating GFR Equations Study   81 
Selection Process      
Figure 4.2  Prescription Patterns of the Entire Cohort Subdivided  85 
ďǇŐĞAM ? ?zĞĂƌƐŽƌA? ? ?zĞĂƌƐ 
Figure 4.3  Prevalence of Co-morbidities in the Entire Cohort   86 
Subdivided by Age < 80 zĞĂƌƐŽƌA? ? ?zĞĂƌƐ 
Figure 4.4  Scatter Plots Examining the Correlation Between   90 
Estimating Equations and Measured GFR 




Figure 5.1  The MDRD Equation is Less Accurate at Higher GFR Levels 104 
Figure 5.2 Performance of the CKD-EPI and MDRD Study Equations 105 
 In Estimating GFR in the CKD-EPI Validation Study 
Figure 5.3 Misclassification of the MDRD Study and CKD-EPI   110 







Figure 6.1 Flow Chart of the Selection Process    127 
Figure 6.2 Estimated GFR Versus Time Graph of a Representative  133 
Patient with Stable CKD and No AKI Events 
Figure 6.3   Estimated GFR Versus Time Graph of a Representative  134 
Patient with Stable CKD and AKI with Complete Recovery  
to Baseline eGFR 
Figure 6.4   Estimated GFR Versus Time Graph of a Representative  135 
Patient with Linear Progression with No AKI Events 
Figure 6.5  Estimated GFR Versus Time Graph of a Representative  136 
Patients with Stepwise Progression Associated with  
Multiple Episodes of AKI 
 
Chapter 7 
Figure 7.1 Possible Chronic Kidney Disease Outcomes Following  152 




    List of Tables 
Chapter 1 
Table 1.1  Stages of Chronic Kidney Disease    19 
Table 1.2  KDIGO Staging of CKD using GFR and Albuminuria   26 
Categories  
Table 1.3  Stages of Acute Kidney Injury     33 
Table 1.4  Risk Factors for Development of AKI    37 
 
Chapter 2 




Table 3.1  Seminal Studies of Proteinuria and CKD Progression  61 
Table 3.2  Definitions of Acute and Chronic Kidney Disorders  65 
 
Chapter 4 
Table 4.1  Characteristics of the Entire Study Population Subdivided  84 
by Age < 80 Years or A? ? ?zĞĂƌƐ 
Table 4.2  Measured and Estimated GFR of Entire Study Population 89 
^ƵďĚŝǀŝĚĞĚďǇŐĞAM ? ?ĂŶĚA? ? ?zĞĂƌƐ ? 
 
Table 4.3   Performance of the MDRD and CKD-EPI Equations   93 
Compared to Measured GFR, Stratified by GFR < 60 or  
 A? ? ? ml/min/1.73 m2 
 
Table 4.4   Performance of the MDRD and CKD-EPI Equations   95 
Compared to Measured GFR, in Participants < 80 Years 
^ƚƌĂƚŝĨŝĞĚďǇ'&ZAM ? ?ŽƌA? ? ? ml/min/1.73 m2 
 
Table 4.5  Performance of the MDRD and CKD-EPI Equations   96 
Compared to Measured GFR, iŶWĂƌƚŝĐŝƉĂŶƚƐA? ? ?zĞĂƌƐ
^ƚƌĂƚŝĨŝĞĚďǇ'&ZAM ? ?ŽƌA? ? ? ml/min/1.73 m2 
 







Table 6.1  Demographics of Patients     130 
 
Table 6.2  Table of the Number of AKI Events in Those with Stable  138 
CKD, Linear or Stepwise Progressive CKD   
   










    Abbreviations 
 
AASK  African-American Study of Kidney Diseases and Hypertension 
ACEI  Angiotensin Converting Enzyme Inhibitor 
ACKD  Acute-on-Chronic Kidney Disorders 
ACR  Albumin to Creatinine Ratio 
AKD  Acute Kidney Disease 
AKI  Acute Kidney Injury 
AKIN  Acute Kidney Injury Network 
AusDiab Australia Diabetes Study 
ARB  Angiotensin Receptor Blocker 
ARIC  Atherosclerosis Risk In Communities 
BMI  Body Mass Index 
BP  Blood Pressure 
BSA  Body Surface Area 
CHS  Cardiovascular Health Study 
CI  Confidence Interval 
CKD  Chronic Kidney Disease 
CKD-EPI Chronic Kidney Disease Epidemiology Collaboration 
CKiD  Chronic Kidney disease in Children  
CV  Cardiovascular 
eGFR  Estimated Glomerular Filtration Rate 
EKHUFT East Kent Hospitals University NHS Foundation Trust 
ESRD  End Stage Renal Disease 
FU  Follow Up 
GFR  Glomerular Filtration Rate 
GISEN  Gruppo Italiano di Studi Epidemiologica in Nephrologica 
HOPE  Heart Outcomes and Prevention Evaluation 
Hr  Hour 
ID-MS  Isotope Dilution Mass Spectrometry 
IL  Interleukin 
IQR  Interquartile Range 
KDIGO  Kidney Disease: Improving Global Outcomes 
KDOQI  Kidney Disease Outcomes and Quality Initiative 
KIM-1  Kidney-Injury Molecule-1 
MAP  Mean Arterial Pressure 
MDRD  Modification of Diet in Renal Disease 
Min  Minute 
N  Number 
NCEPOD National Confidential Enquiry into Patient Outcomes and Death 
NEOERICA NEw Opportunities for Early Renal Intervention by Computerised 
Assessment 
NGAL  Neutrophil Gelatinase-Associated Lipocalin 
NHANES National Health and Nutrition Examination Surveys 
NHS  National Health Service 
NICE  National Institute for Health and Clinical Excellence 
NIST  National Institute for Standardisation and Technologies 
11 
 
NKD  No known Kidney Disease 
NKF  National Kidney Foundation 
NSAID  Non-Steroidal Anti-Inflammatory Drug 
NSF  National Service Framework 
QOF  Quality and Outcomes Framework 
P30  Percentage of estimates with 30% of the reference test 
PCR  Protein Creatinine Ratio 
Pmp  Per million population 
PREVEND Prevention of REnal and Vascular ENd-stage Disease 
RAS  Renin-Angiotensin System 
REIN  Ramipril Efficacy In Nephropathy 
RENAAL  Reduction of End-points in Non-insulin dependent diabetes mellitus 
with the Angiotensin II Antagonist Losartan 
RIFLE Risk, Injury, Failure, Loss and End-stage renal disease 
Rpm  Revolutions per minute 
RRT  Renal Replacement Therapy 
sCr  Serum creatinine 
SD  Standard Deviation 
SDMA  Symmetric Di-Methyl Arginine 
SHARP  Study of Heart And Renal Protection 
SRM  Standardised Reference Material 
UK  United Kingdom 
UKPDS  United Kingdom Prospective Diabetes Study 
US  United States 
Yr  Year 








I am grateful to the Department of Renal Medicine, East Kent Hospitals University 
NHS Foundation Trust (EKHUFT) where this work was performed. Dr Edmund Lamb 
and the staff in the Clinical Biochemistry department, EKHUFT provided 
biochemistry results and were welcoming and supportive with the laboratory work. 
Professor Neil Dalton at the Welchild Clinicaů>ĂďŽƌĂƚŽƌǇ ?ǀĞůŝŶĂŚŝůĚƌĞŶ ?Ɛ 
Hospitals, London, provided the mass spectrometry iohexol and creatinine 
measurements and laboratory support and supervision. I also wish to thank the 
Department of Renal Medicine research team in particular the research nurses 
Gillian Eaglestone and Sarah Knight for their help with recruitment and sampling in 
the iohexol study. The iohexol study proposal received statistical advice from Drs A. 
Laurence and E. Bassett of the Institute of Mathematics, Statistics and Actuarial 
Science, University of Kent, Canterbury, Kent. I would like to thank my supervisors Dr 
Chris Farmer and Professor Simon Coulton for their support in completing this study 
and to Dr Paul Stevens for his encouragement and support. I am grateful to the Alan 
Squirrel Charity Trust who funded my post as a renal research specialist registrar. 
I acknowledge the support of the National Institute for Health Research (NIHR), 
through the Comprehensive Clinical Research Network (Research for Patient Benefit 








Results from the iohexol study have contributed to two publications in a peer 
reviewed journal of which I was first author of one. Results however were combined 
with work carried out by Dr Jo Carter also from Clinical Biochemistry department, 
EKHUFT who performed cystatin C measurements on all samples taken for the 
ŝŽŚĞǆŽůƐƚƵĚǇĂŶĚƚŚĞĞƐƚŝŵĂƚŝŶŐĞƋƵĂƚŝŽŶƐ ?ƉĞƌĨŽƌŵĂŶĐĞƐǁĞƌĞĐŽŵƉĂƌĞĚďĂƐĞĚŽŶ
serum creatinine alone, serum cystatin C alone and creatinine and cystatin C 
combined.  Dr Carter and I collaborated together with Dr Edmund Lamb and Dr Paul 
Stevens to publish these multi co-author papers (Appendix 1). Subsequent to the 
publications of the first paper, the BIS estimating equations were developed and 
published, claiming superior performance in the elderly population. The results of 
the iohexol study were then used to assess the performance of the BIS estimating 
equations and this work was carried out by Dr Inji Alshaer, EKHUFT who was first 
author of the second publication (Appendix 2).  
 
All laboratory measurement of iohexol and serum creatinine using mass 
spectrometry were performed by Professor Neil Dalton and his laboratory staff at 
ƚŚĞtĞůĐŚŝůĚůŝŶŝĐĂů>ĂďŽƌĂƚŽƌǇ ?ǀĞůŝŶĂŚŝůĚƌĞŶ ?Ɛ,ŽƐƉŝƚĂůƐ ?>ŽŶĚŽŶ ?The analytical 
variations between iohexol and creatinine assays were also assessed by his staff. All 
urinary albumin, protein and creatinine measurements for the iohexol study were 
carried out by the Clinical Biochemistry staff, EKHUFT. 
14 
 




Accuracy of the MDRD and CKD-EPI equations for Estimation of GFR in the 
Elderly.   
Kilbride H, Stevens P, Eaglestone G, Knight S, Carter J, Delaney M, Farmer C, 
K ?ZŝŽƌĚĂŶ ?^ ?ĂůƚŽŶE ?>Ăŵď 
American Journal of Kidney Disease (2013) 61; 57-66 
 
 External Validation of the Berlin Equation for Estimation of GFR in the Elderly. 
Alshaer I, Kilbride H, Stevens P, Eaglestone G, Knight S, Carter J, Delaney M, 
&ĂƌŵĞƌ ?/ƌǀŝŶŐ: ?K ?ZŝŽƌĚĂŶ^ ?ĂůƚŽŶE ?>Ăŵď 




 American Society of Nephrology (ASN), Denver 2010 
Applicability of the MDRD and CKD-EPI Equations for Estimation of GFR in 
Older People. 
Kilbride H, Stevens P, Eaglestone G, Knight S, Carter J, Delaney M, Farmer C, 
K ?ZŝŽƌĚĂŶ ?^ ?ĂůƚŽŶE ?>Ăŵď 
 
American Society of Nephrology (ASN), San Diego 2009 
Unrecognised Acute Kidney Injury and Chronic Kidney Disease: Chicken or 
Egg?  







World Congress of Nephrology (WCN), Rio de Janiero 2007 
ŝƐĐƌĞƚĞ ? ‘^ŝůĞŶƚ ?ƉŝƐŽĚĞƐŽĨĐƵƚĞ<ŝĚŶĞǇ/ŶũƵƌǇŽŶƚƌŝďƵƚĞƚŽŚƌŽŶŝĐ<ŝĚŶĞǇ
Disease.  




 South, West and East Kidney Society (SWEKS), London 2011 
Applicability of the MDRD and CKD-EPI Equations for Estimation of GFR in 
Older People. 
Kilbride H, Stevens P, Eaglestone G, Knight S, Carter J, Delaney M, Farmer C, 
K ?ZŝŽƌĚĂŶ ?^ ?ĂůƚŽŶE ?>Ăŵď 
  
British Renal Society (BRS) and Renal Association (RA), Manchester 2010 
 Unrecognised Acute Kidney Injury and Chronic Kidney Disease: Chicken or 
Egg?  
Kilbride H, Stevens PE, Hobbs H, John RI, Farmer C 
 
British Renal Society (BRS) and Renal Association (RA), Manchester 2007 
ŝƐĐƌĞƚĞ ? ‘^ŝůĞŶƚ ?ƉŝƐŽĚĞƐŽĨĐƵƚĞ<ŝĚŶĞǇ/ŶũƵƌǇŽŶƚƌŝďƵƚĞƚŽŚƌŽŶŝĐ<ŝĚŶĞǇ
Disease.  







Chronic Kidney Disease and Acute Kidney Injury  
 
1.1 Chronic Kidney Disease - Background 
 
Chronic kidney disease (CKD) is a common condition that affects a diverse population 
and is a growing worldwide public health problem. It is estimated to affect 
approximately 8-11% of the population with a higher prevalence in the elderly (1, 2). 
CKD is often irreversible and a long-term condition that is detected by abnormalities 
in kidney function either in the urine or blood, or structural abnormalities identified 
by radiological methods. The term CKD covers a heterogeneous group of conditions 
that varies in severity, clinical presentation and progression. It can be caused by 
primary intrinsic renal conditions, predominantly glomerular and tubulo-interstitial 
disease, obstruction and cystic kidney disease, however, the most prevalent cause in 
the developed and developing world is diabetes (1). The prevalence of CKD is rising 
partly due to the better detection and increasing awareness of the condition but 
mostly due to the increasing prevalence of risk factors for developing CKD such as 
hypertension, diabetes, cardiovascular disease and obesity in an increasingly aged 
population. In the UK, the NEw Opportunities for Early Renal Intervention by 
Computerised Assessment (NEOERICA) project demonstrated the age-standardised 
prevalence of CKD was 10.6% for females and 5.8% for males however > 75% of 
patients with more advanced stages of CKD were A? 70 years (2). 
 
CKD is often asymptomatic until its later stages and symptoms are often due to 
complications of reduced renal function which when severe may require renal 
replacement therapy (RRT). As a result, people are often referred late with advanced 
disease when treatments to reduce progression and potential for recovery are 
limited (3, 4). At earlier stages of CKD, patients are often asymptomatic and regular 
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monitoring of renal function is necessary to determine whether CKD is progressive or 
stable. The rate of progression of CKD can vary from months to decades. Earlier 
diagnosis allows time for appropriate referral to specialist centres, assessment and 
treatment of complications, reducing cardiovascular risk and mortality, and enables 
necessary preparation and education for patients requiring dialysis therapy or 
conservative management. Although CKD is irreversible in most cases, there is 
evidence that appropriate treatment at earlier stages can often prevent or delay 
disease progression. Several trials have demonstrated that therapeutic interventions 
focusing on targeted blood pressure control and proteinuria reduction not only 
reduce rate of CKD progression but also reduce cardiovascular events and mortality 
in people with CKD and these trials are discussed in more detail in Chapter 3 (5-7). 
 
1.2 Definition and Staging of CKD 
 
The best measure of renal function is direct measurement of glomerular filtration 
rate (GFR) using a filtration marker however these are impractical tests to perform in 
large populations on a frequent basis. In clinical practice, estimated GFR (eGFR) is 
obtained from serum creatinine measurements using estimating equations that 
include age, gender and ethnicity as variables to improve accuracy of the estimation. 
The Modification of Diet in Renal Disease (MDRD) Study equation is currently the 
most commonly used estimating equation and has been adopted by national and 
international guidelines for assessing renal function (8). There have been many other 
estimating equations developed which have claimed better performances in specific 
populations (9). Other markers of renal function may prove more accurate in 
estimating GFR from a single serum assay, such as cystatin C, but these not widely 
used. Methods for measuring renal function are discussed in more detail in Chapter 
2.  
 
The current accepted definition and classification of CKD is based on eGFR and the 
presence of proteinuria or albuminuria. A simplified CKD staging system was 
recommended by the National Kidney Foundation (NKF) - Kidney Disease Outcome 
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Quality Initiative (KDOQI) in 2002 to implement clear strategies and guidelines in the 
management of CKD (10). They defined CKD as the presence of kidney damage or 
GFR less than 60ml/min/1.73m
2
 for three or more months irrespective of the cause. 
They also divided CKD into five stages according to severity of kidney damage as 
measured by GFR (Table 1.1). Stages 3-5 are defined by GFR alone and stages 1 and 2 
require the presence of a structural abnormality detected by imaging or the 
presence of persistent proteinuria, haematuria or albuminuria. Persistent non-visible 
haematuria as detected on urine dipstick testing may indicate urinary tract 
malignancy and requires prompt investigation at appropriate age groups. In the 
absence of malignancy and albuminuria, non-visible haematuria may indicate early 
glomerular damage and these people need annual screening of renal function, blood 
pressure monitoring and albuminuria as some people may progress to more 
advanced stages of CKD and may require further diagnostic evaluation and 
treatment of complications. Stage 5 is described as established renal failure or End-
Stage Renal Disease (ESRD) that has progressed for far that it often requires RRT to 
maintain life. Based on this classification system, the diagnosis of CKD can be made 
by a simple urine test to detect proteinuria/albuminuria or haematuria and a blood 
test to estimate GFR and these changes have facilitated a significant improvement in 
the detection and management of CKD in primary and secondary care.  
 
More recently, amendments to the classification of CKD have been made in response 
to emerging evidence of the prognostic outcomes in CKD. In 2004, Go et al observed 
that there was an independent graded association between reduced eGFR and the 
risk of death and cardiovascular events and this risk rose sharply for subjects with 
eGFR < 45ml/min/1.73m
2 
(11). This association led to the re-definition of stage 3 CKD 
into stage 3a and 3b as having an eGFR < 45ml/min/1.73m
2
 is clearly associated with 












1 A? ? ? Normal or increased GFR with other evidence 
of kidney damage: abnormal urine findings, 
structural abnormalities on imaging or 
histological abnormalities 










Moderate decrease in GFR, with or without 
evidence of kidney damage 
 
4 15-29 Severe decrease in GFR, with or without 
evidence of kidney damage 
 
5 <15 or receiving RRT Established or end-stage kidney disease 
 
Abbreviations: GFR, glomerular filtration rate; eGFR, estimated glomerular filtration rate; RRT, renal 
replacement therapy; CKD, chronic kidney disease. 
 
Table 1.1  
This table shows the stages of CKD. The stages are differentiated according to level 
of eGFR. Stages 1 and 2 require other evidence of kidney damage whereas stages 3 
to 5 are based on the eGFR category alone. Stage 3 is subdivided into 3a and 3b as 
there is clear evidence suggesting different prognostic outcomes between the two 
subgroups. This staging system was introduced by the Kidney Disease Outcome 




1.3 Risk Factors for CKD and Progression 
 
CKD has become recognised as a significant public health problem and it is important 
to appreciate the characteristics of our population to understand why. CKD is 
increasingly prevalent in the elderly and we are facing an increasingly aged 
population with 16% of the UK population currently aged over 65 years (13). The 
population characteristics across most of the developed world suggest that the 
population will continue ageing for many years to come. It is projected that there 
will be a rise of 31% in the number of people reaching state pension age in the UK 
between 2012 and 2037 taking into account the future rises of the state pension age. 
Factors associated with CKD progression overlap to a large extent with factors 
associated with increased cardiovascular risk particularly between diabetes, 
hypertension, cardiovascular disease and CKD. Diabetic renal disease remains the 
single most common cause of ESRD accounting for 42% of those on dialysis in the US 
(14) and 25% in the UK (15). Over the past two decades there has been an increase 
in the incidence of ESRD mainly due to the rising prevalence of diabetes but this rise 
in incidence is also thought to be associated with the improved survival from 
cardiovascular events (16).  Hypertension alone accounts for 7% of patients 
commencing RRT in the UK (15). Six per cent of the UK population have diabetes and 
30% are hypertensive and are therefore at risk of developing CKD. (17, 18) The 
NEOERICA study found that across stages 3-5 CKD the odds ratio for hypertension 
was 2.1, diabetes 1.33 and cardiovascular disease 1.69 (2). Moreover people with 
both diabetes and hypertension have a 5-6 fold increased risk of developing ESRD. 
Obesity is also growing in incidence and is partly responsible for the rise in 
prevalence of diabetes and hypertension. Often these conditions co-exist and the 
development of CKD may be multi-factorial in nature and it therefore difficult to 
assign these cases of CKD to a single causative factor.  
 
With an aging population and the growing prevalence of associated risk factors for 
CKD, in particular diabetes and hypertension, the incidence of CKD is set to rise and 




CKD in the Elderly 
 
The prevalence of CKD stages 3 to 5 in people aged over 70 years is estimated to be 
as high as 25% in the UK and with our ageing population numbers are expected to 
rise significantly (2). In the USA, using data from the NHANES III, the highest 
prevalence of CKD (45%) was found among subjects aged 80 years and over (19). The 
overall population growth rate in the UK is 1.1% per year but it increases to 2.6% in 
those > 60 years and 3.9% in those > 80 years (20). There has been a great deal of 
controversy surrounding the decline of GFR with age which debates whether the 
decline is an inevitable consequence of senescence or whether it represents a 
disease process. Some researchers have shown that vascular changes in the renal 
vessels as in other systemic vessels occur with age and are often due to co-
morbidity, but these changes have also been documented in the absence of co-
morbid conditions (21). It is suggested that these changes eventually cause 
glomerulosclerosis, interstitial fibrosis and tubular atrophy in the cortex, with 
compensatory hypertrophy and hyperfiltration of the remaining functioning 
glomeruli, eventually manifesting as CKD. In the autopsy study by Neugarten et al, 
older age was associated with increased numbers of sclerotic glomeruli and 
interstitial fibrosis with a loss of about 20-30% of the glomeruli compared to younger 
patients (22). In other studies, ageing was associated with a loss of renal mass by 20-
25% from the ages of 30 to 80 years and the length of the kidney was found to 
decrease by 15% from the age of 17 to 85 years of age (23-25). Significant loss of 
renal function however is not always an inevitable consequence of ageing. 
 
In 1950, a cross-sectional study was published by Shock et al, which found that 
measured GFR using the gold standard inulin clearance, declined with advancing age 
ŝŶ ‘ŶŽƌŵĂů ?ŝŶĚŝǀŝĚƵĂůƐindependent of hypertension or cardiovascular disease 
suggesting that there is a natural decline in GFR which occurs with age in males (26). 
Studies have shown that the co-morbid conditions in this population associated with 
an accelerated rate of GFR decline are hypertension, diabetes, atherosclerotic 
disease and cardiac insufficiency. Other cross-sectional studies have reported that 
the decline in GFR can start from ages 30-40 years (27). The major limitation of these 
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cross-sectional studies is that they introduce a bias as only the highly selected people 
who survive to reach old age are studied.  This is known as selective mortality and as 
a result the cohort studied have little co-morbid burden. Longitudinal studies 
observing serial measurements of renal function overcome the bias of cross-
sectional studies. 
 
Perhaps the two most recognised longitudinal studies in ageing were performed by 
Rowe et al in 1976 (27) and later by Lindeman et al in 1985 (28) as part of the 
Baltimore Longitudinal Study of Ageing.  The earlier study assessed creatinine 
clearance as a measure of renal function in 293 men aged 30 to 80 years with no 
history of diabetes. They found the average decline in creatinine clearance was 45 
ml/min/1.73m
2
 with a rate of decline in eGFR of 0.9 ml/min/1.73m
2
/year. There are 
limitations however to longitudinal studies as the validity of the results can be 
compromised by a limited time of observation, too long or too short an interval 
between testing, and infrequent testing can cause inaccuracy in determining a 
ƐƚĂƚŝƐƚŝĐĂůĐŚĂŶŐĞŝŶĞ'&Z ?ZŽǁĞ ?ƐƐƚƵĚǇƌĞƋƵŝƌĞĚ ?ŽƌŵŽƌĞƐĞƌƵŵĐƌĞĂƚŝŶŝŶĞ
clearance determinations over a mean interval of 6 years which is clearly inadequate 
to estimate rate of decline of eGFR. Creatinine clearance is also often criticised for its 
inaccuracies at estimating renal function and has been shown to overestimate GFR 
compared to measured GFR using inulin clearance by as much as 22% (29). The study 
concluded that in order to achieve a minimally acceptable accuracy of the slope of 
decline, a minimum of annual tests over 18 years would be required.
 
 
The Baltimore Longitudinal Study of Ageing measured serial creatinine clearance in 
293  ‘ŶŽƌŵĂů ?healthy males aged 22 to 97 years with no other co-morbidities and 
required a minimum of 5 creatinine clearance measurements over 8-14 years (28). 
Creatinine clearance was stable in healthy men < 35 years old and in men aged 35-60 
years, approximately one third of healthy individuals showed no decline in GFR with 
ageing but the remaining two-thirds had a creatinine clearance decline of up to 
8ml/min/1.73m
2
/year and 21.6% had a statistically significant higher rate of decline. 
This decline in creatinine clearance declined more steeply after the age of 60 years. 
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Again this study was subject to the inaccuracies of creatinine clearance as a measure 
of renal function, limited to male subjects ďƵƚĂůƐŽŝŶĐůƵĚĞĚĚŝĂďĞƚŝĐƐŝŶƚŚĞ ‘ŶŽƌŵĂů ?
group confounding the results as glomerular hyperfiltration is known to occur in 
diabetic patients. These studies suggested that the age-related decline in GFR is 
likely to be both due to physiological and pathological consequences of ageing.  
 
Guidelines now suggest that age-related decline in GFR is thought to decrease by no 
more than 1-2 ml/min/1.73 m
2
/year after the age of 40 and a more accelerated 
decline is due to pathological damage due to progressive CKD (10). Using the KDOQI 
CKD staging system where CKD 3-5 is based on eGFR definition alone, many 
individuals over 65 years will be labelled as having CKD even though their eGFR is in 
the normal range for their age and gender grouping many at CKD stage 3a. A GFR of 
< 30 ml/min/1.73 m
2
 in older people though does predict an increased mortality and 
a lower eGFR is more frequent in frailer subjects (30).  
 
It has also been suggested that the increased prevalence of CKD in older people may 
be partly related to the equations used to estimate GFR from serum creatinine, 
especially in older females and there have been questions raised concerning the 
validity of the estimating equations used in GFR measurement in older people. 
Several publications have suggested that the current methods of estimating GFR may 
underestimate GFR in elderly patients leading to incorrect CKD staging and 
consequently inappropriate management of these patients (9, 31). With an ageing 
population prevalent with cardiovascular disease, diabetes and hypertension who 
are often exposed to complex poly-pharmacy, it is important to have accurate 
methods of measuring GFR so we can appropriately manage those with CKD stages 
3-5. 
 
Progression of CKD 
 
There has been much debate about the definition of progressive CKD but it has been 
generally accepted as a decline in eGFR of > 5 ml/min/1.73m
2
 in 1 year or > 
10ml/min/1.73m
2
 in 5 years and patients with progressive CKD would benefit from 
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referral for renal specialist care (12).  There is a great variability in rate of CKD 
progression yet the majority of patients with CKD do not progress. Progression to 
ESRD in earlier stages of CKD is low and progression in those with stage 4-5 CKD is 
much higher bur despite this only a small proportion of patients with stages 4-5 CKD 
inexorably progress. Data from the third National Health and Nutrition Examination 
Survey (NHANES III) in 2004 estimated that 20 million adults in US have CKD yet only 
2% of the CKD population had progressive CKD to ESRD requiring RRT (1). Keith et al 
performed a longitudinal study of 28,000 CKD patients and found the rate of RRT 
over a 5-year follow-up was 1.1%, 1.3% and 19.9% respectively for stages 2, 3 and 4 
CKD however, in this study, progression was defined as developing ESRD (32). 
 
Cause of CKD clearly has an influence on CKD progression to ESRD with certain 
conditions such as chronic glomerulonephritis, inherited renal disease and cystic 
kidney disease often displaying an inexorable decline in renal function to ESRD. Data 
from the prospective longitudinal trial, Chronic Kidney Disease in Children (CKiD), 
demonstrated a more rapid decline in renal function in children whose underlying 
cause of CKD was due to a glomerular cause with an annual rate of decline in 
measured GFR of 10.5% compared to those with a non-glomerular cause who had a 
rate of decline of only 3.9% (33). Population studies have identified other risk factors 
associated with the progression of CKD: atherosclerotic disease (34), diabetes (35), 
hypertension (36), proteinuria (37), chronic use of non-steroidal anti-inflammatory 
medications (NSAIDs) (38), and Black or Asian ethnicity (39) which will be discussed 
in Chapter 3. These risk factors are highly prevalent in our UK population. There are 
many patients with CKD stages 4 and 5 who do not progress but this raises the 
question of how they got there in the first place. Patients with stable CKD may have 
an isolated event causing an acute decline followed by a partial recovery with no 
further event and another period of stability. 
  
Albuminuria and Proteinuria 
 
Diagnosis and staging of CKD not only requires eGFR but also requires testing for 
proteinuria or albuminuria. Proteinuria is a general term for the presence of 
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increased amounts of protein in the urine that reflects abnormal loss of protein 
derived from the kidney or lower urinary tract. Proteinuria is a common finding in 
CKD and is an early marker of glomerular disease often presenting prior to a 
reduction in GFR.  Albumin is a type of plasma protein found in the urine in small 
quantities in normal subjects and in larger quantities in patients with CKD. 
Albuminuria is a common finding in CKD but significant albuminuria is not always 
present in CKD. Proteinuria is an important factor linked with progression of CKD 
disease and poor outcomes (32).  
 
More recently, CKD guidelines emphasize testing for albuminuria rather than 
proteinuria due to emerging evidence of its strong association with CKD progression, 
prediction of cardiovascular risk and increased sensitivity in detecting glomerular 
damage. I discuss these seminal studies in more detail in Chapter 3. Albuminuria is 
expressed as a urine albumin to creatinine ratio (ACR) and the persistent presence of 
ĂŶZA? ?ŵŐ ?ŵŵŽůĨŽƌAN ?ŵŽŶƚŚƐŝŶĚŝĐĂƚĞƐ< ? 
 
The importance of albuminuria was highlighted in 2013 when KDIGO recommended 
that albuminuria strata, represented as ACR, be added within each GFR stage (ACR 
<30 mg/g, 30 W ? ? ?ŵŐ ?Ő ?ŽƌA? ? ? ?ŵŐ ?Ő ?in the CKD classification system (Table 1.2) 
(12). The recommendation for predicting outcome of CKD is to identify the following 
variables: Cause of CKD; GFR category; albuminuria category; other risk factors and 
co-morbid conditions. The risk associations of GFR and albuminuria categories 
appear to be largely independent of one another so neither the GFR or ACR category 
can fully capture the prognosis for a patient with CKD. These categories have been 
combined to identify those at greater risk of progression or poor outcomes in order 
to create a referral guide which is shown in Table 1.2.  
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Table 1.2 KDIGO Staging of CKD using GFR and Albuminuria Categories 
 
 






G1 Normal or high A? ? ? 
G2 Mildly decreased 60-89 
 








G4 Severely decreased 15-29 
 






Terms ACR (mg/mmol) 
A1 Normal to mildly 
increased 
< 3  
 
A2 Moderately increased  3-30 
 
A3 Severely increased >30 
 
 
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate; ACR, albumin to creatinine 
ratio; Kidney Disease: Improving Global Outcomes, KDIGO. 
 
 
Table 1.2  
The most recent classification system of CKD adopted the subdivision of GFR 
categories and included 3 albuminuria categories for each GFR category. This was 
introduced to indicate risk of CKD progression and poor prognosis. The grades G1  W 
G5 indicate categorisation of CKD by GFR and are differentiated according to level of 
GFR. Categories A1-A3 differ according to urine ACR levels. This classification was 
introduced by the Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work 




1.4 CKD Outcomes 
 
The major risk to the majority of people with CKD is not so much progression to 
ESRD but the significant association with increased mortality and morbidity 
predominantly from cardiovascular disease (40-41). A longitudinal follow-up study in 
2004 showed that even among those with advanced stage 4 CKD, death prior to RRT 
is twice as likely as progression to ESRD (32). Death was far more common than 
dialysis at all stage with five-year mortality rates were 19.5%, 24.3% and 45.7% for 
CKD stages 2, 3 and 4 respectively.  Even mild CKD is an independent risk factor for 
cardiovascular disease and death (42). 
  
Hospitalisation among people with CKD is also high. Khan et al demonstrated that 
during a median follow-up of 11.4 months, 47% of subjects with CKD had at least one 
hospitalisation with an average of 0.96 hospital admissions, 6.6 in-patient days and 4 
nephrology outpatient visits per person per year (43). Amongst the dialysis 
population this rose to 2.2 hospital admissions and a mean length of stay of 14.8 
days.  
 
CKD is also associated with numerous adverse health outcomes including anaemia 
renal bone disease, infections and impaired physical function. Even cognitive 
impairment has been associated with CKD not only in the elderly but in those aged 
20 to 59 years with ESRD or with a GFR between 30-59 ml/min/1.73m
2
 (44-45). 
These complications of CKD lead to an additional impact on the high morbidity, 
mortality and costs. 
 
 Only a minority of people with CKD will progress to develop more advanced disease 
and only 1-2% of patients will progress to develop end-stage renal disease (ESRD) 
which, without renal replacement therapy (RRT), in the form of dialysis or 
transplantation, leads to death (15). The financial burden of RRT on the health 
service is immense with over 2% of the total National Health Service (NHS) budget 
being spent on dialysis and transplantation alone. The total cost of CKD in England in 





Good management of patients with CKD requires strong links between primary and 
secondary care. Identification and management of CKD stages 1-3 usually takes place 
in primary care and often combines reduction of cardiovascular risk along with 
regular monitoring of renal function and management of the complications of CKD. 
Strategies to reduce blood pressure to recommended targets and reduce 
albuminuria are measures that have been consistently found to significantly reduce 
progression of CKD and its associated adverse outcomes, and this is discussed in 
Chapter 3. There is a growing body of evidence that treatment of other traditional 
cardiovascular risk factors in CKD patients are of benefit, which include smoking 
cessation and lipid lowering treatments. Halimi et al demonstrated that smoking is 
associated with CKD progression (47) however no studies have supported that 
smoking cessation delays progression of disease. The Study of Heart and Renal 
Protection (SHARP) was the largest randomised controlled trial of CKD patients and 
found lipid lowering resulted in a 17% reduction in atherosclerotic events (48). 
Avoidance of non-steroidal anti-inflammatories (NSAID) and other nephrotoxic 
agents have also been shown to reduce progression risk. Gooch et al determined 
that high cumulative NSAID exposure is associated with increased risk for rapid CKD 
progression in an elderly cohort, a population with a high prevalence of CKD and 
NSAID use (38). 
 
Specialist management focuses on delaying progression of disease, treating 
complications of CKD, timely preparation for RRT or pre-emptive transplantation or if 
opting for conservative management, preparation for end of life care and symptom 
control. Late referrals to nephrology services often result in unplanned dialysis 
initiation and are associated with increased morbidity and mortality, increased 
hospitalisation rates and increased costs (49-50). There has been a variable 
definition of what constitutes late referral from < 1 month to < 1 year but is 
generally accepted as referrals made less than 3 months prior to dialysis initiation 
which is thought to be the minimum amount of time required for adequate 
assessment, education and preparation for RRT including creation of access for 
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dialysis. Late referrals are considered an adverse measure and although certain 
conditions can cause a rapid progressive decline in renal function where late 
commencement of renal replacement therapy is unavoidable, they account for only 
25% of late referrals in the UK (15).  
 
CKD Screening and Referral Guidelines 
 
Studies have looked at whether the systematic monitoring of adults with CKD stages 
1 W3 for worsening kidney function or damage is actually of benefit in improving 
clinical outcomes. Undesirable consequences from CKD screening and monitoring 
may include misclassification of patients with CKD, unnecessary tests, the associated 
adverse psychological effects of being labelled with CKD, adverse effects associated 
with pharmacological treatments initiated or changed after a CKD diagnosis, and 
possible financial and insurance ramifications of a new CKD diagnosis. 
In 2002, the European Best Group Practice published guidelines for CKD 
management and recommended patients with an eGFR < 30ml/min/1.73m
2
 and 
declining eGFR be under nephrologist care (51). In 2002, NKF-KDOQI reiterated the 
recommendation that patients who reach CKD stage 4 (i.e. eGFR < 30 ml/min/m
2
) 
receive timely education for RRT from renal specialists (10). In 2006, the Quality and 
Outcomes Framework (QOF) introduced renal incentives creating a register of 
people in primary care with an eGFR <60 ml/min/1.73m
2
 (i.e. stages 3-5 CKD). In the 
same year, a national strategy was launched to report eGFRs automatically with 
every serum creatinine request from all clinical chemistry laboratories. In 2006, the 
Royal College of Physicians together with the Renal Association published and 
disseminated UK guidelines for identification and referral of CKD (52). In 2008, the 
National Institute for Health and Care Excellence (NICE) disseminated national 
guidelines for best practice in managing CKD in primary and secondary care (53). 
These initiatives were all developed to promote early identification of CKD and 
management with guidance for referral and have no doubt influenced referral 
patterns. The fundamental problem with all these guidelines that although they 
were designed to reduce late referral of people with advanced CKD, they do not take 
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into account the impact that following these guidelines would have in the short-term 
on referral rates to specialist centres (54), on the increased workload it would create 
in primary care or its cost implications. Guidelines have not been specific enough 
increasing unselected referrals and studies have shown that the number of patients 
referred to renal services significantly increased after April 2006 (55-56). 
 
In July 2014, NICE updated their CKD guidelines and highlighted the importance of 
identifying patients with progressive CKD altering their referral criteria (57). The 
recommendations focussed on strategies aimed at earlier identification and 
prevention of progression to ESRD. They suggested re-defining accelerated 
progression of CKD as a sustained decreased in eGFR by 25% or more and a change 
in GFR category within 12 months, or a sustained decrease in GFR of 
15ml/min/1.73m
2
 per year.  Calculating rate of CKD progression is recommended by 
obtaining a minimum of 3 GFR estimations within a minimum period of 90 days and 
planning intervention strategies in a timely fashion if they are predicted to require 
RRT in their lifetime. 
 
These guidelines have improved the identification of patients with CKD and UK 
prevalence data has indicated there has been a recent steady national decline in late 
referrals with an overall rate of 20% with some centres achieving < 10% (15). We 
now need to focus on appropriately identifying and managing those patients in the 
earlier stages of CKD who are at risk of progression so they can benefit from earlier 















1.5 Acute Kidney Injury (AKI) - Background 
 
AKI, previously termed acute renal failure, is a complex disorder with multiple 
aetiologies and outcomes. AKI is a common condition, which in contrast to CKD, is 
often reversible, often iatrogenic in aetiology and potentially preventable (58-59).  
AKI usually develops over hours to days and leads to an abrupt rise in serum urea 
and creatinine levels often causing electrolyte disturbances, metabolic acidosis and 
reduced urine output. The incidence of AKI is higher in hospitalised patients 
occurring up to 18% of all hospital admissions with reports of up to 65% in critically 
ill patients in the intensive care setting (60-61). AKI encompasses a wide spectrum of 
illnesses and varies in severity from minor increases in creatinine of only 26µmol/l 
(0.3mg/dl) through to critically unwell patients requiring RRT. The incidence of AKI in 
the UK ranges from 486-630 per million population (pmp) per year in published 
series (61-62). The incidence of AKI is increasing partly due to better recognition but 
also due to the rising prevalence of similar risk factors responsible for the rise in CKD 
such as an increasingly aged population and the increased incidence of diabetes, 
cardiovascular disease and other chronic diseases. AKI is potentially preventable for 
those at risk through appropriate medical and drug interventions and increased 
vigilance and testing. 
 
Very few cases of AKI are actually due to intrinsic renal conditions and approximately 
70% of cases of community-acquired AKI are due to pre-renal causes (63). More 
severe cases often require higher dependency care or renal specialist support in 
order to initiate appropriate treatment in a timely fashion in order to optimise renal 
recovery and outcomes. Several studies have demonstrated that non-specialist 
management of AKI is sub-optimal. Stevens et al demonstrated in a 12-month 
period, 18% of cases of AKI initially managed by non-specialists were preventable 






1.6 Definition and Staging of AKI 
 
The concept and understanding of AKI and advances in research, in comparison to 
CKD, is relatively new and this has been partially due to the lack of a universally 
accepted definition of AKI. Having a uniform standard for diagnosing and classifying 
AKI has enhanced our understanding and management of AKI. In 2002, the Acute 
Dialysis Quality Initiative (ADQI) was created with the primary goal of developing a 
consensus in the definition and evidence-based guidelines for the prevention and 
treatment of AKI. They introduced the RIFLE criteria, an acronym of Risk, Injury, 
Failure, Loss and End-stage renal failure, to define AKI (64). The RIFLE classification 
system was demonstrated to be suitable for assessing mortality and AKI particularly 
in intensive care units (65-67) but was criticised for including outcomes (Loss and 
End-stage renal failure) in the staging criteria (68). In 2004, the Acute Kidney Injury 
Network (AKIN) was formed who advised that the definition of AKI encompass the 
full spectrum of the disease, from mild to severe, and removed the outcomes loss of 
function and ESRD in the classification system (69). The AKIN staging system of 
severity of AKI is shown in Table 1.3 and is based on rises in serum creatinine and 
urine output criteria and differs from RIFLE as it is defined as changes within 48 
hours while RIFLE defined AKI over 7 days. This new staging system reduced the 
need for a baseline creatinine but it does require at least two creatinine 
measurements within 48 hours. In 2012, KDIGO published clinical practice guidelines 
for AKI combining the RIFLE and AKIN definitions. KDIGO defined AKI as presence of 
any of the following; increased in serum creatinine by > 26µmol/l within 48 hours, or 
an increase in serum creatinine 1.5 times above baseline within 7 days and a urine 
output < 0.5ml/kg/hr over 6 hours (70). Since then it has become apparent that the 
incidence of AKI is significantly higher than previously thought and the true impact 







Table 1.3  Stages of Acute Kidney Injury 
 
 
Stage Serum Creatinine Urine Output 
1 A? ? ? ?-1.9 times baseline 
                  
                  or 
 
Increase in creatinine A?0.3 mg/dl  
(26 µmol/l)  
< 0.5 ml/kg/hr for 6-12 hrs 
2 A? ? ? ?-2.9 times baseline 
 
AM ? ? ?ŵů ?ŬŐ ?ŚƌĨŽƌA? ? ?ŚƌƐ 
 
 
3 A? ? ? ?ƚŝŵĞƐďĂƐĞůŝŶĞ 
                  
                  or 
 
Increase in creatinine A? ? ? ?ŵŐ ?Ěů  
(353 µmol/l) 
                  or 
 
On renal replacement                    
therapy 
 
<  ? ? ?ŵů ?ŬŐ ?ŚƌĨŽƌA? ? ?ŚƌƐ 
                     
                    or  
 
     AŶƵƌŝĂĨŽƌA? ? ?ŚƌƐ 





This is the classification system for AKI adopted by KDIGO modified from the Risk, 
Injury, Failure, Loss of kidney function , End-stage kidney (RIFLE) and Acute Kidney 
Injury Network (AKIN) criteria based on rise in serum creatinine and/or urine output 
changes. AKI is defined as an abrupt reduction in renal function (within 48 hours) 
ĚĞĨŝŶĞĚĂƐĂŶŝŶĐƌĞĂƐĞŝŶƐĞƌƵŵĐƌĞĂƚŝŶŝŶĞA? ? ?ʅŵŽů ?ů ? ? ? ?ŵŐ ?Ěů ? ?A? ? ?A?ŝŶĐƌĞĂƐĞ in 
serum creatinine (1.5-fold from baseline) or a reduction in urine output < 





Measuring Renal Function in AKI 
 
Diagnosis of AKI is exceptionally easy and is obtained by a simple blood test 
measuring serum creatinine and/or measurement of urine output. In order to 
diagnose and assess the severity of an AKI episode, knowledge of baseline kidney 
function is required if known. A problem arises when the baseline creatinine is not 
known and estimating baseline function can be subject to a degree of interpreter 
variability. Inaccurate determination of the baseline renal function can sometimes 
lead to a misclassification of AKI. There has been a lot of debate about the 
implications of the choice of measurements of the baseline kidney function when 
defining the presence and severity of AKI. Several hospital-based studies have made 
assumptions on baseline serum creatinine in the absence of outpatient values when 
investigating acutely ill hospitalised patients (64-66). This approach ignores the 
association that pre-existing CKD often contributes to the development of AKI. 
 
The KDIGO AKI guideline suggests that an estimated creatinine can be used, provided 
there is no evidence of CKD (70). However there remain many cases of CKD in the 
community that have not been previously appreciated, and hence estimating the 
baseline serum creatinine may lead to a diagnosis of AKI when in fact the patient has 
previously un-recognised CKD. Recently, a proposed national algorithm standardising 
AKI definition has been endorsed by NHS England with plans to introduce a wide-
scale uptake of an automated computer software algorithm to detect AKI according 
to AKI stage (71-72). This algorithm defines the baseline creatinine as the lowest 
value if measured 0-7 days prior to the AKI episode or the median of results within 8-
365 days. If no results are available within 365 days then results are compared to 
reference intervals related to age and gender. 
 
Other Markers of Acute Kidney Injury 
 
Despite the fact that serum creatinine is affected by several non-renal factors 
(muscle bulk, gender, concomitant drugs) and takes 24-48 hours to rise after the 
initial renal insult, it remains the traditionally used parameter to diagnose AKI. It is a 
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reasonably cheap test and a fairly reliable and available assay. Estimated GFR does 
not accurately reflect true GFR in AKI as it does in CKD and in light of the 
inadequacies of conventional markers of renal damage in the acute setting, there 
have been numerous studies investigating newer AKI biomarkers including urinary 
Neutrophil Gelatinase-Associated Lipocalin (NGAL) (73), Kidney Injury Molecule 
(KIM)-1, IL-18 and cystatin C (74). These biomarkers aim to detect AKI before a 
detectable serum creatinine rise to aid diagnosis and improve management and 
outcomes. As the aetiology of AKI is not uniform, these biomarkers need to 
consistently perform accurately across a wide range of settings. So far few 
biomarkers of AKI have been adopted in routine clinical use as studies have reported 
variable results with inconsistent performances across specific conditions and they 
are neither practical nor cost-effective in clinical practice (75).  
 
1.7 Risk Factors for AKI 
 
Several risk factors have been identified for the development of AKI that occur 
across a wide range of settings which can be modifiable or non-modifiable and these 
are summarised in Table 1.4. Sepsis is the leading cause of hospital-acquired AKI and 
studies have shown that septic AKI confers a higher intensive care unit (ICU) and 
hospital mortality when compared to non-septic AKI (76). One of the most important 
risk factors for the development of AKI is the presence of co-morbidities. Diabetes, 
CKD, vascular diseases and cardiac insufficiency are frequently associated with 
development of AKI. The presence of pre-existing CKD dramatically increases the risk 
of development of AKI and the relationship of these two conditions is discussed in 
more detail in subsequent chapters (77).  
 
The elderly population are at particularly high risk of community and hospital-
acquired AKI (78-79). The segment of the population in which the incidence of AKI 
has been increasing the most rapidly is those with advanced age.  It is suggested that 
background changes in the kidney, related to age and CKD, together with an increase 
in the prevalence of clinical situations such as dehydration, drug toxicity and co-
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morbidities put this patient population at higher risk of developing AKI. Elderly 
patients are more likely to have chronic illnesses, cardiovascular disease or diabetes 
and are more likely to be on complex polypharmacy.  Urinary tract obstruction is a 
major cause of AKI almost exclusively observed in the elderly and is responsible for 
25% of AKI occurring in the elderly (80). With more co-morbidity, older people are 
likely to under-go more surgical procedures and require more interventions or 
imaging with exposure to nephrotoxic contrast media.  
The most important modifiable risk factors for AKI are dehydration, hypovolaemia, 
toxicities related to medications or contrast media, surgery related complications, 
sepsis and cardio-renal syndrome. Hospital-acquired AKI following surgery is an 
important contributor to post-operative morbidity and mortality and is often 
associated with pre-renal causes of AKI. Pre-renal causes can represent true volume 
depletion as well occur in conditions which decrease effective arterial blood volume 
causing renal hypo-perfusion. The incidence of AKI can range from 0.1% in general 
surgery to 31% following cardiac surgery highlighting the variable nature of this 
condition (81). The high prevalence of co-morbidities in the older population often 
leads to an increase in demand for interventional invasive tests and surgical 
procedures with higher perioperative complications. The potential nephrotoxicity of 
commonly used drugs is often misunderstood and medication-related toxicity often 
leads to the development of AKI of which the common culprits are NSAIDs, diuretics, 
angiotensin blocking agents and contrast agents.  
Several studies have identified that AKI almost always occurs due to multi-factorial 
risk factors. Some studies have developed and prospectively validated risk-
stratification scores most notably after cardiac surgery and coronary angiography to 
categorise patients according to risk of developing AKI (82-83). Further work is 
needed to cross-validate these risk scores across different populations and in various 
settings due to the multiple aetiologies of AKI.  


















































Abbreviations: CKD, chronic kidney disease; AKI, acute kidney injury 
 
 
Table 1.4   
This table lists the commonly recognised risk factors associated with the 
development of AKI. Risk factors are divided into pre-existing conditions, acute 
clinical conditions and the common medications often related to the development of 
AKI. Co-morbidities including CKD and vascular diseases and older age are common 
pre-existing non-modifiable risk factors.  Certain clinical conditions with increased 
risk of reduced blood flow and medication-associated AKI are common modifiable 
risk factors. Many drugs contribute to the development of AKI and therefore should 




Incidence of AKI 
 
Hsu et al examined a cohort of beneficiaries of the health-care delivery system Kaiser 
Permanante in North California and found the use of acute RRT in patients with AKI 
was 295 pmp per year (pmp/yr) and an increased incidence of AKI not requiring 
dialysis of 522 per 100,000 person-years (78). They also found that the incidence of 
community-acquired AKI increased with age until the ninth decade (1232 pmp/yr in 
patients aged 70-79 year; 625 pmp/yr in 80-89 years). Hospital-acquired AKI is 
thought to be approximately 5-10 times more frequent than community-acquired 
AKI (84) but this figure varies according to studies and local demographics. 
Community-acquired AKI occurring in more rural settings rarely reach hospital and 
therefore are not captured in accurate measurement of AKI incidence. Severe AKI 
requiring ICU admission occurs in 11 patients per 100,000 population per year and 
AKI has been reported to occur in 30-67% of all ICU admissions usually as a manifest 
of multi-organ failure (85). 
 
1.8 AKI Outcomes 
 
AKI is often reversible and early detection of AKI is vital as instituting appropriate 
management can lead to complete recovery. Many studies have addressed variable 
short-term and long-term outcomes of AKI most frequently assessing mortality. AKI 
can result in multi-organ failure and can accelerate cardiovascular disease and CKD. 
 
AKI in hospitalised patients is associated with increased mortality and this risk is 
even higher in patients requiring renal replacement therapy and increases according 
to severity of AKI (60, 84). AKI is associated with a number of changes in the vascular 
endothelium and it has been suggested that these have an impact on cardiovascular 
health. There is emerging evidence that even minor increases in serum creatinine 
concentration of 26µmol/l (0.3 mg/dl) are associated with increased mortality, 
increased length of hospital stay and increased costs to the healthcare economy 




Despite important technical advances in clinical care, the prognosis for patients with 
AKI remains poor and mortality rates can exceed 40-80% in the intensive care setting 
(88). Furthermore, it is also suggested that an episode of AKI confers an increased 
risk of subsequent mortality following recovery and discharge from hospital. Studies 
have previously looked at 30 and 90-day survival and renal recovery at these time 
points (89). From our local data studying the incidence of AKI in a district general 
hospital, 15% of all admissions sustained an episode of AKI with increased 
subsequent short and long-term morbidity and mortality, even in those with AKIN1 
(90).  Only 56% of patients who experience an episode of severe AKI in hospital 
survived to be discharged, and only 28% survived to 3 years post discharge.  
In a study that examined survival in both young and old patients, AKI and older age 
were independently associated with the risk of long-term death (91). Recent cohort 
studies have shown that despite new therapeutic interventions the incidence of AKI 
is increasing but mortality is decreasing (84). 
 
Not all AKI is reversible and patients may be rendered RRT dependent or be left with 
a significant residual loss of renal function. Ishani et al demonstrated that AKI 
increased the risk of ESRD by 13-fold (87). The differences in rates of recovery from 
AKI between the young and old remain unclear but we know that the chances of 
renal recovery are greatly deceased in the presence of CKD. As CKD is more 
prevalent in elderly people and GFR decline occurs in ageing, it is very probable that 
the elderly population have a reduced likelihood of recovering renal function. 
 
Very few studies have looked at the long-term quality of life in AKI survivors. One 
small study looked at a small cohort (n=16) of survivors of an AKI of a total original 
cohort of 117 patients with an AKI requiring RRT and found a significantly lower 








Management of AKI 
 
Strategies to reduce the incidence and severity of AKI involve identifying relevant 
risk factors with regular monitoring of renal function and immediate treatment when 
AKI occurs. Management of AKI usually involves supportive measures and most cases 
remain under the care of the admitting clinical team however the more severe cases 
of AKI (AKIN 3) often require renal specialist or ICU input. Supportive measures 
include fluid resuscitation, prompt recognition and treatment of sepsis, cessation 
and avoidance of nephrotoxic agents, managing complications of AKI and close 
haemodynamic monitoring. Management of AKI in the elderly can be more 
challenging particularly in extreme age or the presence of multiple co-morbidities.  
 
Complications of AKI such as hyperkalaemia, acidosis, volume overload and 
encephalopathy can increase mortality and risk for persistent decline of kidney 
function and need treating promptly. Very few studies have shown a benefit from 
pharmacological interventions and even timing of initiation and type of renal 
replacement therapy have shown little in terms of prognostic benefit (92-94). 
 
Early diagnosis of AKI and establishment of these supportive measures are vital in 
reducing AKI severity and preserving functioning nephrons, hence improving patient 
and renal outcome and there have been significant advances in the research and 
intervention in AKI since it has become evident what the true incidence of AKI is. It is 
now clear that AKI has a significant impact on morbidity and mortality increasing the 
burden on our health services.  It has been known for some time that many cases of 
AKI are iatrogenic in origin and up to 30% are preventable (59). An example of this is 
contrast-induced nephropathy, a condition associated with up to a 6-fold increase in 
mortality (95). Simple precautions such as pre-hydration prior to contrast 
administration, discontinuation of drugs which reduce renal blood flow or reduce 
intravascular volume, using minimal volume of contrast and if possible avoidance of 
contrast by alternative diagnostic methods have been shown to minimise risk for 
developing contrast associated AKI (96). It is important that patients with AKI or at 
risk of developing AKI are recognised at the earliest opportunity and that instituting 
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supportive measures is directed at minimising further injury and development of its 
complications. 
 
The importance of AKI on patient outcomes and overall poor care in the 
management of AKI was emphasised in 2009 by the National Confidential Enquiry 
into Patient Outcomes and Death (NCEPOD) report on hospitalised patients with AKI 
(97). This report investigated the management of patients who died as result of AKI. 
It identified significant failings in the recognition and management of AKI 
highlighting widespread deficiencies in the clinical care of these patients. The report 
included recommendations for the early diagnosis, prevention and management of 
AKI in acute hospitals and suggested organisational changes. Since then there has 
been a huge national drive in improving awareness with publication of national 
guidelines, development of computer AKI alert systems and formation of AKI 
networks all in order to aid better detection and management to improve clinical 
outcomes. The NCEPOD report has resulted in a significant increase in research in 
the field of AKI and has raised the awareness of AKI and led to the introduction of 
structured management guidelines. Much of the current focus in AKI research has 
been on identifying risk factors for AKI and developing strategies to prevent AKI in 
high-risk patients. 
 
CKD is increasingly prevalent yet few people with CKD progress to ESRD. AKI is 
increasingly common and recently significant advances have been made to improve 
prevention, recognition and management of AKI. There is increasing evidence that 
AKI events may contribute to the progression of CKD yet there are multiple 
unanswered questions about their relationship. dŚŝƐƐƚƵĚǇĂŝŵƐƚŽĂŶƐǁĞƌ ‘ŝƐƚŚĞ




Measuring Renal Function 
 
 
Publication of ƚŚĞƐĞĐŽŶĚƉĂƌƚŽĨƚŚĞĞƉĂƌƚŵĞŶƚŽĨ,ĞĂůƚŚ ?ƐEĂƚŝŽŶĂů^ĞƌǀŝĐĞ
Framework (NSF) for Renal Services (10) in 2005 highlighted the importance of CKD 
but changed the focus of care delivery from treatment of established renal disease 
to early identification and prevention of CKD. The guidelines suggested identifying 
people at risk of developing CKD and initiating interventions to prevent progression 
of disease, minimise cardiovascular risk and identify those at risk of progression to 
ESRD. Delivering these quality requirements relies on accurate measures of kidney 
function in order to treat and screen those with or at risk of developing CKD 
appropriately. 
 
Diagnosis of CKD and assessment of progression of disease is dependent on 
monitoring of renal function and the best measure of renal function is glomerular 
filtration rate. A reduction in GFR precedes kidney failure in all forms of progressive 
renal disease. In addition, estimated GFR is used in clinical practice to allow for 
proper drug dosing of medications that are excreted by glomerular filtration in order 
to avoid drug toxicity. Where a highly accurate measure of GFR is required such as 
monitoring during chemotherapy, a gold standard measure of GFR is usually 
recommended (12). Inaccuracies in methods used to estimate GFR would incur 
serious consequences and increase the risk of unsafe drug prescribing and may lead 









2.1 Serum Creatinine Measurement 
 
Serum creatinine levels were until recently used to assess level of kidney function in 
both the acute and chronic setting. Creatinine is a chemical waste product of 
creatine phosphate which is formed physiologically by muscle metabolism and is 
produced at a fairly constant rate. Creatinine is exclusively removed from the body 
by the kidneys primarily by glomerular filtration but also by proximal renal tubule 
secretion and higher levels of serum creatinine indicate worsening renal function. 
Little or no tubular reabsorption occurs. Each day approximately 1-2% of muscle 
creatine is converted into creatinine. A rise in serum creatinine is only observed after 
a significant number of functioning nephrons are lost and is therefore unsuitable at 
detecting early stages of kidney damage. Serum creatinine measurement is a simple 
obtainable investigation that requires a single blood sample and is available in all 
medical laboratories.  
 
Biological Variability of Serum Creatinine Measurements 
 
The use of serum creatinine level alone is considered inaccurate in measuring renal 
function and assessing CKD as it has several limitations. Many studies have 
documented that creatinine production varies substantially across sex, age and 
ethnicity (98). More so, there is considerable variability in the individual muscle mass 
of the population. The reference values associated with serum creatinine have been 
traditionally stratified by gender and age to reflect differences in muscle mass 
however they are often inadequate in estimating muscle mass and also do not take 
ethnicity into account. Differences in muscle metabolism and variable rate of 
secretion of creatinine in the proximal tubules will also affect serum levels.  
Certain medications such as trimethoprim and cimetidine reduce tubular creatinine 
secretion limiting the ability to accurately estimate GFR. Increased dietary intake of 
creatine or high ingestion of meat or fish can also increase creatinine levels (99-100). 
The NICE CKD guidelines now recommend avoidance of meat consumption 12 hours 
prior to serum creatinine measurement (57).  The inability to relate creatinine to GFR 
was believed to have led to the under-diagnosis and misclassification of CKD stage in 
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patients who may well have benefited from earlier intervention. Despite its 
limitations, serum creatinine testing remains one of the most frequently used 
indicators of renal function and is a standard component of a panel of tests 
requested at most medical care centres.  
 
Standardisation of Serum Creatinine Measurements 
 
Prior to 2006, normal creatinine value ranges varied significantly among different 
laboratories due to variability in their analytical methods and assays. This raised 
concerns of a possible detrimental impact in the clinical care of patients and called 
for global public health efforts to highlight the importance of reliable serum 
creatinine measurements in identifying people with CKD. It is now an international 
priority that serum creatinine assays must be properly calibrated and traceable to 
high-order reference systems in order to eliminate or reduce variation among 
laboratories. Expert professional bodies recommend that clinical laboratories now 
align their creatinine measurements against a new standardised isotope dilution 
mass spectrometry (IDMS) method using a commutable IDMS-traceable reference 
material (Standardised Reference Material (SRM) 967) to measure serum creatinine 
in accordance with the NKF-KDOQI CKD guidelines (101-102). IDMS appears to give 
lower creatinine values compared to older methods when the serum creatinine 
levels are relatively low.  
 
2.2 Measuring Glomerular Filtration Rate 
 
Measured GFR is generally accepted as the best overall measure of renal function.  It 
provides an accurate measure of the filtration capacity of the kidneys and, as the 
total GFR is equal to the total filtration rate of each of the functioning nephrons, this 
can be used to indicate the total functioning renal mass. Reduction in the GFR 
precedes CKD and persistent decline in function indicates progressive CKD. The GFR 
measured as clearance of creatinine can be a difficult test to accurately execute in 
clinical practice. Measuring glomerular clearance of creatinine requires accurate 
timed urine samples and is impractical and costly and hence unfeasible in assessing 
45 
 
CKD in a large cohort. GFR has not been demonstrated as providing an accurate 
assessment of renal function in AKI as it does not accurately reflect tubular damage. 
 
The gold standard measurement of GFR uses reference procedures in which the 
clearance of an infused exogenous substance that is solely excreted by the kidneys is 
measured. This filtration marker must be exclusively eliminated in the urine by 
glomerular filtration of the functioning nephrons and not be affected by tubular 
secretion in order to be an accurate measurement of renal clearance. Inulin was 
traditionally used as the gold standard marker however this is not only expensive but 
measuring inulin levels is technically difficult (103). Measurement of GFR using the 
inulin clearance method is an impractical test partly due to the analytical problems 
associated with the measurement of inulin and due to requirements of bladder 





iothalamate and iohexol are more commonly used as alternative reference markers 
(104). The radio-labelled chelating agent 
51
Cr-EDTA has been the most commonly 
used measured GFR marker in Europe for years however this test is not available in 
the US. This test is performed in nuclear medicine departments but is a difficult and 
time consuming test to perform and inappropriate for routine clinical use and 
dependent on availability of equipment for measuring radio-labelled markers. 
 
Plasma Iohexol Clearance 
 
Iohexol has become one of the most commonly used alternative marker for GFR 
measurement. It is a safe, non-radio-labelled and non-ionic contrast agent. It is not 
metabolised, is less than 2% protein-bound, and is eliminated without being 
metabolised exclusively by glomerular filtration. There is close agreement of GFR 
measured by iohexol renal clearance and iohexol plasma clearance however renal 
clearance measurements require urinary concentrations of iohexol with accurate 
timed urine collections and this is inconvenient in clinical practice. Instead, in order 
to simplify the procedure, plasma iohexol clearance has been developed for use 
clinically as the procedure requires only a single bolus of contrast and subsequent 
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timed serum sampling (105). This method avoids the need for intravenous infusions 
and timed urine collections.  
 
A determination of GFR is obtained from the dose of iohexol administered and the 
area under the curve (AUC) serving as a function of time. Accuracy of the iohexol 
plasma clearance method is dependent on a mathematical model and the iohexol 
sampling times. When the iohexol marker is injected, there is diffusion of the marker 
both in plasma and in various compartments. The plasma concentration of iohexol is 
therefore dependent on 4 factors; the amount of marker administered, urinary 
excretion of the marker, the diffusion rate of the marker within various 
compartments and the retro-diffusion rate of the marker from the deeper 
compartments into plasma. There is thus an initial rapid change in plasma marker 
concentration during the distribution phase and later on, a slower reduction in 
plasma concentration during the excretion phase as the marker re-enters the plasma 
from the compartments. This multi-compartmental model would require several 
blood samples however Brochner-Mortenson et al (106) simplified this method by 
creating a model in which the accuracy of the plasma clearance values after the 
marker injection depends on the timing of the blood samples. The optimal time to 
sample serum is after the distribution phase. The time needed to complete 
equilibrium between plasma and extravascular compartments is inversely 
proportional to level of kidney function so it is recommended that later sampling is 
performed in individuals with reduced renal function to enhance accuracy. 
Characterising the iohexol disappearance curve based on samples only from early 
time points will result in an overestimation of GFR and it is recommended that 
iohexol GFR can be satisfactorily measured with a minimum of 3 measurement 
points within 4-5 hours of administration (105). The iohexol plasma clearance 
method however is not widely available and impractical for a large-scale application 







2.3 Estimating GFR Equations 
 
While GFR can be measured by clearance studies of exogenous markers such as 
iohexol, inulin, iothalamate and Cr
51
-EDTA, they are costly, time consuming and not 
suitable for the routine detection of kidney disease. The accurate measurement of 
glomerular clearance of endogenous substances such as creatinine and urea requires 
serum and timed urine collections and again is impractical in screening large 
populations. It became apparent that the variable interpretation of serum creatinine 
levels often led to misdiagnosis of renal disease so estimating equations were then 
developed based on the serum creatinine level to provide an estimated GFR which 
take into account the effect that age, sex and race have on creatinine production. 
Numerous estimating equations have been developed to predict GFR in both adults 
and children in order to enable better identification of patients with early kidney 
disease who can be helped by therapeutic interventions. In principle, GFR estimating 
equations provide a more accurate estimate of measured GFR than serum creatinine 
levels. Until recently, variation in creatinine measurements between different 
laboratories was a major source of bias of these estimating equations. However 
since the creatinine-standardisation program has been implemented throughout the 
United States and United Kingdom, these equations are more accurate in estimating 
GFR (102). The national introduction of routine eGFR reporting with every serum 
creatinine request in 2006 has also helped to improve the identification of 
individuals with CKD. 
 
 
The Cockcroft-Gault Equation 
 
In 1976, Cockcroft and Gault proposed an estimating equation for GFR using weight, 
gender and age as variables based on serum creatinine levels (107). An important 
characteristic of the Cockcroft-Gault formula is the inclusion of total body weight as 
a reflection of the muscle mass, the main determinant of creatinine generation. The 
calculation of estimated creatinine clearance using the Cockcroft-Gault equation has 
been the most commonly used method to estimate kidney function for drug dosing 
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purposes for decades. This is based on prospective pharmacokinetic studies that 
were conducted on patients whose level of kidney function was determined by 
estimated or measured creatinine clearance. The Cockcroft-Gault equation however 
does not correct for race and a relative limitation of this equation is the need for a 
calculator. Another limitation is that with increasing age, the body composition 
changes with decreasing muscle mass and increasing fat tissue with a reduction in 
lean body mass in the elderly thus causing inaccuracies of this equation in estimating 
GFR in older people. The Cockcroft-Gault equation is no longer recommended by 
KDIGO guidelines in assessing eGFR as it was developed before the era of 
standardisation of creatinine assays (12). 
 
The Modification of Diet in Renal Disease (MDRD) Study Equation 
 
The MDRD study equation was developed in 1999 using data from a base population 
of 1628 out-patients with established CKD (8). Various MDRD equations have been 
published however the most widely used equation by the health care community is 
the abbreviated, four-variable MDRD equation, which has been reformulated to be 
used with a standardized serum creatinine assay (Table 2.1). It uses age, the inverse 
of serum creatinine, gender, and race (African-american versus non Wafrican 
american) as variables. This equation directly relates the accounted variables (e.g.  
serum creatinine, age, gender and race) to GFR adjusted for body surface area. The 
set of equations developed from the data derived from the MDRD study aimed at  
estimating GFR compare to GFR measured by 
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I-iothalamate urinary clearance, the 
reference method used in this study. In contrast to the Cockcroft-Gault formula, the 
MDRD model accounts for the biological relation of creatinine metabolism observed 
in african-americans, but there is no adjustment for other ethnicities. The MDRD 
study equation has shown advantages over most other proposed equations and the 
NKF-KDOQI recommend using this equation, rather than the Cockcroft-Gault 
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              &ĞŵĂůĞƐƌA?61.9 µmol/l    GFR = 166 x (sCr/61.9)-0.329 x (0.993)Age 





             
              DĂůĞƐƌA?79.6 µmol/l    GFR = 163 x (sCr/79.6)-0.411 x (0.993)Age 
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Abbreviations: MDRD, Modification of Diet in Renal Disease study equation; CKD-EPI, Chronic Kidney 
Disease Epidemiology Collaboration equation; GFR, glomerular filtration rate; Scr, serum creatinine. 
 
Table 2.1 
This table shows the MDRD study and CKD-EPI estimating formulae using gender, 
age, and ethnicity as variables. Age is represented in years. Both equations do not 
require weight or height variables but results are reported normalized to 1.73m
2
 
body surface area. The CKD-EPI equation uses a 2-slope spline to model the 
relationship between GFR and serum creatinine, age, sex and race. The CKD-EPI is 
reported to perform more accurately than the MDRD study equation at higher levels 




The MDRD was then suggested to universally substitute the Cockcroft-Gault method 
to determine drug dosing in patients with impaired renal function. The findings of 
several retrospective studies suggest that although the MDRD and Cockcroft-Gault 
equations correlate with measured GFR, the MDRD often overestimated creatinine 
clearance leading to potential errors in drug dosing (108). The studies reported that 
drug dosages determined by the two equations did not agree in 10-40% of cases. As 
the Cockcroft-Gault equation typically yields a more conservative estimate compared 
to the other estimating equations, there is a need for a dose adjustment more 
frequently. Until safety concerns are adequately addressed with other estimating 
equations, the Cockcroft-Gault equation is still recommended for drug dosing in 
impaired renal function. 
The MDRD study equation was developed in people with CKD with a mean 
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I-
iothalamate GFR of 39.8±21.2, and as such its major limitations are imprecision and 
systematic underestimation of measured GFR (bias) at higher levels (8). A further 
confounder to the inaccuracy of the earlier derived MDRD equation was the lack of 
standardised serum creatinine assays that existed prior to 2006, with resultant lack 
of comparability of equation performance. With the advent of international 
creatinine standardisation, the MDRD equation was re-expressed for use with such 
assays (109). The MDRD equation, however, is not recommended for use when the 
GFR is > 60ml/min/1.73m
2
 as estimates become progressively too low and have 
increased variability partly due to the poorer precision methods at lower versus 
higher creatinine concentrations.  
 
 
The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Equation 
 
Shortly after this, in 2009, the CKD-EPI equation was published, having been 
developed in a broader population and claiming to have superior bias compared to 
the MDRD equation at higher levels of GFR (110). It was developed and validated 
from a much larger cohort of 8,254 individuals compared to the MDRD study and 
included people with and without CKD and hence is more accurate at higher levels of 
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renal function. The CKD-EPI equation uses the same 4 variables as the MDRD 
equation but expresses the log serum creatinine modelled as a 2-slope linear spline 
with sex-specific knots at creatinine values of 62 µmol/l in females and 80 µmol/l in 
males (Table 2.1). This introduced a more complex equation and the limitations of 
using serum creatinine as a marker still apply. The CKD-EPI was derived from a 
population consisting of pre-dominantly young or middle aged people with an 
average GFR of 70 ml/min/1.73m
2
. The CKD-EPI equation produces higher GFR 
estimates particularly in those aged < 60 years of age. In the CKD-EPI validation 
study, the CKD-EPI equation had slightly better accuracy than the MDRD equation at 
GFR < 60 ml/min/1.73m
2
 but had good accuracy at GFR > 60 ml/min/1.73m
2
 making 
it suitable for reporting eGFRs in this range (9). 
 
Since the development of the CKD-EPI equation, several studies have evaluated the 
impact of using the CKD-EPI equation compared to the MDRD equation in various 
populations including transplant patients (111), patients undergoing nephrectomy 
(112-113), middle aged subjects without a history of cardiovascular disease (114) 
and non-institutionalised adult Australians (115). The CKD-EPI had a consistent 
performance across these study subgroups including race, gender, and varying body 
mass index. Overall these studies demonstrated that the CKD-EPI equation produced 
a more accurate estimate of GFR and a lower prevalence of CKD. The impact of using 
this equation for estimating GFR is it leads to the reclassification of CKD patients 
from stage 3a to stage 2 CKD. There have been recent proposals for the adoption of 
the CKD-EPI equation in place of the MDRD equation in the routine reporting of 
eGFR from serum creatinine measurements by laboratories worldwide. There is 
however, little known about the consequences of applying the CKD-EPI equation to 
older people. 
 
The MDRD and CKD-EPI equations have limitations. Both were developed in a cohort 
of african-americans and caucasians and do not take other ethnicities into account. 
Both the MDRD and CKD-EPI equations have also not been validated in older people 
and there is little evidence to support their accuracy in this population group. The 
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MDRD equation for GFR estimation was developed amongst 1628 CKD patients with 
a mean age of 50.6±12.7 years and an underrepresentation of elderly patients (8).  
In a large study (n=2095), a sub-analysis in patients >65 years old and with GFR <60 
demonstrated comparable performance of the MDRD equation to that amongst 
younger individuals (mean bias -1.0 ml/min/1.73 m
2
) (116). However, only 57 
subjects were aged A? ? ?ǇĞĂƌƐ. An evaluation of the MDRD equation in a pooled 
dataset of 5504 people found that the MDRD had a minimal negative bias in 
individuals aged over 65 years (n=586) compared to younger individuals but there 
were very few numbers of participants older than 80 years (n=23) (25). In the few 
studies of the MDRD performance in older people there have been inconsistencies in 
the direction of bias of the MDRD equation compared to the measured GFR either 
overestimating or underestimating GFR (117).  
 
Standards for Estimating Equations 
 
In 2002, the NKF-KDOQI published clinical practice guidelines that incorporated the 
evaluation of laboratory measurements for clinical assessment of kidney disease 
(10). They advised that serum creatinine alone should not be used for assessing the 
level of kidney function and that estimated of GFR is the best overall indicator of 
renal function. The MDRD and Cockcroft-Gault equations were recommended in 
estimating GFR in adults and the Swartz and Counahan-Barratt equations based on 
height and serum creatinine were recommended in children (118-119).  
 
The guidelines called for all clinical laboratories to routinely report an estimate of 
GFR using a predicting equation when reporting a serum creatinine measurement 
and that all laboratories should calibrate serum creatinine assays using an 
international standard. Since the standardisation of commercially available 
creatinine assays, a revision of the MDRD equation offers traceability to a reference 
method (120). This modified IDMS-traceable MDRD study equation is now generally 
used to routinely report eGFR when a serum creatinine is requested from 





The guidelines recommended that assessing the accuracy of a prediction equation to 
estimate GFR requires calculating bias, precision and accuracy.  
 Bias expresses the systematic deviation from the gold standard measure of 
GFR. If an estimating equation consistently overestimates or underestimates 
the gold standard measure it will yield a positively or negatively biased 
estimate respectively.  A negative bias indicates that the prediction equation 
underestimates GFR and a positive bias overestimates GFR compared to the 
reference GFR. Bias is defined as the median difference between the 
measured and estimated GFR. In some studies this is expressed as a 
percentage basis and in others it is expressed as ml/min/1.73 m
2
. 
 Precision expresses the variability or spread around the gold standard GFR 
result. Precision can be calculated by the R-square values or the interquartile 
range (IQR) for the differences.  
 Accuracy combines precision and bias. Achieving a high level of accuracy of a 
test would require both a low bias and a high precision. A useful measure of 
accuracy is the percentage of estimates falling within 30% (P30) or 50% (P50) 
above or below the measured GFR. This takes into account greater errors at 
higher values. 
 
The performance of the MDRD and CKD-EPI equations were assessed using these 
three measures in the two validation studies (31, 110). The NKF-KDOQI CKD 
guidelines also recommended that future studies should have at least 100 adults or 
50 children to overcome the unreliable estimates of accuracy from smaller sample 
studies. Another initiative recommended to clinical laboratories to improve the 
performance of estimated GFR calculations was after recalibration of serum 
creatinine measurements to an IDMS method, to set a total error goal for creatinine 
measurements to a maximum 10% error in eGFR. This interprets that laboratories 
need to aim for an analytical bias of < 5% and analytical imprecision of < 8% 
(including between laboratory calibration variability) at serum creatinine 




The current existing estimating equations provide a cost effective method of 
estimating GFR but their precision is limited. The NKF-KDOQI guidelines called for 
newer accurate methods of estimating GFR in terms of bias, precision, accuracy and 
practicality particularly in mild to moderate kidney disease. Future estimating 
measures would have to perform substantially better than the 12.1% median 
difference achieved by the MDRD Study equation in the validation study (31). They 
would need also to achieve P30 values in excess of 90%. To date, across a wide range 
of studies in different settings and using different reference techniques, this has 
rarely been achieved (108, 119). This is partly due to the small sample sizes used in 
many studies. Since accuracy from smaller studies can be unreliable, 
recommendations have been made to re-evaluate them in larger validation studies.  
 
In the MDRD validation study, the MDRD study equation had an overall bias of 
2.7ml/min/1.73 m
2
, a precision of 5.8% and a P30 value (accuracy) of 83%. When 
assessing the performance at GFR levels, the MDRD study equation had little bias for 
eGFR < 60 ml/min/1.73 m
2
, underestimated GFR for levels of eGFR between 60 and 
119 ml/min/1.73 m
2
 and overestimated GFR at eGFR levels > 120 ml/min/1.73 m
2
 
(31). In the CKD-EPI validation study, the CKD WEPI equation performance was 
compared to the MDRD study equation and was found to have less bias (2.5 versus 
5.5 ml/min/1.73 m
2
), improved precision (IQR of the differences 16.6 versus 18.3 
ml/min/1.73 m
2
) and greater accuracy (P30 values of 84.1% versus 80.6%) in the total 
dataset (9).  
 
Nevertheless the updated NICE CKD guidelines published in 2014 (57) recognised 
that inaccuracies of estimated GFR methods increased as true GFR increased and 
have recommended that the CKD-EPI creatinine equation be used to estimate GFR 










Generally studies have demonstrated advantages of the MDRD equation to other  
eGFR equations and its use has been endorsed, however, there remains a dearth of 
supportive evidence for its use in older people. Alternative markers of GFR have 
been proposed. Perhaps the most promising of these is serum cystatin C. Cystatin C 
is a low molecular weight protein which was introduced recently as a GFR estimate 
superior to creatinine. In particular, serum cystatin C is sensitive to detect 
mild GFR reduction between 60 and 90 ml/min/1.73 m
2
 (121).  However, no agreed 
reference method and no uniform calibration material exist for cystatin C yet and 
there are other limitations such as the effect of thyroid dysfunction, high 
glucocorticoid doses and potentially the presence of cardiovascular diseases on 
cystatin C levels. Cystatin C-based equations have been proposed to further improve 
GFR estimation, which seem to be superior to creatinine-based ones however there 
is again limited evaluation amongst older people.  
 
One study by Eriksen et al contradicted these results and demonstrated that cystatin 
C was not a better estimator of GFR than plasma creatinine in the general population 
(122). However, there is now abundant evidence that GFR estimates based on 
cystatin C are more powerful predictors of clinical outcomes than creatinine-based 
eGFR. These findings are strongest for predicting mortality and cardiovascular events 
and the advantage is greater in individuals with GFR > 45 ml/min/1.73m
2
 but without 
proteinuria (123). This group represented 3.6% of the US population and 41% of 
people estimated to have CKD based on creatinine-based eGFR and ACR alone. They 
indicate that use of cystatin C to estimate GFR in this population lead to a more 
accurate estimation of GFR and prediction for adverse outcomes. The 2014 CKD NICE 
guidelines (72) have incorporated cystatin C eGFR and recommend its use at initial 
diagnosis to confirm or rule out CKD in individuals with GFR 45-59 ml/min/1.73m
2
 




With an ageing population and increasingly complex polypharmacy, the accurate 
estimation of GFR and detection and management of renal impairment is clearly an 
important issue in older people. Currently, the MDRD equation is being applied to 
this population amongst whom limited evaluation has been undertaken and the 
relationship between age and eGFR is being extended beyond that in which it was 
established. Other estimating equations have been developed which claim to be 
more accurate in specific populations but all have their limitations and there is 
limited data in the elderly. There is a need for a large-scale study validating use of 




CKD Progression and the Interaction of CKD and  
      AKI 
 
3.1 CKD Progression 
 
Due to the controversies around the effect of ageing on GFR, there has been little 
consensus until recently on the definition of CKD progression. Definitions have 
varied from doubling of serum creatinine, increasing proteinuria and albuminuria, 
decline in GFR to commencement of RRT. Longitudinal studies following healthy 
kidney donors showed that there was a natural decline in GFR with age but no more 
than 2 ml/min/1.73m
2
 (124). Rate of decline in eGFR is now used and a decline in 
eGFR of > 5ml/min/1.73m
2
 in 1 year or > 10ml/min/1.73m
2
 over 5 years defines CKD 
progression. As discussed earlier, there is a significant biological variability in serum 
creatinine quoted up to 5% and this must be taken into account when assessing GFR 
and rate of decline. Small fluctuations in GFR are common and not necessarily 
indicative of CKD progression and interpretation of baseline and rate of decline can 
be difficult particularly with limited numbers of GFR measurements and a short 
duration of follow-up. KDIGO guidelines (101) suggest that a minimum of three eGFR 
levels are obtained within 90 days to identify progressive CKD but the patterns of 
CKD progression can vary significantly even within one individual according to 
development of co-morbid conditions and too frequent testing of renal function is 
often unnecessary and impractical.  
 
This definition of progressive CKD does not take cause of kidney disease into account 
and this can be of fundamental importance in predicting the outcome of CKD. 
A large number of studies have investigated the clinical characteristics that are 
thought to influence CKD progression. Proteinuria and poorly controlled 
hypertension have been consistently found to be independent predictors of 
progressive CKD (35-36). In hypertensive patients with diabetes and CKD stages 1-4, 
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treatment guidelines recommend the use of an ACEI or ARB in combination with a 
diuretic to achieve a target blood pressure < 130/80 mmHg (101). The UK 
Prospective Diabetes Study Group (UKPDS) demonstrated that tight diastolic blood 
pressure control in diabetics not only reduced progression in terms of albuminuria 
but also reduced rate of cardiovascular events and death (125). Other studies have 
also shown that renal function declines more rapidly as the mean arterial pressure 
increases (7). 
  
People with cardiovascular disease have been found to have a significantly increased 
risk of decline in GFR compared to those without (34, 126). Many other risk factors 
have been identified. The effect of smoking on renal function decline has been 
demonstrated in diabetic cohort studies and case-control studies with smokers 
having an increased odds ratio of a 20% decline in GFR compared to non-smokers 
(127-128). In cross-sectional studies, asian and black people with diabetes or 
hypertension had significantly higher rates of progression to ESRD compared to 
caucasians. In a US case series, african-caribbean people with neither diabetes nor 
hypertension at baseline were 3.7 times more likely to develop ESRD than caucasians 
(14). We know that NSAIDs reduce GFR and are associated with tubulo-interstitial 
inflammation and fibrosis and these medications are available without prescription. 
Studies have shown that even after one month of treatment with NSAIDs, there is a 
significant decline in creatinine clearance. Case-controlled studies have 
demonstrated there is a significant risk of progression to ESRD with chronic NSAID 
use (129). Other suggested risk factors for CKD progression include dyslipidaemia 
(48), persistent urinary outflow tract obstruction (130) and more recently AKI (131).  
 
3.2 Albuminuria and Proteinuria 
 
Proteinuria has long been recognised as an independent risk factor for CKD 
progression and is also an independent risk factor for cardiovascular mortality and 
morbidity (35). More recently urine ACR measurements have been recommended in 
preference to urine PCR as albumin measurements provide a more specific and 
sensitive measure of change in glomerular permeability than urinary protein levels 
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and there is substantial evidence linking increasing albuminuria to CKD outcomes.  
Proteinuria is used to define CKD stages 1 and 2 and has now been adopted in the 
classification of CKD staging not only as it is a marker of severity of disease but also 
as it is a powerful prognostic marker of disease progression and cardiovascular and 
all-cause mortality. Table 3.1 contains a summary of the key seminal studies 
investigating proteinuria and progression of CKD.  
 
One of the earliest trials that demonstrated proteinuria was an independent risk 
factor for disease progression was the MDRD study, which grouped patients into 
higher and lower baseline GFR, and assigned them to either normal or low blood 
pressure (BP) targets (7). They found that the patients with a higher baseline 
proteinuria level experienced a faster rate of GFR decline and benefited from tighter 
BP control. More recently, Hemmelgarn et al showed that patients with severe 
proteinuria but without an overtly abnormal GFR had worse clinical outcomes than 
those with moderately reduced GFR and no proteinuria (132). Data from the 
Irbesartan Diabetic Nephropathy Trial (IDNT) also confirmed that baseline 
proteinuria was an important risk factor for renal failure in patients with type 2 
diabetes and overt nephropathy (133). They demonstrated the cumulative incidence 
of ESRD was 7.7% for patients with < 1g/day proteinuria, 11.4% with 1-2 g/day 
proteinuria, 22.9% with 2-4 g/day proteinuria, 34.3% with 4-8 g/day proteinuria and 
64.9% for those with > 8g/day. Doubling of proteinuria was also associated with 
doubling of risk for renal end point. Albuminuria emerged as a more sensitive marker 
of glomerular damage and studies demonstrated significant evidence of its 
associations with poor outcomes. In the PREVEND cohort study, the decline in GFR 
was significantly higher in people with albuminuria compared to the general 
population (-7.2 vs -2.3ml/min/1.73m
2
, p<0.01) (134). Numerous studies have since 
identified that the severity of albuminuria is associated with adverse prognostic 
outcome irrespective of level of kidney function and underlying cause of CKD. 
 
The relevance of finding a reduced eGFR level on its own in the absence of 
proteinuria or co-morbid factors should be interpreted differently when assessing 
the likelihood of progressing to ESRD or requirement of renal replacement therapy in 
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ŽŶĞ ?Ɛlifetime. This requires a degree of confidence in the accuracy of the prediction 
equations we use in clinical practice to estimate GFR. CKD progression can progress 
however in the absence of proteinuria and several studies have demonstrated this 
particularly in patients with diabetic nephropathy or advanced CKD (135-136).  It is 
therefore important to monitor for proteinuria in assessing CKD progression but its 
presence does not clearly determine whether those patients will decline. 
 
The presence of proteinuria also affects outcomes other than disease progression 
and this has been found at all levels of GFR. Studies have demonstrated that 
outcomes in those without proteinuria and GFRs of 30-59 ml/min/1.73m
2
 are better 
than those with proteinuria and higher levels of GFR (137).   A recent meta-analysis 
showed that the presence of an ACR of just > 10mg/g is associated with an increase 
in all-cause and cardiovascular mortality (138).  
 
Studies began to focus on the renoprotective effect of angiotensin converting 
enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB). 
Interventional studies began to investigate whether there was an anti-proteinuric 
beneficial effect of these drugs independent to their anti-hypertensive effect. The 
Heart Outcomes Prevention Evaluation (HOPE) Study investigated the impact of ACEI 
therapy on cardiovascular risk in patients with diabetes and found that ramipril 
lowered cardiovascular end points by 25% and reduced albuminuria and CKD 
progression (139). In 2004, the Reduction in End-points in Noninsulin dependent 
diabetes with the Angiontensin II Antagonist Losartan (RENAAL) study demonstrated 
that baseline albuminuria was almost linearly related to renal outcome and was the 
strongest predictor of a doubling of creatinine or progression to ESRD (140). In the 
Ramipril Efficacy in Nephropathy (REIN) Study, ramipril treatment prevented ESRD 
when used for three to four years in patients with CKD and proteinuria and this 
effect was independent of the effect of blood pressure changes (137). The African 
American Study of Kidney Disease (AASK) was the first trial to demonstrate a 
renoprotective effect of ACEI in african-americans and found a 50% reduction in 
proteinuria at six months was associated with a 72% reduction in risk for ESRD at 5 
years in non-diabetic patients (141). 
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Table 3.1 Seminal Studies of Proteinuria and CKD Progression  
Study Cohort Outcome Measures Findings 
Peterson et al, 
MDRD (Modification 





N = 840 
Patients with CKD, no 
diabetes 
Normal mean arterial 
pressure (MAP) vs low 
BP goal and 
relationship with 
proteinuria 
GFR decline associated with 
higher proteinuria levels 
and those with higher 
proteinuria levels had 








N = 3577 
Patients with diabetes 
with 1 prior 
cardiovascular event or 






lowered risk of combined 
primary  outcome by 25% 
after adjustment for BP 
changes. 
Hemmelgarn et al,  
Alberta Kidney Disease 
Network, 2010 (124) 
Observational cohort 
study 
N = 1, 526 437 





and progression to 
ESRD and relationship 
with proteinuria 
Risk of outcomes and ESRD 
independently associated 
with higher proteinuria at 
given eGFR level 
PREVEND  (Prevention 












Albuminuria was a 
predictor of all-cause 
mortality 
RENAAL (Reduction in 
End-points in 
Noninsulin dependent 
diabetes with the 
Angiotenin II 
Antagonist Losartan) 





Patients with type 2 
diabetes with CKD 
Doubling of serum 
creatinine or ESRD 
Losartan reduced 
albuminuria by 25%. 
Baseline albuminuria was 
almost linearly related to 
renal outcome and the 
strongest risk predictor 
REIN (Renoprotective 





interventional study  
N = 1715 
Hypertensive patients 
with type 2 diabetes  




progression of nephropathy 
but sis not reduce mortality 
AASK (African America 






N = 1094 
Black patients with 
hypertensive CKD 
Doubling of serum 
creatinine, ESRD, all-
cause mortality 
Ramipril was better than 
other anti-hypertensive 
regimes in reducing 
progression of renal disease 
Abbreviations: N, number; BP, blood pressure; MAP, mean arterial pressure; ESRD, end-stage renal 
disease; CKD, chronic kidney disease 
 
Table 3.1 Table of the key observational and interventional studies that have 
demonstrated proteinuria is one of the strongest predictors of progression of CKD 
and associated with all-cause mortality and cardiovascular events. This association 
has been demonstrated in patients with and without diabetes and in different ethnic 
groups (7, 132, 134, 137, 139-141).
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In a meta-analysis of randomized controlled trials of patients with CKD stages 1 W3, 
several treatments involving ACEIs or ARBs reduced the risk of clinical outcomes, but 
the benefits appeared to be limited to specific CKD subgroups, some of which 
already had a clinical indication for the treatment studied (142). When compared to 
placebo, ACEIs and ARBs reduced the risk of ESRD overall, but this benefit appeared 
to be present only among patients with overt albuminuria, most of whom had 
diabetes and hypertension. In patients with CKD stages 1 W3 with only albuminuria or 
impaired eGFR, ACEIs did not reduce the risk for ESRD when compared with a 
placebo. ESRD was also not significantly reduced in patients with CKD stages 1 W3 
who did not have proteinuria. Meta-analyses of these studies also found that taking 
an ACEI or an ARB did not reduce the risk of mortality, except when an ACEI was 
used for patients with microalbuminuria and cardiovascular disease or diabetes and 
other cardiovascular risk factors (142). 
 
CKD guidelines suggest that patients with proteinuria, diabetes and hypertension 
may benefit from ACEI or ARB treatment and patients who have albuminuria and are 
at high risk for cardiovascular complications may benefit from ACEI treatment at 
adequate doses (70). In 2003, a randomised controlled trial of 336 patients with non-
diabetic renal disease (Combination treatment of ARB and ACEI in non-diabetic renal 
disease study (COOPERATE)) published data that dual blockade of the renin-
angiotensin system with an ACEI and ARB reduced the risk of primary end-points 
(143). This study had to be later withdrawn due to scientific misconduct. Since then a 
further study looking at renal outcomes with Telmisartan, Ramipril or both in people 
at high vascular risk (ONTARGET) data has argued against the benefit of dual RAS 
blockade and there now little use of combined ACEI and ARB therapy and there 
remains a distinct safety issue with regard to hyperkalaemia and elevated creatinine 
in dual use (144). More recently there have been concerns that use of ACEI and ARB 
in advanced CKD stages precipitates a more rapid decline to ESRD and we await data 
from the on-going STOP-ACE study which started recruiting in 2014. 
 
A graded relationship seems to exist between the severity of proteinuria or 
albuminuria and adverse health outcomes, including mortality, ESRD and 
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cardiovascular disease. The 2008 NICE CKD guideline defined significant albuminuria 
as an ACR of 30mg/mmol or higher, equivalent to a urine PCR of 50 mg/mmol or 
higher (53). The risk for adverse outcomes conferred by reduced GFR and increased 
albuminuria (or proteinuria) appears to be independent and multiplicative. 
 
 
3.3 The Relationship of AKI and CKD 
 
There is emerging evidence that there is a considerable overlap between the 
relationship between CKD, AKD and AKI (Figure 3.1). Both AKI and AKD can lead to 
CKD and CKD is a risk factor for AKI and AKD. 
 
In order to diagnose AKI there must be an increase in serum creatinine over a period 
of two days but this definition may not capture all episodes of acute injury to the 
kidneys hence a new clinical approach to categorising these patient according to 
functional and structural criteria was proposed by the Kidney Disease: Improving 
Global Outcomes (KDIGO) AKI Work Group (70). In the new KDIGO AKI guidelines, 
AKI is defined as a syndrome, which includes direct injury to the kidney as well as 
acute impairment of kidney function. They introduced the term Acute Kidney 
Diseases and Disorders (AKD) as AKI is one of a number of conditions that acutely 
affects the kidney structure and function. AKD encompasses AKI and any event 
where GFR falls <60 ml/min/1.73m
2
 ĨŽƌAM ?ŵŽŶƚŚƐŽƌďǇA? ? ?A?Žƌwhere serum 
creatinine rises by > 50% for < 3 months. No known kidney disease (NKD) was also 
defined as a category and indicates no functional or structural renal abnormality 






Figure 3.1  







Abbreviations: AKD, Acute Kidney Disease; AKI, Acute Kidney Injury; CKD, Chronic Kidney Disease 
 
Figure 3.1 
This model describes the likely considerable overlap between AKI, CKD and AKD. AKI 
is a subset of AKD. AKI and AKD can occur in patients with CKD. Adapted from Kidney 
Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for Acute 




Table 3.2 Definitions of Acute and Chronic Kidney Disorders 
 
 Functional Criteria 
 
Structural Criteria 
AKI Increase in sCr by 50% within 7d or 
Increase in sCr by 0.3 mg/dl within 2 
days or Oliguria 
 
No criteria 
CKD GFR < 60 for > 3 months Damage for > 3 months 
 
AKD AKI or GFR <60 for < 3 months or 
ĞĐƌĞĂƐĞŝŶ'&ZďǇA? ? ?A?Žƌ
increase in sCr by > 50% for < 3 
months 
Kidney damage for < 3 months 





Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease, AKD, acute kidney diseases and 
disorders; NKD, no known kidney disease; GFR, glomerular filtration rate; sCr, serum creatinine. 
 
Table 3.2  
This table describes the functional and structural criteria for the acute and chronic 
kidney disorders: AKI, CKD, AKD and NKD. It incorporates GFR, serum creatinine, 
urine output changes and structural abnormalities as criteria. This was adapted from 





Both AKI and CKD represent a reduction in kidney function and both disorders can 
lead to ESRD and are associated with increased mortality (145). Both conditions 
share similar risk factors and studies have shown that CKD is an established risk 
factor for developing AKI and hospitalised episodes of AKI have been associated with 
worsening of pre-existing CKD but the extent to which these two conditions are 
related is not clearly understood (146). Although AKI is potentially reversible, several 
studies have shown that non-recovery of AKI leads to ESRD and prolonged 
hospitalised episodes of AKI can often lead to progression of CKD. It has been 
suggested that AKI may the causative factor of how patients who have CKD of 
undetermined aetiology may develop it in the first place  W  ‘ĚĞŶŽǀŽ ?< ? 
 
 
CKD as a Risk Factor for AKI 
 
What makes the determination of the epidemiology of AKI and CKD and 
understanding of their relationship more difficult is the variation in definitions used 
and the different populations studied. In epidemiological studies of hospitalised AKI, 
CKD is found to be not only a risk factor but is a significant risk factor in the 
development of AKI (147-148). This seems to hold true when a correction is made for 
other confounding factors, such as the other co-morbidities associated with CKD. 
This has been consistently observed in the settings of AKI following radio-contrast 
administration, cardiac surgery and sepsis (149). Interestingly, some studies 
demonstrate lower in-hospital mortality rates in patients who develop AKI on a 
background of CKD compared with patients without background CKD (149). One 
explanation would be that patients with CKD require less of an insult to manifest as 
an AKI ĂŶĚĂƌĞŚĞŶĐĞ ‘ůĞƐƐƐŝĐŬ ?ĐŽŵƉĂƌĞĚƚŽƚŚŽƐĞǁŝƚŚŽƵƚ<. It has also been 
suggested that these results may be confounded by malnutrition and lower serum 
creatinine values from low muscle mass. Another explanation is many patients 
ǁŝƚŚŽƵƚ<ĞǆƉĞƌŝĞŶĐŝŶŐ ‘ĚŝƐĐƌĞƚĞ ?</ŝŶƚŚĞĐŽŵŵƵŶŝƚǇ ?ǁŚŝĐŚĚŽŶŽƚůĞĂĚƚŽĂ
hospital admission, will not be captured in most studies, and hence only the more 





The Effects of AKI on CKD Progression 
 
There is mounting evidence that AKI contributes significantly to both CKD, ESRD and 
importantly leads to the progression of CKD. In terms of outcome, observational 
studies demonstrate that development of AKI on a background of CKD, leads to ESRD 
at a greater rate than AKI without a background of CKD (79). The mechanisms are 
unclear but it is hypothesised that this occurs either through ischaemic injury or 
hyperfiltration following sclerosis and loss of functioning nephrons. The theory is 
that a diseased kidney with reduced function and functional reserve has increased 
susceptibility to further injury. This theory is supported by previous experimental 
studies that demonstrated a compromise in structural recovery and worsening 
tubule-interstitial fibrosis after ischaemic injury following unilateral nephrectomy 
(150). There is a large amount of work studying the relationship between reduced 
renal mass, hypertension and hyperfiltration of functioning remaining nephrons and 
progressive interstitial fibrosis. The theory suggests that in a person with CKD or low 
functioning renal mass, an initial insult leads to inflammation and cell injury then 
repair (Initiation). The cell damage is further extended by renal vascular endothelial 
injury and dysfunction (Extension) and endothelial repair is vital for cell recovery. 
This can lead to fibrosis and further cell damage in a continuous cycle (Maintenance) 
leading to progressive linear decline. (Figure 3.2) 
 
Okusa et al (151) using pathophysiological concepts from Sutton et al (150), 
suggested that following an episode of AKI, there appear to be four possible 
outcomes: (1) full recovery, (2) incomplete recovery resulting in CKD, (3) worsening 
of pre-existing CKD accelerating progression to ESRD, and (4) non-recovery of kidney 






Figure 3.2 The Clinical Natural History of Acute Kidney Injury 
 
Abbreviations: GFR, glomerular filtration rate; AKI, acute kidney injury; AKD, acute kidney 
diseases or disorders. 
 
Figure 3.2 
This model illustrates the pathophysiological processes involved of the effect AKI has 
on cellular damage (A) and renal function (B). In patients with pre-existing chronic 
kidney damage, the initial insult of AKI may lead to inflammation and repair 
(Initiation) resulting in fibrosis (Extension) then further damage which can lead to a 
never-ending cycle of progression (Maintenance) eventually leading to end-stage 
disease. Intervening early at the Initiation phase may prevent the development or 
progression of CKD whereas later interventions may only delay progression.  










Abbreviations: GFR, glomerular filtration rate; AKI, acute kidney injury; CKD, chronic kidney disease, 
RRT, renal replacement therapy; d, day, ESRD, end-stage renal disease. 
 
Figure 3.3 
This illustrates the time frame of the pathophysiological mechanisms in AKI. 
Initiation occurs when the initial insult leads to cellular damage and repair. This leads 
to extension of cellular damage through endothelial ischaemic injury (Extension) and 
repair with ongoing inflammation and fibrosis (Maintenance). The graph presents 
the different renal outcomes following the repair phase ranging from full recovery to 
ESRD.  






AKI in the Community 
 
Most studies have observed AKI presenting to or occurring during hospitalisation 
however little is known about the incidence and outcomes of patients who have an 
acutely elevated creatinine in the primary care setting where patients are not 
admitted to hospital. A large proportion of AKI occurs in the community and many 
episodes may remain undetected and there are concerns that this is a previously 
unrecognised health issue. Studies have shown that up to 60% of hospital-based AKI 
is community acquired (62). Minor episodes of AKI often occur in the community 
however there is often a delay in its identification and hence in establishing 
appropriate management of this condition. This may be partly due to the lack of 
awareness of the deleterious effects that minor episodes of AKI may contribute to. 
There is a huge paucity of data regarding the prevalence of community-based AKI as 
most AKI data relates to in-patient studies. 
 
Could it be that these episodes of AKI, which not associated with acute illness or 
hospital admission, are not appreciated to have occurred as renal function is either 
not tested or not properly assimilated? Are they contributing to the development 
and or progression of CKD? The eĨĨĞĐƚŽĨ ‘ĚŝƐĐƌĞƚĞ ?ĞƉŝƐŽĚĞƐŽĨ</ŝŶƚŚĞĐŽŵŵƵŶŝƚǇ 
on the progression of CKD is at present unknown, but may prove to be an important 
factor. The literature clearly documents that there are people with CKD who do not 
progress and never develop ESRD, but there are also people who do progress. In the 
populatŝŽŶǁŝƚŚƉƌŽŐƌĞƐƐŝǀĞ< ?ŝƚŵĂǇĂůƐŽďĞƚŚĂƚ ‘ĚŝƐĐƌĞƚĞ ?ĞƉŝƐŽĚĞƐŽĨ</ŝŶƚŚĞ
community contribute to this progression. 
 
These episodes of AKI in the community need to be captured. Even small isolated 
increases in serum creatinine have an associated increase in short-term morbidity 
and mortality and in longer-term outcomes including 1 year mortality in hospital-AKI. 
Does this risk extend to AKI managed by primary care? dŚĞƐĞ ‘ĚŝƐĐƌĞƚĞ ?Ğpisodes of 
AKI in the community remain to be well defined but may possibly relate to CKD 
progression therefore require further investigation as intervention in this group may 
have a significant beneficial effect on outcomes. 
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CKD is highly prevalent yet few people progress to ESRD suggesting that a large 
number of patients with CKD have stable disease. So how do they develop CKD 
initially and what other factors influence CKD progression aside from the recognised 
risk factors of proteinuria and cause of renal disease. There has been significant drive 
to improve recognition, prevention and management of AKI with emerging evidence 
of the strong overlap between CKD and AKI. Hospital-based AKI events have been 
suggested to contribute to CKD progression. Many episodes of AKI are not 
hospitalised but little is known about their outcomes on long term renal outcome. 
This study aims to study the patterns of progression and assess if these AKI events 




Validating Estimating GFR Equations in the Elderly 
 
With an ageing population and the increased prevalence of impaired renal function 
in the elderly, the number of people with CKD is predicted to rise dramatically in the 
near future. Diagnosis and screening for CKD in at risk populations requires a quick, 
accessible and relatively cheap test which will provide an accurate measure of renal 
function. Estimating equations based on serum creatinine have been developed to 
help provide the physician an easy way of calculating kidney function with a 
reasonable degree of accuracy. Current CKD guidelines recommend that diagnosis, 
staging and progression of CKD are based on these estimating GFR equations and in 
the adult population the MDRD study and CKD-EPI equation are widely applied (12).  
Epidemiological studies using the MDRD study equation suggests an overall non-
institutionalised population burden of all stages (1-5) of CKD of approximately 11%, 
but this figure increases in older people with > 30% of the population > 80 years old 
with an eGFR < 60 ml/min/1.73m
2
 (2).  The MDRD study equation however loses 
accuracy in selected subgroups such as those with GFR > 60 ml/min/m
2
, kidney 
transplant recipients and the elderly (31, 153).  
 
The MDRD and CKD-EPI study equations were developed in a population with a very 
small number of elderly patients. The MDRD study equation originally was validated 
in 1,085 patients with CKD with a mean age of 51 ± 13 years with 22% older than 65 
years (8). The authors subsequently developed the equation in a larger and more 
diverse population of 5,504 patients but again few people were older than 75 years 
(mean age 47 ± 15 years) and only 13% were > 65 years (31).  In the CKD-EPI 
development cohort less than 1% was over the age of 75 years. 
As both equations have not been validated in older people, there have been 




My first hypothesis is that the methods used for estimating GFR are inaccurate in 
assessing renal function in the elderly population who have the highest burden of 
CKD. I hypothesise that the estimating equations (the MDRD study equation and the 
CKD-EPI equation) underestimate GFR in older people particularly at higher GFR 
levels with consequential misdiagnosis and misclassification of CKD leading to a 
falsely high prevalence of CKD.  
 
4.2 Aim 
The aim of this first study is to assess if the estimating equations we use to assess 
renal function accurately reflect true GFR in older people. The MDRD study and CKD-
EPI equations have both been assessed in light of the recommendations by the 
recent NICE CKD guidelines. The aim of this study was to assess the accuracy of the 
MDRD Study and CKD-EPI equations for estimating GFR compared to an iohexol 
reference GFR measurement in an elderly population. The null hypothesis was that 
both the MDRD and CKD-EPI equations perform accurately in terms of bias, precision 
and accuracy when compared to the measured GFR in an elderly population. The 
ƉƌŝŵĂƌǇƌĞƐĞĂƌĐŚƋƵĞƐƚŝŽŶŝƐ ‘ĚŽŽůĚĞƌƉĂƚŝĞŶƚƐŝĚĞŶƚŝĨŝĞĚĂƐŚĂǀŝŶŐ<ƐƚĂŐĞ ?-5 





This study took place in East Kent, a semi-rural area of South East England, with an 
estimated population of just over half a million adults with a high prevalence of 
elderly caucasians. Subjects were recruited and took part in the study from January 
2008 to April 2011. Participants selected for this study were either patients known to 
the EKHUFT Department of Renal Medicine or residents of the local population. 
Advertisements were placed in the local outpatient departments and patients were 
approached in general nephrology clinics. The local population were recruited via a 
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variety of means including presentations at discussion groups in Age Concern 
centres, golf clubs, rotary clubs and residential care homes and through advertising 
the study via media briefings in hospital newsletters, local newspapers and radio 
stations. Overall 38% of participants were recruited via nephrology clinics and 62% 
via other methods. In line with the NKF-KDOQI 2002 guideline, a minimum of 100 
adults were required to validate the study (10). A power calculation was also 
performed to assess the minimum number of patients needed to demonstrate a 
difference between median eGFR and median iohexol GFR where the true difference 
was a minimum of 2.0 ml/min/1.73m
2
. I chose the conventional probabilities of < 
0.05 significance to avoid a type 1 error and a power level of 0.8 to avoid a type 2 
error and the number of patients required was 171 (154). 
All subjects gave informed consent and the study had full ethical approval (East Kent 
REC number: 07/Q1803/37).  
Cohort Description 
All elderly patients aged 74 years or over were invited to participate in the study. 
Initially the inclusion criteria specified recruits aged 80 years and over, however due 
to a high initial refusal rate, recruitment was extended to ŝŶĚŝǀŝĚƵĂůƐĂŐĞĚA? 74 years. 
Exclusion criteria included the following: 
 Any history of untoward reactions to iodinated contrast media or 
allergy to shellfish 
 Any known current active malignancy 
 A predicted life expectancy of less than 3 months 
 An inability to consent due to cognitive impairment or lack of capacity 
 Any recent episode of acute kidney injury within 3 months of 
recruitment 
 Patients receiving renal dialysis treatment 
 Recipient of a functioning or non-functioning renal transplant graft. 
 Hospitalisation at the time of the test 





All patients were either assessed in their residential homes or invited to attend the 
hospital in the morning having avoided any meat consumption on the day of the 
test. Demographic data including gender, age and race were recorded and co-
morbidity data and current prescription lists were documented with particular note 
of medications such as NSAIDs and those affecting the RAAS system and renal 
tubular secretion of creatinine.  Blood pressure (mmHg), weight (kg) and height (m) 
of the individuals were measured prior to the procedure for body surface area (BSA) 
and body mass index (BMI) calculations. 
Co-morbidity history was grouped into the following: hypertension, diabetes (type 1 
and 2), vascular disease and history of malignancy. Vascular disease was considered 
present if there was a history of myocardial infarction, angina, cardiac arrhythmia, 
valvular disease, congestive cardiac failure or a requirement for coronary 
intervention (e.g. angioplasty, coronary artery bypass grafting or pacemaker/cardiac 
defibrillator insertion), cerebrovascular disease or peripheral vascular disease. 
A morning random urine sample was collected for total protein, albumin and 
creatinine measurement. Presence of albuminuria was ĚĞĨŝŶĞĚĂƐĂŶZA? ? ?ŵŐ ?Ő
and heavy albuminuria was recorded as a urine ACR > 300mg/g. 
 
GFR Measurement 
The reference GFR was measured using the 4-sample iohexol plasma clearance 
method (118). Iohexol was selected as the reference GFR in this study and not 
iothalamate clearance which was used in the MDRD and CKD-EPI development 
dataset as iohexol clearance measurements are available for our local paediatric 
population. Estimated GFR was calculated from serum creatinine using the MDRD 
study equation and the CKD-EPI equation. 
 
Sampling 
Blood samples were taken at time zero for baseline serum creatinine measurement 
and for iohexol measurement prior to administration for detection of any 
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background signal from the time 0 sample. A 5 ml bolus of Omnipaque 240 (518 g/L 
iohexol corresponding to 240 g/L of iodine, GE Healthcare www.gelifesciences.com) 
was slowly injected intravenously into the antecubital vein at time zero followed by a 
10 ml normal saline flush either via a 21G cannula or butterfly needle. Patients were 
monitored for any haemodynamic instability or allergic symptoms.  A blood sample 
was taken at 5 minutes from the opposite infusion arm to confirm that the iohexol 
had been administered intravenously without extravasation of contrast. The time 0 
and 5 minute serum samples were also used to assess the analytical variability of the 
iohexol and creatinine assays. Extravasation of a large quantity of the administered 
contrast into subcutaneous tissues would affect the re-distribution phase of iohexol 
thus influencing measured iohexol values. Further blood samples were collected 
from the opposite arm to the infusion at approximately 120, 180 and 240 minutes 
after injection as recommended by the Brochner-Mortenson method as described in 
chapter 2 (106). Earlier samples were not taken due to the inaccuracies of 
interpreting iohexol levels during the redistribution phase. This protocol was 
ĂĚĂƉƚĞĚĨƌŽŵƚŚĞƉĂĞĚŝĂƚƌŝĐĐůŝŶŝĐĂůƉƌŽƚŽĐŽůƵƐĞĚďǇƚŚĞǀĞůŝŶĂ ?ƐŚŝůĚƌĞŶ,ŽƐƉŝƚĂů ?
'ƵǇƐĂŶĚ^ƚdŚŽŵĂƐ ?E,^&ŽƵŶĚĂƚŝŽŶdƌƵƐƚ ?Exact timing of the sampling in relation 
to the bolus injection was accurately recorded. Haemolysed serum samples were 
discarded and repeat samples were taken. 
All blood samples were collected in lithium heparin tubes, mixed, and then 
centrifuged at the end of each study at 3400 rpm for 4 min. Plasma was then 
extracted and stored at -80
o
C prior to analysis. All the above sampling, extraction 
and storage were carried out by myself. 
 
Analytical methods 
Creatinine and Iohexol Measurement 
All samples were transported on ice to the Wellchild Laboratories, London for the 
GFR measurement. Creatinine and iohexol measurements were performed by the 
accredited Wellchild clinical laboratory staff. Plasma creatinine and iohexol were 
measured simultaneously using a modified stable isotope dilution electrospray 
tandem mass spectrometric method reported for creatinine (155). The only 
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the stable isotope reagent, addition of the precursor/product ion pairs (m/z 
821.9/602.9, 826.9/607.9) for iohexol, and, because of the higher sensitivity of the 
Applied Biosystems SCIEX API5000 (Applied Biosystems, 
www.appliedbiosystems.com) instrument used, the precursor/product ion pairs (m/z 
114.0/85.9, 117.0/88.9) were utilised for creatinine. 
 
The NKF-KDOQI initiative to improve the performance of estimated GFR calculations 
was after recalibration of serum creatinine measurements to an IDMS method set a 
total error goal for creatinine measurements to a maximum 10% error in eGFR. The 
guidelines recommend that laboratories need to aim for an analytical bias of < 5% 
and analytical imprecision of < 8% at serum creatinine concentrations of > 88 µmol/l 
(10). 
In order to assess whether analytical assay impression influenced these results, 
between assay imprecision for the plasma iohexol assay was assessed at three 
concentrations, covering the iohexol range of 10-400 µmol/L using timed samples 
taken at 5 minutes and 240 minutes. Plasma iohexol assay imprecision was <7% 
overall. Accuracy of the plasma creatinine assay was assessed using National 
Institute of Standardisation and Technologies (NIST) Standardised Reference 
Materials (SRM) 967 I and II in each assay as per national creatinine standardisation 
protocol (102).  The accuracy of the serum creatinine assay was assessed in 31 
samples: using SRM 967 I, the mean serum creatinine was 65.4 µmol/ml, and using 
SRM 967 II, the mean serum creatinine was 332.4 µmol/ml. The between-assay 
imprecision for serum creatinine was 4.3% and 3.8% respectively which is within the 
recommended target set by national clinical laboratory recommendations (10). 
Iohexol GFR was calculated using a single compartment model,  
GFR (ml/min) = 0.693 x iohexol volume of distribution (L) x 1000/half-life of iohexol 
(min) 
The GFR (ml/min) was corrected for body surface area and the Brochner-Mortensen 
correction applied (106).  
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Urinary creatinine was measured using an enzymatic assay. Urinary albumin was 
measured using an immunoturbidimetric assays and albumin concentration was 
expressed relative to urinary creatinine concentration. Urinary assays were 
undertaken using an Abbott Architect analyser (Abbott Diagnostics Ltd, 
www.international.abbottdiagnostics.com) within 24 hr of sample collection.  
All urine analyses were undertaken by accredited laboratory scientists registered 
with the Health Professions Council at EKHUFT.  
 
Estimated GFR calculations 
GFR was estimated using the simplified isotope dilution mass-spectrometric (ID-MS) 
traceable version of the MDRD study equation and the CKD-EPI equations. The two 
estimating equation formulae are shown in Table 2.1. 
 
Estimating Equation Performance Measures 
 
Iohexol GFR was accepted as the reference measure of GFR against which estimated 
GFR was compared. Performance of both the MDRD and CKD-EPI equations were 
assessed.  Scatter plots comparing estimated and measured GFR were drawn for 
both estimating equations. 
 
The KDOQI clinical practice guidelines for CKD recommend that when evaluating the 
accuracy of an estimating equation, one should consider bias, precision and accuracy 
(10). 
Bias was measured as the median difference subtracting the measured GFR from the 
estimated GFR with positive values indicating higher estimated GFR than measured 
GFR (overestimation).  
Precision was expressed as the interquartile range (IQR) for the differences.  
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Accuracy of the equations was expressed by the percentage of estimates within 30% 
above or below the measured GFR (P30) and this has commonly been used as the 
benchmark for evaluation of estimating GFR equations in clinical practice.  
 
Measured GFR and estimated GFR were compared for each patient graphically by 
plotting iohexol GFR and the difference (estimated GFR minus measured GFR) 
against estimated GFR (Difference Plots). These graphs depict the bias and variability 
of the estimating equations. 
 
Secondary analysis was performed comparing individuals with GFR of <  ? ?ĂŶĚA? ? ?
ml/min/1.73 m
2





Bias precision and accuracy were measured to determine the performance of each 
equation. Measured GFR and estimated GFR datasets were checked to see if they 
were normally distributed using the Shapiro-Wilk test. Both were found to be not 
normally distributed (p<0.001, Shapiro-Wilk test). All data was therefore log 
transformed and non-parametric statistics were used throughout.  
 
The statistical tests performed in this study were similar to the analytical methods 
originally used in the MDRD and CKD-EPI study design to ensure comparable results. 
Bootstrapping methods were used to calculate confidence intervals for bias and 
accuracy and again were employed in the original MDRD and CKD-EPI studies (156). 
Bootstrapping enables more accurate estimates of the population distribution by 
using the information based on a number of re-samples from the original sample. 
The 95% confidence intervals were calculated using 2000 bootstraps i.e. the sample 
results were re-analysed with 2000 randomly selected replacements of samples to 
give a more accurate representation of the cohort studied. 
 
The Wilcoxon test is a nonparametric test that compares two paired groups and was 
used to compare the bias of each of the MDRD and CKD-EPI estimated GFR against 
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measured GFR as in the original MDRD and CKD-EPI studies (8, 9). A p value of < 0.05 
was considered statistically significant. 
 
dŚĞDĐEĞŵĂƌ ?ƐŚŝ-squared test is a nonparametric test used to assess the 
significance of the difference between 2 correlated proportions which are based on 
ƚŚĞƐĂŵĞƐĂŵƉůĞŽĨƐƵďũĞĐƚƐ ?dŚĞDĐŶĞŵĂƌ ?ƐƚĞƐƚ was used to compare P30 values of 
the MDRD and CKD-EPI equations in comparison and was used in the CKD-EPI study 
when comparing performance against the MDRD study equation. A P value of <0.05 
was considered statistically significant. 
 
Percentage misclassification around the GFR threshold of 60 ml/min/1.73 m
2
 was 
also assessed for each equation and percentage proportions were compared. 
Statistical analyses were not performed on the misclassification errors. 





Software Ltd, www.analyse-it.com) and Stata version 12.0 (StataCorp 






A total of 398 subjects participated in the study. Initially 425 subjects volunteered 
however 26 individuals subsequently withdrew for reasons including inter-current 
illness at the time of the scheduled test, following discussion with family members 
and inability to provide alternative care arrangements for their dependents. One 
study participant withdrew from the study after suffering a vasovagal episode on 
initial cannulation and it was subsequently discovered he had haemophobia. Three  
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Abbreviations: n, number. 
 
Figure 4.1 
Flow chart demonstrating the selection process of the study. Of a total 425 patients 
who initially volunteered, 26 withdrew and of the 398 subjects completing the study, 
3 were excluded due to being of african-caribbean ethnicity and 1 was an amputee. 







Total eligible subjects recruited to 
study 
n = 425 
Total subjects completing study 
n= 398 
Subjects declined to 
participate/withdrew 
n = 26 
3 Afro-Caribbeans  and  
1 amputee excluded 
 n = 4 
 
Total subjects included in analysis 
n = 394 
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individuals of african-caribbean ethnicity completed the study but were excluded 
from the final analyses. These exclusions were made after the study was completed 
on the basis that, as a subgroup they were too small to provide meaningful data as 
we know that the estimating equations vary significantly in african-caribbeans. One 
further subject was excluded as they were an amputee on the basis that the 
difference in total body muscle mass may skew GFR calculation. The final study 
cohort therefore consisted of 394 caucasian individuals and the study selection 
process is illustrated in Figure 4.1. Ten individuals lived in supported accommodation 
and completed the study at their residential care homes and the remaining 
participants were free-living and attended the hospital. 
There were no reported adverse or allergic effects from the iohexol administration 
and no cases had to be excluded due to extravasation of iohexol. There was one 
recorded case of death in the study cohort 3 months subsequent to the test but the 
participant died from an unrelated cause (the cause of death was exacerbation of 




The characteristics of the study patients are summarised in Table 4.1. The median 
age of the study group was 80 years (range 74-97 years). There were of 193 subjects 
aged less than 80 years and 201 subjects aged 80 years or over of which 18 were 
over 90 years.  There were similar numbers of males and female with a male to 
ĨĞŵĂůĞƌĂƚŝŽŽĨ ? ?A?ƚŽ ? ?A?ǁŝƚŚĂƐŝŵŝůĂƌƌĞƉƌĞƐĞŶƚĂƚŝŽŶŝŶƚŚĞAM ? ?ĂŶĚA? ? ?ǇĞĂƌ
subgroups.  
 
The median body mass index of the cohort population was 26.1 kg/m
2 
(range 13.7 - 
47.6 kg/m
2
). Median body surface area was 1.87 m
2
 (range 1.24  W 2.59 m2). Height, 
ǁĞŝŐŚƚ ?D/ĂŶĚ^ǁĞƌĞƐŝŵŝůĂƌŝŶƚŚĞAM ? ?ĂŶĚA? ? ?ǇĞĂƌƐƵď-groups. 
Of the 374 (95%) with documented blood pressure measurements, the median BP 
was 140/74 mmHg (range 42-115 mmHg diastolic pressure and 76-203mmHg systolic 
pressure) and acceptable in this age group. Prescription data reflected the high 
incidence of complex poly-pharmacy typically associated with the elderly population 
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predominantly treating hypertension and vascular disease and is illustrated in Figure 
4.2. A large proportion of the study population were on regular prescription 
medications known to reduce GFR: renin-angiotensin system blockers (39%), 
diuretics (37%) and non-steroidal anti-inflammatory drugs (9%). 
 
There was a high prevalence of co-morbidities as expected in this population; (Figure 
4.3) 55% had hypertension, 44% had vascular disease (including cerebrovascular 
disease, peripheral vascular disease and ischaemic heart disease) and 19% had 
diabetes.  A total of 13% had survived and recovered from a previous episode of 
malignancy.  
 
Albuminuria data was available in 368 subjects due to failure to obtain clean catch 
urinary samples in 26 individuals (Table 4.1). There was a high prevalence of 
ĂůďƵŵŝŶƵƌŝĂǁŝƚŚ ? ?A?ŽĨƚŚĞƐƚƵĚǇĐŽŚŽƌƚǁŝƚŚĂƵƌŝŶĞZA? ? ?ŵŐ ?ŐĂŶĚ ?A?ǁŝƚŚĂ
urine ACR > 300mg/g. There was a higher prevalence of significant albuminuria (ACR 










Table 4.1 Characteristics of the Entire Study Population Subdivided by Age <80 
Years or A? 80 Years 
 
 Entire cohort <80 y >80 y 
N 394 193 201 
Median age, years (range) 80 (74-97) - - 
   74-79, n  (%) 193 (49)  - - 
   80-84, n (%) 132 (34)  - - 
   85-89, n  (%) 51 (13)  - - 




Male, n (%) 189 (48) 90 (47) 99 (49) 
 
Median height, m (range) 1.67 (1.24 W1.94)           1.67 (1.43 W1.94) 1.67 (1.24 W1.85) 
Median weight, kg (range) 74 (32-126)  78 (46 W126) 71 (32 W109) 
Median body surface area, m
2
 (range) 1.87 (1.14 W2.59)           1.92 (1.35 W2.59) 1.82 (1.14-2.38) 
Median body mass index, kg/m
2




Median systolic blood pressure, mm Hg 
(range) 
140 (78-203), n=374 140 (95-203), n=187 141 (78-198), n=187 
a
Median diastolic blood pressure, mm 
Hg (range) 
74 (42-115), n=374 
 
75 (50-115), n=187 
 




Albuminuria data available, n (%) 
 
   hƌŝŶĞZA?30 mg/g 














Abbreviations: n, number; y, year; ACR, albumin creatinine ratio 
 
a
Blood pressure data available for 374 (187 individuals <80 years and 187 A?80 years). 
b




WĂƚŝĞŶƚĚĞŵŽŐƌĂƉŚŝĐƐŽĨƚŽƚĂůƐƚƵĚǇĐŽŚŽƌƚĂŶĚĚŝǀŝĚĞĚďǇĂŐĞAM ? ?ĂŶĚA? ? ?ǇĞĂƌƐ ? 
The median age was 80 years with an age range between 74-97 years. There was an 
equal distribution of gender among the subgroups. Although the median body 
surface of the population was 1.87 m
2
 there was a wide range in body surface area 
between 1.14  W 2.59 m2 and this was observed in the 2 age subgroups. Significant 
albuminuria  ?ZA? ? ?ŵŐ ?Ő ? was present in 38% of patients overall. There were no 




Figure 4.2 Prescription Patterns of the Entire Cohort Subdivided by Age < 80 Years 




Abbreviations: n, number; RAS, Renin angiotensin system; NSAIDs, Non-steroidal anti-inflammatory 
drug. 
Figure 4.2  
This bar chart demonstrates the percentage proportion of study patients on 
particular prescription medicines. This illustrates the typical prescription patterns 
seen in elderly patients with 39% of the study cohort on RAS blockers, 37% on 
diuretics and 9% prescribed NSAIDs. Prescription patterns were similar in subgroups 
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Figure 4.3 Prevalence of Co-morbidities of the Entire Cohort Subdivided by Age < 





Abbreviations: n, number 
 
Figure 4.3 
This bar chart demonstrates the percentage proportion of study patients with 
certain co-morbidities and reflects the high co-morbidity burden of these elderly 
patients. Vascular disease was considered if there was a history of myocardial 
infarction, angina, arrhythmia, valvular disease, congestive cardiac failure, 
requirement for coronary intervention (angioplasty, coronary artery bypass graft, or 
pacemaker), or cerebrovascular or peripheral vascular disease. Co-morbid conditions 












< 80 years 






Level of Renal Function 
 
Stratification of the cohort by level of renal function was based on the iohexol GFR 
results. The median measured GFR of the total cohort was 53.4ml/min/1.73 m
2 
however the range of measured GFRs observed was 7.2 - 100.9ml/min/1.73 m
2 
representing a variable spread of level of renal function. Median measured GFR was 
ƐŝŐŶŝĨŝĐĂŶƚůǇůŽǁĞƌŝŶƚŚĞA? ? ?ǇĞĂƌŐƌŽƵƉwith a median GFR of 46.9 ml/min/1.73 m2 





< 80 year group.  
 
Table 4.2 shows subjects split between GFR categories.  A wide range of GFRs was 
ĚĞƐŝƌĞĚƚŽĞƐƚĂďůŝƐŚĂŶĂĐĐƵƌĂƚĞĂƐƐĞƐƐŵĞŶƚŽĨƚŚĞĞƐƚŝŵĂƚŝŶŐĞƋƵĂƚŝŽŶƐ ?ŽǀĞƌĂůů
performances across a range of kidney function. Of the total study cohort, 40% had a 
GFR > 60ml/min/1.73m
2
, 43% had a GFR between 30-60 ml/min/1.73m
2
 (Stage 3a 
and 3b CKD) and 16% had a GFR below 30 ml/min/1.73m
2
 (Stage 4-5 CKD). Only 1.5% 
had a GFR > 90 ml/min/1.73 m
2
. There was almost double the proportion of patients 
in with CKD stage 3b-5 (i.e. GFR < 45 ml/min/1.73m
2
) observed in the A? ? ?ǇĞĂƌ
subgroup compared to those < 80 years of age. 
 
Performance of Estimating Equations 
 
Performance of both the MDRD and CKD-EPI equations were assessed compared to 
the measured (iohexol) GFR using bias (mean difference between estimated and 
measured GFR), precision (IQR of the difference) and accuracy (percentage of 
estimates within 30% of measured GFR, P30).  
 
A higher median estimated GFR was observed using the MDRD study and CKD-EPI 
estimating equations compared to measure GFR and this was also seen in both age 
subgroups. The median MDRD eGFR was 57.6 ml/min/1.73 m
2
 (range 13.3-156 
ml/min/1.73 m
2
) and median CKD-EPI eGFR was 57 ml/min/1.73 m
2
 (range 12-98.2 
ml/min/1.73 m
2
) compared to a median measured GFR of 53.4 ml/min/1.73 m
2
 
(range 7.2-100.9 ml/min/1.73 m
2
). A wide range of estimated GFRs was observed 
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with a notably wider range using the MDRD study equation compared to the CKD-EPI 





 using CKD-EPI equation and a measured GFR of 100.9 
ml/min/1.73m
2
hence potentiating increased inaccuracy of the results. 
 
Scatter plots of the two estimating equations against measured GFR are shown in 
Figure 4.4. These graphs visually represent the variability of estimated GFR to 
measured GFR when using both estimating equations to the identity line which are 
more notable in the MDRD equation at higher levels of GFR. Three particular outliers 
in the MDRD graph stand out which are not observed in the CKD-EPI graph 
supporting the evidence of better performance of the CKD-EPI equation at higher 
GFR when compared to the MDRD study equation. The CKD-EPI scatter plot 








Table 4.2 Measured and Estimated GFR of Entire Study Population ^ƵďĚŝǀŝĚĞĚďǇŐĞA? ? ?ĂŶĚA? ? ?
Years 
                                                                                  Entire cohort            <80y                   
    A? ? ?Ǉ 








 (range)                          53.4 (7.2  W 100.9)     60.6 (7.2  W 96.3)     46.9 (15.0  W 100.9) 
Measured iohexol GFR  
by GFR category, n (%) 
 
A? ? ?                                                                         64 (16.2)                   22 (11.4)                42 (20.9) 
30-44                                                                       79 (20.1)                   27 (14.0)                52 (25.9) 
45-59                                                                       91 (23.1)                   46 (23.8)                45 (22.4) 
60-89                                                                       154 (39.1)                 95 (49.2)                59 (29.4) 




                                   57.6 (13.3  W 156.0)    62.0 (16.0  W 129.8)    52.3 (13.3  W 156.0) 




                                57.0 (12.0  W 98.2)      63.1 (14.9  W 94.4)      50.3 (12.0  W 98.2) 
(range) 
 
Abbreviations: GFR, glomerular filtration rate; eGFR, estimated glomerular filtration rate; n, number; 
y, year; MDRD, Modification of Diet in Renal Disease study equation; CKD-EPI, Chronic Kidney Disease 
Epidemiology Collaboration equation. 
a
Serum creatinine expressed in µmol/l 
b
 GFR expressed in ml/min/1.73m
2 
Table 4.2 
Measured and estimated GFR results of the study population. Measured GFR was 
determined by the reference iohexol method and eGFR was estimated using the MDRD 
study and CKD-EPI equations. Values for the continuous variables expressed as the median 
value with the ranges of values shown in brackets. Values for categorical values are 
expressed as a number with the percentage of the total study population shown in brackets. 
Median measured and estimated GFR results are shown and the proportion of patients in 
ĞĂĐŚ'&ZƌĂŶŐĞŝƐƐŚŽǁŶ ?dŚĞƌĞǁĂƐĂƐƵďƐƚĂŶƚŝĂůůǇůŽǁĞƌŵĞĚŝĂŶ'&ZŝŶƚŚĞA? ? ?ǇĞĂƌ
subgroup with a median measured GFR of 46.9 ml/min/1.73 m
2
 compared to 60.6 
ml/min/1.73m
2
 in the <80 year subgroup. A wide range of GFRs was observed however in 
both subgroups representing a variable spread between GFR categories. There were a higher 
proportion of patients with CKD stages 3b-5 in the older subgroup. A higher median 
estimated GFR is observed using the MDRD study and CKD-EPI estimating equations 





Figure 4.4 Scatter Plots Examining the Correlation Between Estimating Equations 
and Measured GFR 
  
 
Abbreviations: MDRD, Modification of Diet in Renal Disease study equation; CKD-EPI, Chronic Kidney 




Scatter plots of the estimated GFR (ml/min/1.73 m
2
) plotted on the y axis versus the 
measured Iohexol GFR plotted on the x axis. Graph a represents the performance of 
the MDRD study equation and graph b represents the CKD-EPI estimating equation. 
An identity line of best fit helps to depict the increased variability of the MDRD study 
equation when compared to the CKD-EPI equation particularly at higher GFR levels 
with 3 significantly overestimated outliers observed in the MDRD study equation 














The performances of the MDRD Study and CKD-EPI equations overall are 
summarised in Table 4.3. The median differences between estimated and measured 
GFR were calculated using the two equations. The minimum difference of the MDRD 
study equation was 0 ml/min/1.73m
2
 and maximum value was 73.8 ml/min/1.73m
2
. 
The minimum difference of the CKD-EPI equation was 0 ml/min/1.73m
2
 and 





When assessing bias, both the MDRD and CKD-EPI equations showed positive bias 
compared to the reference test. The MDRD study equation had an overall positive 
bias of 3.5 (95% CI 1.9-4.8) and at GFR < 60 ml/min/1.73m
2
 the bias was lower at 2.0 
at '&ZA? 60 ml/min/1.73m2 the bias increased to 5.5. The CKD-EPI equation across 
the whole study population had a smaller positive bias of 1.7 (95% CI 0.3-3.2) with a 
lower bias in GFR < 60 ml/min/1.73m
2
 (0.6) and a positive bias of 4.3 in GFR > 60 
ml/min/1.73m
2
. Using the Wilcoxon paired t-test to compare measured versus 
estimated GFR, bias achieved statistical significance overall and in GFR < 60 
ml/min/1.73m
2 ĂŶĚŝŶ'&ZA? ? ?ŵů/min/1.73m2 subgroups (p < 0.05). In individuals 
with '&ZA? ? ?ŵů/min/1.73m2, bias was higher in both the MDRD and CKD-EPI 




Precision was assessed as the IQR of the difference of measured GFR from estimated 
GFR. Precision of the MDRD and CKD-EPI equations was similarly poor with an IQR of 
13.7 and 13.1 respectively across the study group. Comparatively, the CKD-EPI 
equation had better precision Ăƚ'&ZA? ? ?ŵů/min/1.73m2 but overall both equations 
performed similarly and demonstrated that precision appears to decline at higher 
levels of renal function. 
 
Accuracy 
The overall P30 of the MDRD equation was 81% and it performed ďĞƚƚĞƌĂƚ'&ZA? ? ?
ml/min/1.73m
2





. The CKD-EPI equation had a P30 of 83% and again accuracy was 
ďĞƚƚĞƌŝŶ'&ZA? ? ?ŵů ?ŵŝŶ ? ? ? ? ?ŵ2 with a P30 of 93% compared to 76% in GFR < 60 
ml/min/1.73m
2
. The CKD-EPI equation appeared to be more accurate than the 
MDRD equation in all subjects however statistical significance was only achieved in 
ƚŚŽƐĞǁŝƚŚ'&ZA? ? ?ŵů ?ŵŝŶ ? ? ? ? ?ŵ2. No equation achieved a P30 of 90% or greater in 





Table 4.3 Performance of the MDRD and CKD-EPI Equations Compared to 
Measured GFR, Stratified by GFR <  ? ?ŽƌA? 60 ml/min/1.73 m2 
  GFR (ml/min/1.73 m
2
) 
All participants Overall (n=394) <60 (n=234) A? ? ? ?ŶA? ? ? ? ? 
 
Bias (estimated minus measured GFR), median difference (95% CI) 
 
MDRD 3.5 (1.9 to 4.8)* 
 
2.0 (0.8 to 3.9)* 
 




1.7 (0.3 to 3.2)* 
 
0.6 (-0.7 to 2.3)* 
 
4.3 (1.2 to 6.2)* 
 
 






13.7 (11.4, 16.0)  {0, 73.8} 
 
11.4 (9.5, 13.3) {0, 50.5} 
 




13.1 (11.7, 14.6)  {0, 39.6} 
 
 
11.7 (9.8, 13.6) {0, 34.6} 
 
 
15.8 (13.0, 18.7)  {0.1, 39.6} 
 
 
Accuracy, percentage of estimates within 30% of measured GFR (P30) (95% CI) 
 
MDRD 81 (77, 85) 
 
78 (72, 83) 
 
86 (79, 91)* 
 
CKD-EPI 83 (79, 87) 
 
76 (70, 81) 
 
93 (88, 97)* 
 
Abbreviations: n, number; CI, confidence interval; GFR, glomerular filtration rate; IQR, interquartile 
range; MDRD, Modification of Diet in Renal Disease study equation; CKD-EPI, Chronic Kidney Disease 
Epidemiology Collaboration equation. 
*Indicates reached statistical significance (p < 0.05) 
 
Table 4.3 
Results are shown of the MDRD and CKD-EPI eGFR in terms of bias, precision and accuracy 
(percentage of estimates within 30% of the measured GFR (P30)) of the total cohort and split 
by subgroups GFR <  ? ?ŽƌA? 60 ml/min/1.73 m2. Bias was calculated as the median difference 
of the estimated minus the measured GFR.  The Wilcoxon matched-pairs signed rank test 
was used to compare the bias of each of the MDRD and CKD-EPI GFR estimates against 
measured GFR. Both equations demonstrated a statistically significant positive bias 
overestimating GFR with a more positive bias using the MDRD study equation and this bias 
increased at GFR A? ? ? ml/min/1.73 m2. Precision was calculated as the IQR of the median 
differences. Precision was similar in both equations overall but declined at GFR A? ? ? 
ml/min/1.73 m
2
.  The McNemar test was used to compare P30 values of the MDRD and CKD-
EPI equation GFR estimates. The CKD-EPI equation was only statistically better in terms of 
accuracy compared to the MDRD study equation at GFR A? ? ? ml/min/1.73 m2 and was the 
only subgroup to achieve a P30 of > 90%.
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WĞƌĨŽƌŵĂŶĐĞŽĨƚŚĞĞƐƚŝŵĂƚŝŶŐĞƋƵĂƚŝŽŶƐŝŶƚŚĞAM ? ?ĂŶĚA? ? ?ǇĞĂƌƐŽf age and the 
GFR < 60 ml/min/1.73 m
2
 ĂŶĚA? ? ?ŵů/min/1.73 m2 subgroups are presented in 
Tables 4.4 and 4.5 respectively. 
 
In participants < 80 years old, the MDRD had a positive bias of 3.0 and the CKD-EPI 
had a positive bias of 3.1. The over estimation of both equations was more 
ƉƌŽŶŽƵŶĐĞĚŝŶƚŚŽƐĞĂŐĞĚA? ? ?ǇĞĂƌƐ and the CKD-EPI equation performed slightly 
better than the MDRD equation. The CKD-EPI equation was found to be unbiased in 
people with a GFR < 60 ml/min/1.73m
2
 A? ? ?ǇĞĂƌƐ. Again the bias observed was 
ǁŽƌƐĞĂƚ'&ZA? ? ?ŵů/min/1.73m2 for both equations. Similar trends in precision of 
the estimating equations were seen whether individuals were < 80 or A?80 years of 
ĂŐĞǁŝƚŚůĞƐƐƉƌĞĐŝƐŝŽŶĂƚ'&ZA? ? ?ŵů/min/1.73m2.  
 
The P30 of the MDRD study equation was 81% in individuals aged <80 years and 78% 
in aged A? ? ?ǇĞĂƌƐŽůĚ ?dŚĞ<-EPI P30 values were 83% in ďŽƚŚƚŚĞAM ? ?ǇĞĂƌĂŶĚA?
80 year subgroups. The superiority of the CKD-EPI equation compared to the MDRD 
equation reached statistical significance only in the very elderly with a '&ZA? ? ?
ml/min/1.73m
2
 with 97% of all estimates falling within 30% of measured GFR ŝŶƚŚĞA?
80 year subgroup.   
 
Amongst males, the MDRD and CKD-EPI equations were unbiased; male MDRD bias 
was 1.6 (95% CI 0.0 to 3.9, P=0.07) and male CKD-EPI bias was 0.1 (95% CI -1.9 to 
1.1), P=0.9).  Amongst females the MDRD (4.8 (95% CI 3.0 to 6.6), P<0.001) and CKD-
EPI (4.3 (95% CI 1.8 to 5.9) P<0.001) equations both overestimated measured GFR 
with a significantly positive bias. 
   
Figure 4.5 shows the difference plots of the measured against estimated GFR for 
both estimating equations. In the MDRD graph, one observes 1 extreme outlier and 
we re-analysed data to see what effect this outlier would have on overall bias. 
Excluding this outlier, the MDRD bias reduced from 3.5 to 2.6 but it remained 




Table 4.4 Performance of the MDRD and CKD-EPI Equations Compared to 






Overall (n=193) <60 (n=95) >60 (n=98) 
 
Bias, median difference (95% CI) 
 
MDRD 3.0 (0.8 to 5.1)* 
 
2.1 (-0.9 to 5.0)* 
 
4.6 (0.8 to 7.2)* 
 
CKD-EPI 3.1 (0.3 to 4.9)* 
 
1.2 (-1.5 to 4.8)* 
 
3.6 (0.3 to 6.6)* 
 




MDRD 13.3 (10.4, 16.2)  {0, 50.5} 11.9 (8.0, 15.7) {0, 50.5} 15.7 (10.9, 20.5)  {0.2, 44.3} 
 
CKD-EPI 13.0 (11.0, 15.0) {0.1, 39.6} 12.8 (8.9, 16.7) {0, 28.8} 
 
13.2 (9.9, 16.5) {0.2, 39.6} 
 
Accuracy, percentage of estimates within 30% of measured GFR (P30) (95% CI) 
 
MDRD 84 (78, 89) 
 
79 (69, 87) 
 





83 (77, 88) 
 
 
75 (65, 83) 
 
 
91 (83, 96) 
 
Abbreviations: n, number; CI, confidence interval; GFR, glomerular filtration rate; IQR, interquartile 
range; MDRD, Modification of Diet in Renal Disease study equation; CKD-EPI, Chronic Kidney Disease 
Epidemiology Collaboration equation; IQR, interquartile range. 
*Indicates reached statistical significance (p < 0.05) 
 
Table 4.4 
Results are shown of the MDRD and CKD-EPI eGFR in terms of bias, precision and accuracy 
(percentage of estimates within 30% of the measured GFR) of the total cohort and split by 
ƐƵďŐƌŽƵƉƐ'&ZAM ? ?ŽƌA? ? ? ml/min/1.73 m2 in subjects < 80 years. Bias was calculated as the 
median difference of the estimated minus the measured GFR.  The Wilcoxon matched-pairs 
signed rank test was used to compare the bias of each of the MDRD and CKD-EPI GFR 
estimates against measured GFR. Both equations demonstrated a statistically significant 
positive bias overestimating GFR with a more positive bias using the MDRD study equation 
and this bias increased at GFR A? ? ? ml/min/1.73 m2. Precision was calculated as the IQR of 
the median differences. Precision was similar in both equations overall but declined at GFR A?
60 ml/min/1.73 m
2
.  The McNemar test was used to compare P30 values of the MDRD and 
CKD-EPI equation GFR estimates. Only the CKD-EPI equation at GFR A? ? ? ml/min/1.73 m2 
achieved a P30 of > 90% but no equation was performed statistically significantly better than 
the other in all subgroups. 
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Table 4.5 Performance of the MDRD and CKD-EPI Equations Compared to 






Overall (n=201) <60 (n=139) >60 (n=62) 
 
Bias, median difference (95% CI) 
 
MDRD 3.8 (1.6 to 5.2)* 
 
2.0 (0.8 to 4.1)* 
 
8.3 (3.8 to 12.9)* 
 
 
CKD-EPI 1.2 (-0.1 to 2.6)* 
 
0.5 (-1.2 to 2.2) 
 
 
4.4 (-0.1 to 10.0)* 
 
 








13.3 (10.9, 15.7) [51.4] 10.9 (8.4, 13.4) [50.9] 
 
19.1 (15.3, 22.9)  [40.7] 
 
Accuracy, percentage of estimates within 30% of measured GFR (P30) (95% CI) 
 
MDRD 78 (72, 84) 
 
77 (69, 84) 
 
81 (69, 90)* 
 
CKD-EPI 83 (77, 88) 
 
77 (69, 84) 
 
97 (89, 100)* 
 
Abbreviations: n, number; CI, confidence interval; GFR, glomerular filtration rate; IQR, interquartile 
range; MDRD, Modification of Diet in Renal Disease study equation; CKD-EPI, Chronic Kidney Disease 
Epidemiology Collaboration equation; IQR, interquartile range. 
*Indicates reached statistical significance (p < 0.05) 
 
Table 4.5 
Results are shown of the MDRD and CKD-EPI eGFR in terms of bias, precision and accuracy 
(percentage of estimates within 30% of the measured GFR) of the total cohort and split by 
ƐƵďŐƌŽƵƉƐ'&ZAM ? ?ŽƌA? ? ? ml/min/1.73 m2 in subjects aged A? 80 years. Bias was calculated 
as the median difference of the estimated minus the measured GFR.  The Wilcoxon 
matched-pairs signed rank test was used to compare the bias of each of the MDRD and CKD-
EPI GFR estimates against measured GFR. Both equations demonstrated a statistically 
significant positive bias overall however the CKD-EPI did not have a significantly positive bias 
in GFR < 60 ml/min/1.73m
2
. Bias increased at GFR A? ? ? ml/min/1.73 m2 in both estimating 
equations. Precision was calculated as the IQR of the median differences. Precision was 
similar in both equations overall but declined at GFR A? ? ? ml/min/1.73 m2. The McNemar 
test was used to compare P30 values of the MDRD and CKD-EPI equation GFR estimates. The 
CKD-EPI equation was only statistically better in terms of accuracy compared to the MDRD 











Abbreviations: MDRD, Modification of Diet in Renal Disease study equation; CKD-EPI, Chronic Kidney 
Disease Epidemiology Collaboration equation; eGFR, estimated glomerular filtration rate; mGFR, 
measured GFR.  
Figure 4.5  
Bias plots showing the difference of the estimated GFR (ml/min/1.73m
2
) and measured GFR. 
Graph a displays the MDRD study equation and graph b displays the CKD-EPI equation. 
White circles are represented by subjects <80 years and black circles are subjects aged A? 80 
years. The dotted line represents zero bias and solid line indicates the median bias of the 
estimating equation. There was an increased variability using the MDRD equation 
particularly at higher GFRs with significant outliers in the MDRD compared to the CKD-EPI 
graph. Both equations demonstrated a positive bias with a 3.5 positive bias using the MDRD 
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Misclassification errors followed the bias of the equations as would be expected. 
Both the MDRD and CKD-EPI equations were positively biased compared to 
reference GFR and were more likely to wrongly classified individuals as having an 
Ğ'&ZA? ? ?ŵů/min/1.73m2. A total of 29 (14%) patients were misclassified according 
to GFR < or > 60ml/min/1.73m
2 
s in the MDRD group and 24 (11.9%) in the CKD-EPI 
group and is shown in Table 5.7. Only 4 (2%) individuals using the MDRD equation 
and 6 (3%) individuals using the CKD-EPI equation were wrongly considered to have 
a GFR < 60ml/min/1.73m
2
. In contrast, 25 (12.4%) people using the MDRD equation 





For both equations, misclassification errors appeared worse 
amongst individuals <80 years old compared to individuals aged 80 years and over. 
 
In summary, this study has shown that the MDRD study and CKD-EPI equations are 
fairly accurate in assessing renal function in an elderly Caucasian population with a 
slightly better performance by the CKD-EPI equation particularly at higher GFRs. 
They are more likely to overestimate GFR which may have an effect on the 




Table 4.6 Misclassification Errors 
 
 
Wrongly considered to have GFR 
<60 ml/min/1.73 m
2
, n (%) 
 
      All    < 80 years    A? ? ?ǇĞĂƌƐ 
MDRD                                           
 
CKD-EPI                                        
 
    20 (5.1) 
 
    21 (5.3) 
16 (8.3) 
 
       15 (7.8) 
      4 (2) 
   
      6 (3) 
Wrongly considered to have GFR 
A? ? ?ml/min/1.73 m2, n (%) 
 
          
MDRD                                           
 
CKD-EPI                                        
 
     45 (11.4) 
 
     38 (9.6) 
       20 (10.4) 
 
       20 (10.4) 
      25 (12.4) 
 
      18 (9) 
Total misclassified, n (%) 
 
   
MDRD                                            
 
CKD-EPI                                          
 
     65 (16.5) 
 
     59 (15) 
      36 (18.6) 
 
      35 (18.1) 
      29 (14.4) 
  
      24 (11.9) 
 
Abbreviations: n, number; CI, confidence interval; GFR, glomerular filtration rate; IQR, interquartile 
range; MDRD, Modification of Diet in Renal Disease study equation; CKD-EPI, Chronic Kidney Disease 




This table shows the number and proportion of patients who were wrongly 
misclassified as having a GFR < 60ml/min/1.73m
2
 or A? ? ?ŵů ?ŵŝŶ ? ? ? ? ?ŵ2 when 
estimating GFR using the MDRD and CKD-EPI equations. These results show that 






. For both equations, misclassification errors appeared worse 





This study has demonstrated that the MDRD equation performs reasonable well in 
estimating GFR when compared to measured GFR in older people. The MDRD study 
equation had a positive bias tending to overestimate GFR particularly in those with a 
'&ZA? ? ?ŵů/min/1.73m2 ĂŶĚƚŚĞƌĞǁĂƐůŝƚƚůĞĚŝĨĨĞƌĞŶĐĞƐĞĞŶŝŶƚŚŽƐĞAM ? ?ŽƌA? ? ?
years old. In terms of accuracy the MDRD achieved P30 levels of 81% overall which 
falls short of the > 90% KDOQI guideline but accuracy improved at higher GFR levels. 
The CKD-EPI equation performed similarly but slightly better that the MDRD 
equation in terms of bias, precision and accuracy and this was also seen in the < 80 
and A? ? ?ǇĞĂƌƐƐƵďŐƌŽƵƉƐ ? In the entire population studied, both the MDRD and CKD-
EPI equations overestimated GFR.  The MDRD and CKD-EPI equations also 
overestimated measured GFR when analysing the subgroups with a GFR < 60 
ŵů ?ŵŝŶ ? ? ? ? ?ŵ ?ĂŶĚA? ? ?ŵů/min/1.73 m2. The CKD-W/ƐŚŽǁĞĚŶŽďŝĂƐŝŶƉĞŽƉůĞA?
 ? ?ǇĞĂƌƐǁŝƚŚ'&ZA? ? ?ŵů/min/1.73m2 and achieved P30 values >90% in both age 
ƐƵďŐƌŽƵƉƐĂƚ'&ZA? ? ?ŵů/min/1.73m2. Inaccuracies of the MDRD and CKD-EPI 
estimating equations led to misclassification of 16% and 15.5% of the total study 
cohort respectively with a greater degree of misclassification in those aged < 80 


























The prevalence of CKD has risen not only in association with the rising incidence of 
diabetes, hypertension and vascular disease but also with our increasingly aged 
population. A very small minority of elderly patients with CKD will progress to end 
stage renal disease and the remaining majority with CKD will have the associated 
cardiovascular morbidity and mortality associated with CKD. Roderick et al have 
demonstrated that in the UK, in subjects aged 70 years and older, there is a graded 
and independent increase in all-cause mortality and cardiovascular risk particularly 
in those with eGFR < 45 ml/min/1.73m
2
 (157). Hence it is important to ensure our 
methods of monitoring function and assessing eGFR are validated in this particularly 
susceptible group.  Conversely, incorrectly labelling frail and elderly people with a 
condition like CKD can also lead to unnecessary referrals to specialist centres 
involving travelling long distances, subjecting them to complex polypharmacy and 
often significant concern and worry. Assessment of performance of these estimating 
GFR equations in the elderly was urgently needed to ensure our methods of 
diagnosing CKD are valid. 
 
This study is the first large prospective study to evaluate the performance of the 
contemporary GFR estimating equations in an older Caucasian population. I 
hypothesised that the reported high incidence of CKD is partly due to the 
inaccuracies of the estimating equations used to assess renal function in older 
people. The aim was to assess the accuracy of the MDRD study and CKD-EPI 
equations estimated GFR in older people in comparison to measured GFR. The 
MDRD study equation was assessed because currently it is national practice to 
report eGFR derived from the MDRD study equation with every serum creatinine test 
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(10) into clinical practice due to its perceived increased accuracy. The CKD-EPI 
equation was also assessed as there have been recommendations to adopt it use in 
place of the MDRD study equation.  
 
Overall this study has shown that the MDRD and CKD-EPI equations perform fairly 
well in an elderly Caucasian cohort. In comparison with previous studies, this study 
has demonstrated that the P30 values observed for both MDRD and CKD-EPI 
equations in older people appear reasonable and the inferiority of the MDRD 
equation was only significant amongst individuals with GFR A? 60 ml/min/1.73 m2. 
The P30 values are slightly lower than those observed in the original MDRD and CKD-
EPI validation cohorts, (8; 110) but consistent with other independent evaluations 
(108, 111-113, 115, 117, 122) Further, bias against the reference method, although 
significant for the MDRD and CKD-EPI equations, was small in clinical terms. Notably, 
the underestimation of GFR reported for the MDRD equation in some other studies 
(110-112, 117) was not seen in this study. There was in fact a small positive bias 
observed even, and especially, at higher levels of GFR. The CKD-EPI equation was 
more accurate than the MDRD equation at higher levels of GFR.  
 
Since the publication of the MDRD equation in 1999 (8), there have been many 
evaluations of its performance. The MDRD equation was developed in a population 
with CKD and a general observation has been that the equation has not performed 
so well outside of that population. In particular, it has been found to report 
negatively biased estimates of GFR when GFR exceeds 60 ml/min/1.73m
2 
(158). 
Several studies have shown that the MDRD equation performs less well at higher 
levels of renal function with observations of a divergence of the bias of the MDRD 
equation from the identity line as GFR increases, particularly in younger populations 
(116). This was well illustrated in the study by Froissart et al, which compared MDRD 
estimated GFR to measured GFR using renal clearance of 
51
Cr-EDTA in a cohort of 
2096 European subjects. Their findings raised caution regarding its use in stage 1 and 
2 CKD and reported similar scatter plots and difference plots observed in this study 
with greater inaccuracy at higher GFRs (Figure 5.1). The inaccuracy of the equation 




Several studies have undertaken direct comparison of the MDRD and CKD-EPI 
equations and a variety of statistical approaches have been used. Bias, precision and 
accuracy have been traditionally used to assess the performance of these estimating 
equations. Bias can often reflect systematic differences between the development 
datasets and the populations in which the equation is used. Typically, and 
understandably, equations have generally performed less well outside of the cohorts 
in whom they were developed (109, 159).  
 
In the original MDRD validation cohort the MDRD equation achieved a P30 of 91% (8) 
whereas in the CKD-EPI cohort this fell to 81% (110). Amongst studies that have 
subsequently directly compared the CKD-EPI and MDRD equations in large (n > 100) 
adult Caucasian populations using standardized serum creatinine assays, the CKD-EPI 
equation has been superior to the MDRD equation with a lower bias particularly at 
higher eGFRs (>60 ml/min/1.73 m
2
) whereas the MDRD equation performed better 
at lower eGFR values (114). Figure 5.2 illustrates the performance of both equations 
in the CKD-EPI validation set. Both ĞƋƵĂƚŝŽŶƐ ?bias plots show increased scatter at 
higher eGFR levels but the CKD-EPI equation yielded improved median bias and was 
assessed as being as accurate as the MDRD study equation in those with an eGFR < 
60 ml/min/1.73 m
2
 and substantially more ĂĐĐƵƌĂƚĞŝŶƚŚŽƐĞǁŝƚŚĂŶĞ'&ZA? 60 
ml/min/1.73 m
2
 consistent with the findings in this study (110). These results were 
consistent across subgroups defined by age, gender, race, presence of diabetes and 


















Abbreviations: GFR, glomerular filtration rate; eGFR, estimated glomerular filtration rate; MDRD, 




Froissart et al, demonstrated the relationship between measured GFR using renal 
clearance of 
51
Cr-EDTA as the reference method and MDRD eGFR. Bland and Altman 
plots comparing measured GFR and MDRD eGFR is on the right with the mean 
difference (M) represented by the dashed line. This demonstrates the inaccuracy of 
the MDRD equation as it reaches higher levels of GFR.   
 





Figure 5.2. Performance of the CKD-EPI and MDRD Study Equations in Estimating 
GFR in the CKD-EPI External Validation Study 
 
   
 
Abbreviations: MDRD, Modification of Diet in Renal Disease study equation; CKD-EPI, Chronic Kidney 
Disease Epidemiology Collaboration equation; GFR, glomerular filtration rate 
 
Figure 5.2 
In 2009 Levey et al, assessed the performance of the MDRD and CKD-EPI equations in the 
CKD-EPI external validation set. Bland and Altman plots of the measured GFR and estimated 
GFR using the MDRD and CKD-EPI equations are shown. The mean difference (bias) is 
represented by the thick line. This demonstrated both equations underestimated GFR and 
bias increased as GFR increased. The CKD-EPI performed superior to the MDRD equation.




Observed P30 values from studies evaluating the estimating equations have ranged 
from 73% to 93% for the MDRD equation and from 80% to 95% for the CKD-EPI 
equation (114). A recent large retrospective study from the Mayo clinic did not 
report P30 values but observed that the relative bias of the two equations differed 
depending on the clinical presentation, with the CKD-EPI being superior in kidney 
donors and inferior among CKD patients (160). In 2002, the NKF-KDOQI called for 
future GFR estimating equations to achieve P30 values in excess of 90% (10) yet 
across a wide range of studies, this has rarely been achieved to date (114).  This 
study has demonstrated that both the MDRD and CKD-EPI equations fail to meet this 
standard in the elderly population overall with the exception of the CKD-EPI 
ĞƋƵĂƚŝŽŶŝŶƚŚĞƐƵďŐƌŽƵƉǁŝƚŚ'&ZA? 60 ml/min/1.73 m2. 
 
So how do our study results compare with previous smaller studies in older people? 
With the exception of the study by Jones et al, who included a small number of older 
individuals (115), most but not all studies (108, 111-113, 117, 122) have included 
very few individuals over 75 years of age.  The MDRD equation was originally 
validated in 1085 patients with CKD with a mean age of 51±13 years (22% >65 years) 
(8). The authors subsequently evaluated the equation in a larger (n=5504) and more 
diverse population, but again, few people were >75 years old (mean age 47 ± 15 
years, 13% > 65 years) (31). Although very few elderly people were included, it is 
interesting to note that the bias they observed amongst the > 65 year subgroup was 
smaller than amongst younger individuals. The bias was minimal (-0.3 ml/min/1.73 
m
2
) even when GFR exceeded 60 ml/min/1.73 m
2
, with a P30 of 88% being observed 
in this subgroup. It may be that the numbers in the study were too small as it is 
possible to end up with a smaller bias by chance. By contrast, MDRD underestimated 
measured GFR amongst younger individuals with higher GFR (by -6.4 and -10.6 
ml/min/1.73 m
2
 in individuals 40 to 65 years and <40 years respectively).  
 
In the study by Froissart et al, a sub-analysis of patients aged > 65 years with GFR < 
60ml/min/1.73m
2
 showed that the performance of the MDRD equation was 
generally comparable to that amongst younger individuals tending to give a slightly 
negatively biased estimate of GFR (mean bias -1.0 ml/min/1.73m
2
) (116).  Only 57 
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subjects in this study, however, were aged 80 years or more. In a reanalysis of data 
from a small study performed by Lamb et al, eGFR using the MDRD equation showed 
minimal bias (mean bias -2.0 ml/min/1.73m
2
) and reasonable precision (166). Data 
was from 46 patients with a mean age of 80 years (ranging from 69-92 years) and the 
median GFR was 55 ± 17 ml/min/1.73m
2
. These two studies were relatively small in 
terms of numbers of older people and pre-date both internationalised 
standardisation of creatinine and the publication of the CKD-EPI equation. 
Nevertheless, they pointed towards good estimation of GFR in older people with the 
MDRD study equation.  
 
In the CKD-EPI equation, the development and external validation datasets had 
mean ages of 47 ± 15 and 50 ± 15 years respectively and again included very few 
elderly people (110). Nevertheless, bias of the CKD-EPI and MDRD estimates in the 
external validation data set were minimal and broadly equivalent (-1.3 and -1.4 
ml/min/1.73 m
2
 for MDRD and CKD-EPI respectively) amongst individuals > 65 years, 
whereas larger biases were observed amongst younger individuals, in particular for 
the MDRD equation (e.g. -9.7 ml/min/1.73 m
2
 for individuals < 40 years).  
 
A study of Australian individuals also reported a similar age-related shift (115) and 
CKD-EPI eGFR was reported to be 3 ml/min/1.73 m
2
 lower than MDRD eGFR in North 
American octogenarians (161). The recent large study of Murata et al (n=984) 
observed that both equations overestimated GFR (MDRD 9%; CKD-EPI 5%) in 
individuals >70 years with CKD and underestimated GFR in younger healthy 
individuals (e.g. amongst 40-69 year olds CKD-EPI -9%; MDRD -17%) (160).  
 
Overall, a picture emerges of differences between the CKD-EPI and MDRD equations, 
and the differences between these equations and the reference methods being 
diminished amongst older compared to younger people. The MDRD equation was 
developed in a cohort of patients with CKD (mean GFR 40 ml/min/1.73 m
2
). Its 
underperformance in healthy individuals with higher GFR has been attributed to the 
fact that few such individuals were included in the original development dataset. The 
CKD-EPI equation was developed in a broader cohort with better kidney function 
108 
 
(median GFR was 68 ml/min/1.73 m
2
), purposefully including healthy individuals, 
thus explaining its superior performance at higher levels of GFR. Nevertheless, it was 
predominantly developed amongst cohorts of diseased individuals, in particular 
patients with CKD and/or diabetes (8). 
 
As age increases, the body composition changes with an increase in body fat 
composition and a significant reduction in lean body mass particularly in those of 
extreme old age (24). These age-related changes may have an important effect on 
creatinine clearance and GFR measurements. Both the MDRD and CKD-EPI equations 
try to overcome these factors by incorporating body surface area in their calculations 
hence GFR per 1.73 m
2
. One can speculate that the relationship between muscle 
mass, dietary protein intake (and thus creatinine) and GFR amongst older people is 
more akin to that of the diseased development cohorts of the MDRD and CKD-EPI 
equations than some of the various younger populations in which they have 
subsequently been tested. Consequently these equations work reasonably well and 
broadly equivalently in an elderly Caucasian population. This is a fortunate 
coincidence since the major burden of CKD in most populations resides amongst the 
elderly. Furthermore, whereas in middle-aged populations the CKD-EPI equation 
appears to better identify clinical risk than the MDRD equation, amongst older 
people, risk estimates based upon the two equations appear similar. This present 
study confirms acceptable performance of the MDRD and CKD-EPI equations in older 
people. 
 
Of note, however, analysis of the characteristics of the outliers falling outside the P30 
reference GFR revealed a higher proportion of females particularly in the CKD-EPI 
dataset (72 female vs 35 male). The extreme outliers were also associated with a low 
body surface area so the discordance between measured and estimated GFR using 
both equations may well be related to low muscle mass and hence low serum 
creatinine measurements. The NICE guidelines recommend that eGFR be interpreted 
with caution in cases of extremes of muscle mass such as amputees or muscle 
wasting disorders (57).  For this reason, one participant was excluded from the study 
as he was an amputee on the basis that differences in muscle mass would affect the 
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study results. This highlighted that the original exclusion criteria were not robust 
enough. Studies have also shown the MDRD equation significantly underestimates 
GFR in obese subjects with GFR > 60 ml/min/1.73m
2
 demonstrating the effect 
differing body habitus has on eGFR values (162). 
 
Accumulating evidence suggests that the CKD-EPI equation better identifies clinical 
risk than the MDRD equation, (163-164) including amongst older people (165). It 
therefore seems likely that the CKD-EPI will be introduced routinely in clinical 
practice and it is important to understand how this will impact on the CKD 
prevalence rates. Reporting eGFR using the MDRD study equation is widespread 
nationally and internationally so a change in the estimating equation used by clinical 
laboratories would have significant implications. As the CKD-EPI equation has greater 
differences at higher GFRs, applying the CKD-EPI equation would lead to a higher 
estimated GFR in the population. It would be less sensitive but more specific in 
detecting people with eGFR < 60 ml/min/1.73m
2
. This in turn would have public 
health implications leading to a lower prevalence estimate but higher risk profile for 
people within this range of GFR. It would enable better use of finance and resources 
in caring for patients with a reduced GFR predominantly in the primary care setting 
rather than nephrology services.   
 
In a population based study in Australia, the estimated CKD prevalence decreased 
from 13.3% to 11.5% when the CKD-EPI equation was used (163). The prevalence 
was particularly lower in women but remained high in the elderly. The 
reclassification was mainly from stage 3a to 2 and mainly affected those in whom 
eGFR was the only diagnostic feature and those with kidney damage remained 
unchanged. Figure 5.3 illustrates the impact of using the CKD-EPI equation and 










Abbreviations: MDRD, Modification of Diet in Renal Disease study equation; CKD-EPI, Chronic Kidney 
Disease Epidemiology Collaboration equation; GFR, glomerular filtration rate. 
 
Figure 5.3 
The AusDiab (Australian Diabetes, Obesity and Lifestyle) study was a large population 
based survey which compared the effect of utilising the MDRD study and CKD-EPI 
equations on prevalence of CKD. The greatest misclassification errors were observed 
in the KDOQI stage 3a. The estimated CKD prevalence decreased from 13.3% to 
11.5% when the CKD-EPI equation was used.  
        White et al, 2010 (163) 
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As the MDRD study equation is inaccurate at higher levels of GFR, guidelines 
recommend that eGFR is reported as a range i.e. > 60 ml/min/1.73m
2
, at higher 
levels of GFR. Differentiating between stages 1 and 2 using serum creatinine based 
equations would be risky using the MDRD study equation as it is unreliable in GFR > 
60ml/min/1.73m
2
. Moreover, the CKD staging system suggests that an eGFR of 90 
ml/min/1.73m
2
 is the lower limit of normal when in reality only a minority of the 
population have an eGFR > 90 ml/min/1.73m
2
 most of whom are young men (1). Use 
of the CKD-EPI equation will enable reporting of an actual numerical value 
throughout the full range of GFR. Conversely, use of the CKD-EPI equation will 
overestimate GFR and slightly increase bias at lower GFR values so clinicians caring 
for these patients would have to be aware of this limitation.   
 
This study reported only 2% individuals using the MDRD equation and 3% individuals 
using the CKD-EPI equation were wrongly considered to have a GFR < 
60ml/min/1.73m
2
 misclassifying them as having CKD stage 3a. There was, however, a 
higher proportion (12.4% MDRD and 18% CKD-EPI) of subjects wrongly considered to 
ŚĂǀĞĂ'&ZA? ? ?ŵl/min/1.73m2 which may have a significant impact on CKD 
prevalence estimates. Froissart et al, found that only 70.8% of subjects were 
classified in the proper KDOQI CKD category across all CKD stages and approximately 
20% of subjects with measured GFR > 60ml/min/1.73m
2
 were classified as having 
stage 3 CKD using the MDRD equation to estimate GFR (116).  
 
dŚŝƐƐƚƵĚǇ ?ƐŽďƐĞƌǀĂƚŝŽŶƐĂůƐŽĨŝƚǁĞůůǁŝƚŚĚĂƚĂĨƌŽŵƐĞǀĞƌĂůƐƚƵĚŝĞƐƚŚĂƚŚĂǀĞ
looked at the relative prevalence of CKD amongst populations and across age strata 
(110, 163, 166-177)). In the CKD-EPI validation studies, median eGFR was 
9.5ml/min/1.73m
2 
higher using the CKD-EPI equation reducing the prevalence 
estimate of CKD by 1.6%. In all cases, whilst a decrease in CKD prevalence when 
assessed using the CKD-EPI equation rather than the MDRD equation has been 
observed in middle-aged populations, the two equations give similar prevalence 
estimates due to virtual abolition of negative bias at GFR >60 ml/min/1.73 m
2
 
amongst older people. For example, in the East Kent population, one study observed 
the mean estimated GFR using the CKD-EPI equation to be 11.2% higher than the 
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MDRD eGFR amongst individuals aged 40 to 49 years: this difference gradually 
diminished to 0.7% amongst the 70-79 year olds (167). In people aged over 80 years 
the MDRD equation actually gave a lower CKD prevalence estimate than the CKD-EPI 
equation. dŚĞƐŝŐŶŝĨŝĐĂŶĐĞŽĨƚŚŝƐƐƚƵĚǇ ?ƐŵŝƐĐůĂƐƐŝĨŝĐĂƚŝŽŶĚĂƚĂŽŶŶĂƚŝŽŶĂů<
prevalence is unclear however as the study population is not a typically reflection of 




Demonstrable improvements in the CKD-EPI equation to the MDRD study equation 
were marginal in this study but it is possible that the study was underpowered to 
detect additional benefits. East Kent is a peninsula and therefore may not be a 
representative population for reasons such as obesity prevalence and social 
deprivation. It is also predominantly of caucasian ethnicity. Local population data 
shows only 1.3% of the population to be black and a further 1.9% recorded as asian 
(168). Hence this study has only validated the use of these equations in the older 
caucasian population. The initial study cohort included three african-caribbean 
participants, however they were excluded from the final study analysis, as race is 
known to affect GFR and the number was too small to have any meaningful data.  
 
The CKD-EPI and MDRD study equations were developed in North American and 
European populations that compromised mainly of african-caribbean and caucasian 
persons. There are known racial and ethnic differences in muscle mass and diet and 
further studies will need to be performed in other ethnically diverse groups. In 
studies examining the performance of the estimating equations in other ethnicities 
compared to North Americans, Europeans or Australians, both the MDRD and CKD-
EPI equations were less accurate (P30 ranging from 29 to 94%)(169-170). Studies 
have shown that even in the population of North America, Europe and Australia 
(AusDiab study), the CKD-EPI equation does not meet the 2002 KDOQI benchmark of 
a P30 of greater than 90% (163). Zuo et al found the MDRD underestimated true GFR 
at normal function and overestimated GFR at lower levels in 684 Chinese individuals 
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achieving a P30 of 80% (169).  Some studies have developed a coefficient to adjust for 
racial variation but these coefficients do not consistently improve accuracy in other 
ethnic populations. In Japan, the Japanese coefficient- modified CKD-EPI equation 
was found to be more accurate than the Japanese coefficient-modified MDRD 
equation leading to a lower estimated prevalence of CKD in Japan (7.9% vs 10%) 
(171). Incorporating locally derived coefficients to minimise bias in different ethnic 
populations can be used to improve accuracy of these estimating equations but 
would require increased resources and introduce complexity to a widely used 
screening and diagnostic test. We need better assessment and evaluation of these 
equations used to estimate GFR in other ethnically diverse groups many of whom 
have a high burden of CKD. 
 
In order to reduce bias from the biological variability of serum creatinine levels, 
study participants were asked to avoid meat consumption prior to the procedure, a 
known confounder of serum creatinine measurement (99). Avoidance of meat in the 
study protocol could be viewed as a weakness as well as a strength. Although pre-
test avoidance of meat was protocol, there were invariably participants who did not 
completely adhere to protocol. Lack of dietary regulation with a potential to affect 
serum creatinine measurements may have contributed to the inaccuracies of the 
prediction equations in this study. Physiologically, protein intake increases GFR and 
cooking meats converts creatine to creatinine. It is readily absorbed and causes 
increased serum creatinine levels and the effect persists for hours. Recent meat 
intake clearly has a significant impact on eGFR but the impact in the real world is 
unclear.  Other foods high in protein content such as fish have also been proven to 
alter serum creatinine measurements. It is possible that a meat meal would have a 
differential effect in the elderly. The effect on eGFR has been largely ignored and no 
robust recommendations had been made regarding sampling until recently. There is 
probably variable adherence to meat avoidance for serum creatinine testing in the 
everyday setting. 
 
In 2007, Preiss et al studied the effect of a meat meal on serum creatinine levels and 
eGFR and found the median eGFR fell by 25 ml/min/1.73m
2
 1-2 hours post 
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consumption of meat and remained 20 ml/min/1.73m
2
 lower than baseline up to 4 
hours later (99). The MDRD study, NHANES data and AusDiab studies all used fasting 
samples to overcome these inaccuracies (1, 8, 163). Of note, cystatin C was robust in 
the face of meat ingestion. Recent NICE guidelines have recommended that ideally 
blood samples or eGFR should be obtained with the individual avoiding meat 
consumption 12 hours prior to blood sampling (57). 
 
No study participants were receiving cimetidine, trimethoprim or co-trimoxazole 
prescriptions at the time of the test. These medications are known to inhibit 
creatinine secretion in renal tubules increasing serum creatinine levels. The study 
cohort however composed of a high proportion of patients prescribed medications 
known to reduce GFR such as ACEIs and ARBs and NSAIDs and almost 50% of the 
individuals in this study were on one or more anti-hypertensive agents including 
diuretics. Although these may have had an impact on GFR at the time of the test, the 
prescription patterns are typically representative of an elderly population.  
 
Inaccuracies of the estimating equations around Ğ'&ZAMŽƌA? ? ?ŵů ?ŵŝŶ ? ? ? ? ?ŵ2 may
lead to misclassification of CKD with consequences on CKD prevalence data.  
Perfect measurement of GFR, however, is not so necessary at the earlier stages of 
CKD clinically. Decreased GFR is a well known risk factor for cardiovascular disease, 
mortality and progression to kidney failure so misclassification of patients at the 
more severe CKD stages (CKD 3b-5) may have important implications for clinicians 
and patients clinically. A limitation of this study is that it did not analyse the level of 
inaccuracy of the estimating equations in all the CKD stages GFR subcategories and 
analysis of misclassification waƐůŝŵŝƚĞĚƚŽ<ƐƚĂŐĞ ?ĂŶĚ ?ĂǁŝƚŚĞ'&ZAM ? ?ŽƌA? ? ?
ml/min/1.73m
2
, levels at which the 2 estimating equations perform more accurately.  
This study demonstrated less bias but better accuracy of both estimating equations 
at higher GFRs in both <  ? ?ĂŶĚA? ? ?ǇĞĂƌƐƵďŐƌŽƵƉƐ ?Misclassification of individuals 
and inaccuracies of the estimating equations at lower CKD stages has an important 
effect clinically as the clinician relies on eGFR for detecting disease, predicting 
prognosis, guiding therapy and drug dosing. Further analyses of their performance in 
each of the different CKD stages would have been of interest. Misclassification errors 
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need to be interpreted with caution however as misclassification can occur with a 
bias of only 1 ml/min/1.73m
2
. It is contradictory that GFR can be estimated yet 
diagnosis of CKD cannot.  
 
Another criticism of this study is the choice of iohexol GFR as the reference GFR 
method. Standard clearance of inulin, including ƵƌŝŶĞĐŽůůĞĐƚŝŽŶ ?ƌĞŵĂŝŶƐƚŚĞ ‘ŐŽůĚ-
ƐƚĂŶĚĂƌĚ ? method for GFR measurement but few studies use this. Most evaluations 
of GFR equations have used radio-labelled plasma clearance methods which are 
assumed to be closely related to inulin clearance, although it is increasingly 
appreciated that such methods are not all equivalent (172). Radio-labelled 
iothalamate plasma clearance was the method used for developing the MDRD (8) 
and CKD-EPI equations (9). The CKD-EPI equation validation dataset used a variety of 
reference GFR methods including iohexol with small differences in clearance 
compared with iothalamate
 
(110). There has been much debate about which is the 
more accurate method for measuring GFR. Iohexol clearance is widely used in clinical 
and research practice and there is no convincing evidence that it is better or worse 
than other reference GFR procedures compared to urinary inulin clearance (118).  
Prior to clinical introduction of the iohexol GFR method used in this study, it was 
compared with our existing GFR method (plasma clearance of Inutest) primarily used 
in children and the results were not significantly different. Seegmiller et al found that 
renal clearance of iohexol was slightly lower than renal clearance of iothalamate 
across a wide range of GFRs (173). This difference may be due to a greater plasma 
binding property of iohexol compared to iothalamate. One study suggested that 





Due to problems of ensuring complete bladder emptying in this population, it was 
not possible to collect timed urine samples and plasma iohexol was sampled over a 
4-hour period in this study. The study would be more robust if a 24 hour sample was 
taken to improve accuracies at lower GFRs but practical limitations meant that 
collecting a delayed 24 hour blood sample was also not feasible. Plasma clearance of 
iohexol is dependent on level of GFR and some studies recommended later sampling 
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of iohexol measurements in those with GFR < 30 ml/min/1.72m
2
 at 6 hours, 8 hours 
and 24 hours (175). They argued that later sampling would be more representative 
of the final exponential phase in the iohexol disappearance curve.  Plasma clearance 
of iohexol using a 4-hour procedure has been shown to overestimate, (176) 
underestimate (177) or accurately reflect reference urinary clearance measures 
(178). The variety of sampling protocols, compartmental models used, patient mix 
and GFR ranges studied in the literature makes interpretation of these various 
reports difficult.  
 
More recently, the Berlin Initiative Study (BIS) group assessed correlations between 
4 hour and 5 hour iohexol clearance measurements in an elderly population and 
found that GFR can be satisfactorily measured within 3 measurements points within 
4 hours after iohexol administration (179). They found no benefit for GFR calculation 
by extending the measurement to 5 hours across the range of GFRs. 
 
Furthermore, irrespective of how accurately ƚŚŝƐƐƚƵĚǇŚĂƐĂƐƐĞƐƐĞĚ ‘ƚƌƵĞ ?'&Z ?ƚŚĞ 
conclusions regarding the relative performance of the two GFR estimating equations 
remain valid. This data suggests that GFR estimation using the MDRD and CKD-EPI 
estimating equation in older Caucasian people is as accurate as it has been reported 
to be in younger individuals. Although calls for the adoption of the CKD-EPI equation 
into regular clinical practice have been made, it fails to consistently achieve the 2002 
KDOQI recommendations of P30 values > 90%. Newer estimating equations more 
recently have been proposed which claim to have less bias and better accuracy than 
the MDRD and CKD-EPI equations. The BIS group proposed a new equation (BIS) 
which is reportedly unbiased against measured GFR and achieved P30 values of 95% 
in an older population (179). Further work from this study has gone on to evaluate 
the performance of the BIS equation in this study cohort (180). In contrast to 
Schaeffner et al, the BIS equation was negatively biased compared to measured GFR 
ĞƐƉĞĐŝĂůůǇŝŶƚŚŽƐĞŝŶĚŝǀŝĚƵĂůƐǁŝƚŚ'&ZA? ? ?ŵů ?ŵŝŶ ? ? ? ? ?ŵ2 and negligible in 
individuals with GFR < 60ml/min/1.73m
2
. Both cohorts however were of northern 
European white origin with broadly similar age, gender, body habitus and co-
morbidity characteristics and validation and experience of the BIS equation remains 
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restricted to older white populations. Further studies are required to confirm that 
the BIS equation performs well in a younger cohort and in other ethnic groups as 
adopting various estimating equations in different age groups may be outweighed by 
the practical difficulties applying them in clinical practice.  
 
Many of the inaccuracies of these estimating equations are down to the biological 
variability of serum creatinine. Alternative filtration markers ƐƵĐŚĂƐɴ-trace protein, 
cystatin C and symmetric dimethyl arginine (SDMA) have shown promise in 
improving estimating equation performance in. Perhaps the most studied is cystatin 
C which is thought to be more accurate a measure of renal function as is it not 
believed to be related to muscle mass or diet. In a pooled dataset of 3,134 people 
with CKD, cystatin C levels alone provided GFR estimates that were nearly as 
accurate as serum creatinine level adjusted for age, sex and race (181). Several 
equations based on serum cystatin C have been created to estimate GFR. Recently 
the CKD-EPI group published 2 additional CKD-EPI equations: one based on cystatin C 
concentrations (CKD-EPIcys) and once using both cystatin C and serum creatinine 
(CKD-EPIcr-cys) (121). They demonstrated better performance of the equations 
combining creatinine and cystatin C compared to the CKD-EPI equation. In the 
external validation datasets of Inker et al, the CKD-EPIcys and the CKD-EPIcr-cys 
equations achieved P30 values of 86% and 92% respectively.  The BIS group 
developed the BIS2 equation which utilises both creatinine and cystatin C and 
reported P30 values of 96% in older people (179). Further work from this study 
performed by Carter et al, has evaluated these 2 cystatin C based estimating 
equations in older people using serum from the study time 0 samples (180, 182). 
They reported broadly equivalent bias, precision and accuracy in comparison to the 
creatinine based estimating equations. Recent studies have also confirmed the good 
performance of the cystatin C based equation in specific populations such as patients 
with diabetes and individuals with mild to moderately impaired kidney function 
(183). This better performance is also supported by studies that show a better 
estimate of mortality risk compared to creatinine based equations (184-185). These 
cystatin C equations have however been developed by the use of a limited sample of 
test subjects and have yet to be validated across a wide range of populations and 
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there have been concerns regarding the lack of standardisation of cystatin C assays 
and the unavailability of the assay in many centres. Nonetheless, these cystatin C 
based equations show promise and have been adopted in the 2014 NICE CKD 
guidelines as an additional diagnostic tool for patients with a borderline diagnosis of 
CKD which may result in a significant proportion of people reclassified as not having 
CKD. 
 
In an ideal world, in order to overcome its limitations, improvement of this study 
would incorporate a larger dataset across a diverse ethnic population with a wide 
range of co-morbidities and of varying body surface areas. To silence critics of the 
selected reference method, both iothalamate and iohexol GFR would be measured 
to enable better comparison with other studies and also assess the performance of 
the 2 reference methods comparably. Patient abstinence from ingestion of meat and 
fish for at least 12 hours prior to sampling would need to be enforced to reduce 
biological variation of creatinine levels. Timed urine samples to measure urine 
creatinine and iohexol levels and a 24 hour serum sample collection would be 
included in the protocol to enhance accuracy of iohexol GFR measurement at lower 
GFR levels. The problem with this, however, is that in order or the equations to be 
applicable in clinical practice, one would have to enforce these measures in routine 
clinical practice. With a larger dataset, analysis of performance in more specific 
subgroups, particularly the very elderly,  those with low body mass and in the 
different CKD stage GFR categories would highlight in which subjects caution is 
needed in interpreting GFR. Misclassification errors at all the stages of CKD would 
help to predict what the implications of adopting the CKD-EPI equation into routine 
practice in the future will be. The inaccuracies of the estimating equations fall largely 
down to the biological and, to a lesser degree, analytical variability of serum 
creatinine levels so measurement of other markers of renal function, such as cystatin 
C, in this study design would help to determine a better marker for measuring renal 
function that is accurate, quick, practical to apply in a large-scale basis and 
transferable across wide range of populations. The definition of CKD is however 
subject of debate most notably in the elderly (186-187). These aspirations however 
fall outside the remit of the study which set out to assess whether the prevalence of 
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In conclusion, this study has demonstrated good performance of the current 
estimating equations in an independent validation cohort inclusive of a large number 
of older people drawn from secondary care and the community with co-morbidity 
and pharmacotherapy typical of such populations in the western world. Although it 
falls short of the > 90% P30 aspiration of the 2002 KDOQI guideline (10), the GFR 
estimating equations appear to work just as well in older compared with younger 
populations. This study found no evidence that the MDRD study equation was 




. This study has found discrepancies in CKD prevalence in using both 
estimating equations with a tendency to misclassify individuals as not having CKD or 
stage 1-2 CKD when in fact measured GFR classified them as stage 3a CKD. More 
epidemiological studies using GFR measurements with a reference method are 
urgently required to evaluate the newer estimating equations across a broad 
population. This work has led on to the eGFR-C study which is currently recruiting 
and aims to compare the accuracy and precision of the CKD-EPI estimating equations 
based on creatinine and cystatin C over a 3 year period. Its aims are to assess its 
performance in people with CKD stage 3 according to ethnic groups (particularly 
caucasians, african-caribbeans and south-asians) and patients with diabetes and 







CHAPTER 6  
     Multiple AKI Episodes and CKD Progression 
 
If the estimating equations we use to determine GFR are accurate, the question 
remains why the prevalence of CKD is so high when the numbers progressing to 
ESRD are so low. Epidemiological studies have shown an independent graded 
association with CKD, death and cardiovascular events with an increased risk ratio of 
death of 3.2 and 5.9 in CKD stages 4 and 5 respectively (188). Mortality rates alone 
do not account for the discrepancy in numbers. CKD progression is defined by as a 
sustained decline in eGFR of > 5ml/min/1.73m
2
/year (12). The use of such a 
definition suggests that progression of disease occurs in a linear pattern. In clinical 
practice, the use of this definition may be limited by few GFR estimates or a limited 
time.  
 
Albuminuria, underlying renal diagnosis, hypertension and low GFR are associated 
with progression of CKD (29-32), however some patients with these risk factors do 
not progress and conversely there are many patients who progress to ESRD without 
these risk factors. One possible explanation is that episodes of AKI lead to the 
development or progression of CKD. The integrated syndrome between AKI and CKD 
is still largely being discovered. CKD is a risk factor for AKI and studies have shown 
that incomplete recovery from a hospital-managed AKI event may result in new 
incident CKD and that severity of hospital-managed AKI predicts progression to 
chronic kidney disease. AKI can be hospital-acquired, community-acquired admitted 
to hospital and community-acquired and managed by primary care. Little is known 
about the characteristics and outcomes of the latter subgroup and clinicians may not 




Perhaps a proportion of people with CKD have periods of stable renal function 
followed by an acute illness manifesting as an AKI event with incomplete recovery 
back to baseline but a subsequent period of stability in function. Many patients 
however who survive an AKI event eventually fully recover renal function. What 





This second study tests the hypothesis that multiple community-AKI events are an 




The main objective of this study was to determine whether multiple episodes of AKI 
occurring in the community are associated with progression of CKD in a cohort or 
patients with CKD referral to renal services. A secondary objective was to examine 
the different patterns of CKD progression that occurred in this CKD population 




This was a retrospective observational cohort study examining the characteristics 
and CKD disease pattern in a selected group of patients referred to the Department 




All new adult patients referred to the Department of Renal Medicine, EKHUFT, 
outpatient services between 1
st
 April 2005 and 31
st
 March 2006 with stage 3-5 CKD 
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were included. Referrals were received from primary care providers or secondary 
care specialists. 
 
All patients younger than 18 years at referral were excluded. Any patients residing 
outside Kent or from the West Kent catchment area were excluded due to lack of 
access to historical pathology data. Patients with eGFR measurements greater than 
60ml/min/1.73m
2
 at time of referral were removed to exclude any patients without 
a diagnosis of CKD. Any patients who had limited pathology data dating back less 
than one year, or with less than four serum creatinine measurements prior to 
referral date were removed from the study as it was deemed insufficient to 
determine progression of CKD. Patients coded as having a diagnosis of end-stage 
renal failure undergoing renal replacement therapy and renal transplant recipients 
were excluded. 
 
Ethical approval was granted by the National Research Ethics Service (NRES) 
Committee South East Coast and the Research and Development department, 




Demographic data were collected, which included age at referral, eGFR at referral, 
gender, and co-morbidity prevalence from referral letters, patient notes and hospital 
computer patient records. Primary cause of CKD (if known) and co-morbidity data 
were also obtained from the Department of Renal MedicinĞ ?Ɛrenal patient database 
system (RenalPlus). Co-morbid conditions were grouped into the following 
categories; urological, malignant, cardiovascular, diabetes and hypertension. All 
biochemistry requests in the East Kent catchment requested in the community or in 
hospital are processed in the EKHUFT biochemistry laboratories and therefore 
available on local pathology databases for this study. The date and result of every 
serum creatinine measurement for each individual was recorded together with any 
clinical information provided at the time of the pathology request. No pathology 
data was available prior to 1998. Estimated GFR was estimated from serum 
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creatinine using the MDRD study equation (8). Although this study earlier 
demonstrated superiority of the CKD-EPI compared to the MDRD study equation, the 
MDRD study equation was used for this study as it was carried out prior to the CKD-
EPI validation study was reported and it is currently still national practice to report 
eGFR using the MDRD study equation. To remove systematic bias in creatinine and 
eGFR levels, calibrated and standardised creatinine assays were used in the study as 
per KDIGO guidelines for all serum creatinine results after April 2006 (10). Creatinine 
assays used in Kent were directly calibrated to the method employed by the central 
laboratory used for the MDRD Study (Beckman Rate Jaffe/CX3 Synchron assay). This 
in turn enabled indirect calibration of the other creatinine assays used in the 
laboratories prior to April 2006 to ensure comparable creatinine and eGFR levels in 
the different time periods (155).   
 
Pathology databases were interrogated for albuminuria and proteinuria data. Results 
and dates were recorded of the first measured urine ACR or urine PCR (mmol/ml) 
before and after referral. Levels of albuminuria and proteinuria were graded 1-3 
according to the albuminuria categories recommended by KDIGO in 2012. Grade 1 
was defined as no significant albuminuria i.e. a urine ACR < 3mg/mmol (< 30mg/g), 
Grade 2 was defined as an urine ACR 3-30 mg/mmol (30-300 mg/g) or urine protein 
creatinine ratio between 5-50mmol/ml, and Grade 3 was defined as an ACR > 
30mg/mmol (> 300mg/g) or a urine PCR > 50 mg/mmol. Length of follow up was 
calculated from the date of the first serum creatinine measurement to the most 




Accumulated demographic and renal function data was entered into a Microsoft 







Stable vs Progressive CKD 
 
Patients were divided into stable or progressive CKD according to rate of decline of 
kidney function.   
Stable CKD was defined as a decline in eGFR of < 10 ml/min/m
2
 over 5 years or <2 
ml/min/m
2
 per year over the total observation period accordance with the KDIGO 
guidelines, 2012 (72).   
Progressive CKD was defined as a decline in eGFR of > 2 ml/min/m
2
 per year or 10 
ml/min/m
2
 over 5 years from the baseline over the total observation period.  
Baseline creatinine was calculated as the median creatinine over previous 365 days 
prior to the recorded result but any creatinine values measured during AKI events 
were excluded from baseline calculations. 





Any acute decline in kidney function from the predicted eGFR trajectory was 
assessed as to whether it fulfilled criteria for an AKI episode. We used serum 
creatinine levels to assess incidence of AKI. For each event we calculated baseline 
creatinine as the lowest serum creatinine in the 12 months prior to the acute rise to 
define AKI.  
An episode of AKI was defined as either a rise in serum creatinine > 26µmol above 
baseline or an acute rise in creatinine > 1.5 times above baseline creatinine as per 
AKI network criteria introduced in 2007(69). This study was carried out prior to the 
publication of the KDIGO AKI guidelines (72). 
AKI was treated as a binary variable, in other words the severity of AKI was not 
assessed because the frequency of AKIN 2 and AKIN 3 events were very low. The 
total number of AKI episodes was determined for each patient ? ‘DƵůƚŝƉůĞ</ ?ǁĂƐ 
defined as 2 or more AKI events and patients were categorised into those with and 
those without multiple AKI events. Mean age at referral, mean eGFR at referral, 
gender and co-morbidity were compared between the 2 subgroups. The presence of 
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multiple AKI episodes were then compared between the stable and progressive CKD 
groups.  
 
Linear and Stepwise Progression Subgroups 
 
Two patterns of CKD progression emerged, therefore patients with CKD progression 
were further sub-divided into Linear and Stepwise (non-linear) subgroups according 
to their pattern of eGFR trajectory. Linear decline was defined as individuals with 
eGFR trajectories with close fit to the linear regression lines. Stepwise was identified 
as individuals with a fall in eGFR followed by a period of stability in kidney function 
without recovery of eGFR to the predicted baseline. The stepwise sub-group were 
characterised by deviation from the linear regression line with either a more rapid 
decline than that predicted or a period of stability. A period of stability was defined 
as a one year period with no decline in eGFR or improvement in eGFR from that 
predicted. 
 
The Delphi technique is a method of obtaining a consensus amongst a panel of 
experts. Using the Delphi technique (189), five nephrologists independently analysed 
each eGFR vs time graph for all study patients. The panel were initially asked to 
assess the pattern of progression and individually categorise each patient into one of 
the three groups: stable, linear and stepwise. The CronďĂĐŚ ?ƐĂůƉŚĂĐĂůĐƵůĂƚŝŽŶŝƐĂ
test of reliability and a measure of internal consistency and this was applied to the 
ƉĂŶĞů ?ƐŝŶĚŝǀŝĚƵĂůĂŶĂůǇƐĞƐŽĨ the progression patterns. ŚƌŽŶďĂĐŚ ?ƐĂůƉŚĂ
reliability of 0.70 or higher indicates a reasonable level of agreement. The 
ƌŽŚŶďĂĐŚ ?Ɛalpha reliability for this study was 0.83 indicating a good level of 
agreement. Cases where agreement in classification of pattern was not initially 










Gender, cause of renal disease, co-morbidity prevalence and grade of albuminuria 
were compared between each category and the percentage prevalence within the 
study population was calculated. Skewness and kurtosis were determined for age at 
referral and eGFR at referral to determine whether data were normally distributed. 
Age at referral was not normally distributed whereas eGFR at referral was. Mean 
values and standard deviations were calculated accordingly. Data that was not 
normally distributed was log transformed to allow statistical analysis. 
 
The Pearson Chi-squared test assesses the relationship between two categorical 
variables. The Pearson Chi-squared test was therefore used to test whether there 
was an association between each of the variables; co-morbidity, gender and grade of 
albuminuria, between the stable CKD and CKD progression groups. Statistically 
significance was considered with p values <0.05.  
 
Analysis of Variance (ANOVA) was then applied to determine whether there was an 
association between each of the two continuous variables mean age and mean eGFR 
at referral, and CKD progression. A p value of < 0.05 was considered statistically 
significant. 
 
Demographics of patients with multiple AKI episodes were compared with the stable 
and progressive group and the Chi-squared test was used to determine association 
between each variable and progression. Any significant categorical variables were 
then included in a logistic regression analysis to allow for any potential non-linearity 
in the risk relationships to CKD progression. This was performed to determine 
whether these categorical variables had a dependent or independent association 
with CKD progression. Again, a p value of < 0.05 was considered to show statistical 
significance. These statistical tests were repeated in the subgroup analyses to 
identify any variables associated with linear or stepwise patterns of CKD progression. 
 
All statistical analyses were carried out using IBM SPSS Statistics program. 
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Flow chart illustrating the selection process of study subjects. Figure in brackets 
represents percentage of the total number of patients referred to the Department of 
Renal Medicine, East Kent within the study period of April 2006 - April 2007. A total 
of 1029 subjects referred to Kent renal services. 295 were excluded as they either 
did not have a GFR < 60ml/min/1.73m
2
 or had end-stage renal failure. Only 483 
subjects were included in the study. The remainder excluded were either from West 
Kent with out of area laboratory data or had insufficient retrospective biochemistry 
results dating back < 1 year prior to the study period or < 4 prior serum creatinine 
levels. 
Patients referred to East Kent 
Renal Services between 
1
st




 N = 1029 
Patients with GFR 
<60ml/min/1.73m
2
 and not 
on RRT 
  
N = 734 (71%) 
 
 
Patients with sufficient 
retrospective sCr 
measurements > 1yr prior to 
referral 





Figure 6.1 illustrates the study selection process. A total of 1029 people were 
referreĚƚŽƚŚĞĞƉĂƌƚŵĞŶƚŽĨZĞŶĂůDĞĚŝĐŝŶĞ ?<,h&d ?Ɛ outpatient services 
between 1
st
 April 2005 and 31
st
 March 2006 as recorded on our CKD Referral 
database. There were 295 patients excluded as they either had ESRD and were 
receiving renal replacement or had an eGFR > 60ml/min/m
2
 at the time of referral 
and may have been referred with structural abnormalities or hypertension.
 
 Of the 
734 patients remaining, 164 were excluded as they resided out of the East Kent 
catchment area hence did not have pathology data recorded on our local pathology 
databases. A further 69 subjects were excluded due to pathology data dating back 
less than 1 year prior to referral and 18 were excluded as they had less than 4 
measured creatinine values recorded prior to referral. After all exclusions, a total of 




Baseline characteristics of the patients are summarised in Table 6.1.  There were 274 
males (57%) and 209 females (43%) in total. As age and eGFR data at referral were 
normally distributed, mean and standard deviation were expressed. The mean age of 
patients at the time of referral was 73.2 years (SD 12.43) with a range from 23 to 96 
years. The mean eGFR of patients at referral was 36.1 ml/min/m
2
 (SD 12.1). The 
highest prevalent co-morbid disease was hypertension, this was present in 78.7% of 
study patients. The second most common co-morbid condition was cardiovascular 
disease (44.1%) followed by diabetes mellitus (38.9%) and 10.8% patients had a 
documented malignancy.  
 
Coding of cause of CKD was obtained from our renal patient database and recording 
of diagnosis was often incomplete. Patients with incomplete records were 
categorised as having an unknown aetiology of CKD. As this group accounted for the 
majority of the patients (65%), statistical analysis was not performed on aetiology of 
CKD. The commonest coded cause of CKD was renovascular or hypertensive renal 
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disease accounting for 10.4% cases. Urological condition accounted for 9.3% patients 
and diabetic nephropathy was the primary aetiology in 7%.  Very few (3.5%) had a 
histologically proven primary intrinsic renal pathology or inherited genetic renal 
condition as a primary renal diagnosis.  
 
Albuminuria data was not available on 82 patients. Of the 401 with recorded 
albuminuria data, 26.7% subjects had A1 (ACR < 3 mg/mmol or PCR < 5 mg/mmol), 
33.7% subjects had A2 (ACR 3-30 mg/mmol or PCR 5-50mg/mmol) and 22.6% 
patients had documented significant albuminuria (A3) at referral with an ACR >30 
mg/mmol or PCR >50mmol/ml.  
 
Stable vs Progressive CKD 
 
Of the total 483 subjects studied, 309 (64%) had stable CKD whereas 174 (36%) 
individuals were classified as having progressive CKD. There were a higher 
proportion of men in both groups with a male to female ratio of 55:45 in the stable 
group and 59:41 in the progressive group. Gender was not found to be associated 
with CKD progression. 
The mean age at referral was 73.1 years (SD 11.6) in the stable group and 74.2 (SD 
10.8) in the progressive group and this did not reach statistical significance. There 
was a significant difference in mean eGFR at referral between the stable and 
progressive groups with mean eGFR of 39.5 ml/min/1.73m
2
 (SD 11.7) and 30.3 
ml/min/1.73m
2
 (SD 11.2) respectively suggesting a lower eGFR at referral is 





Table 6.1 Demographics of Patients 














    Male , % 
















Mean Age at Referral, years (SD) 73.2 (11.3) 73.2 (11.6) 74.2 (10.8) 72.4 (12.4) 75.1 (9.8) 
 
Mean eGFR at Referral, ml/min/m
2
 (SD) 36.1 (12.1) 39.5 (11.7) 30.3 (11.2)* 31.5 (12.1) 29.7 (9.3) 
 
Co-morbidity, % 
    Hypertension 
    Diabetes 
    Cardiovascular 


























Cause of CKD, % 
    Urological 
    Drug related 
    Reno-vascular 
    Diabetes 
    AKI 
    Primary renal 









































Albuminuria grade  
 
   A1, ACR<3, % 
   A2 ACR 3-30, % 
   A3 ACR>30, % 

























Abbreviations: CKD, chronic kidney disease; ACR albumin to creatinine ratio; AKI, acute kidney injury; 
n, number; eGFR, estimated glomerular filtration rate; SD, standard deviation.  
* Indicates p values reached statistical significance (p < 0.05). 
 
Table 6.1 shows the characteristics of total study cohort. Patients were grouped into stable 
and progressive CKD according to rate of decline in eGFR and patients with progressive CKD 
were further subdivided into linear or stepwise progression according to their pattern of 
eGFR versus time trajectories.  Pearson ?s Chi-squared test was used to determine 
association between the categorical variables gender, co-morbidity and albuminuria with 
progression whereas ANOVA was used to determine association of eGFR and age at referral 
with progression. Cause of renal disease was not analysed due to poor recording of data but 
is tabulated for interest. The variables associated with CKD progression were low eGFR at 
referral, presence of diabetes or malignancy and grade A3 albuminuria, whereas presence of 
hypertension and grade A1 albuminuria appear to be protective against progression. There 
were no significant variants between the linear and stepwise progressors. 
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The prevalence of hypertension was similar in both groups (stable 78.3% and 
progressive 79.3%) but there were a significantly higher proportion of diabetics in 
the progressive group compared to the stable group (45.4% vs 35.2%).  Malignancy 
was also associated with progression with a prevalence of 14.9% in the progressive 
group and only 8.4% in those with stable CKD (p = 0.03). Cardiovascular disease 
appeared to be protective against progression and was more prevalent in the stable 
group (69.5%) compared to the progressive group (52.9%). 
 
Of the 309 subjects with stable CKD, 32.7% had no significant albuminuria compared 
to 16.1% subjects with progressive CKD. Grade A2 albuminuria was present in equal 
proportions in the stable and progressive group (33.7% and 33.9%) however there 
was a statistically significantly higher proportion of patients with A3 albuminuria in 
the progressive group (32.8%) compared to stable CKD (16.8%). The results suggest 
that the presence of significant albuminuria (A3) is associated with CKD progression. 
 
Linear and Stepwise Sub-groups 
 
Graphs of eGFR versus time were plotted for each individual studied to aid analysis 
of progression pattern. On further analysis of the progressive group, there appeared 
to be two patterns of progression; linear and stepwise. The linear sub-group had 
eGFRs that appeared to decline in a linear pattern whereas the stepwise sub-group 
had a decline in baseline eGFR followed by a variable period of stability in renal 
function. Examples of each category; stable, linear and stepwise are illustrated in 
Figures 6.2-6.5. Of the 174 patients with progressive CKD, 66% were categorised as 
following a stepwise decline in function and 33% following a linear pattern of 
decline.  
 
Patient characteristics between linear and stepwise sub-groups were analysed and 
found to be broadly comparable. Male to female ratios were similar between both 
the linear and stepwise groups and there was no significant difference in mean age 
at referral (75.1 (SD 9.8) years in the stepwise group compared to 72.4 (SD 12.4) 





 in the stepwise group and 31.5 ml/min/1.73m
2
 in the linear 
group. Analysis of the co-morbidities between the two sub-groups did not reach 
statistical significance and albuminuria data was similar in both groups with 32.8% 
and 33% of the linear and stepwise groups respectively documented to have A3 







Figure 6.2 Estimated GFR Versus Time Graph of a Representative Patient with 
Stable CKD and No AKI Events 
      
 
Abbreviations: GFR, glomerular filtration rate; eGFR, estimated glomerular filtration rate;  CKD, 





) results are plotted against time from first recorded 
eGFR in this subject. Estimated GFR was calculated using the MDRD study equation 
based on serum creatinine levels. An AKI episode was defined as a rise in serum 
creatinine > 26µmol or > 1.5 x above baseline creatinine. Baseline creatinine was 
calculated as the median creatinine over the previous 365 days. Any creatinine 
values measured during AKI events were excluded from baseline calculations. Stable 
CKD was defined as a decline in eGFR of < 10 ml/min/1.73m
2
 over 5 years or < 2 
ml/min/1.73m
2
 per year. 
This scatter plot is a graphic example of a patient with stable CKD with no recorded 



















Figure 6.3 Estimated GFR Versus Time Graph of a Representative Patient with 
Stable CKD and AKI with Complete Recovery to Baseline eGFR 
      
 
 
Abbreviations: GFR, glomerular filtration rate; eGFR, estimated glomerular filtration rate; CKD, chronic 





) results are plotted against time from first recorded 
eGFR in a subject. Estimated GFR was calculated using the MDRD study equation 
based on serum creatinine levels. An AKI episode was defined as a rise in serum 
creatinine > 26µmol or > 1.5 x above baseline creatinine. Baseline creatinine was 
calculated as the median creatinine over the prior 365 days. Any creatinine values 
measured during AKI events were excluded from baseline calculations. Stable CKD 
was defined as a decline in eGFR of < 10 ml/min/1.73m
2
 over 5 years or < 2 
ml/min/1.73m
2
 per year. 
This scatter plot is a graphic example of a patient with stable CKD with multiple AKI 
























Figure 6.4 Estimated GFR Versus Time Graph of a Representative Patient with 
Linear Progression with No AKI Events 
      
 
 
Abbreviations: GFR, glomerular filtration rate; eGFR, estimated glomerular filtration rate; CKD, chronic 





) results are plotted against time from first recorded 
eGFR in a subject. Estimated GFR was calculated using the MDRD study equation 
based on serum creatinine levels. An AKI episode was defined as a rise in serum 
creatinine > 26µmol or > 1.5 x above baseline creatinine. Baseline creatinine was 
calculated as the median creatinine over the prior 365 days. Any creatinine values 
measured during AKI events were excluded from baseline calculations. Progressive 
CKD was defined as a decline in eGFR of > 10 ml/min/1.73m
2
 over 5 years or > 2 
ml/min/1.73m
2
 per year. 
This scatter plot is a graphic example of a patient with progressive CKD with a linear 























Figure 6.5 Estimated GFR Versus Time Graph of a Representative Patients with 
Stepwise Progression Associated with Multiple Episodes of AKI 
 
 




Abbreviations: GFR, glomerular filtration rate; eGFR, estimated glomerular filtration rate; CKD, chronic 





) results are plotted against time from first recorded eGFR in 
a subject. Estimated GFR was calculated using the MDRD study equation based on serum 
creatinine levels. An AKI episode was defined as a rise in serum creatinine > 26µmol or > 1.5 
x above baseline creatinine. Baseline creatinine was calculated as the median creatinine 
over the prior 365 days. Any creatinine values measured during AKI events were excluded 
from baseline calculations. Progressive CKD was defined as a decline in eGFR of > 10 
ml/min/1.73m
2
 over 5 years or > 2 ml/min/1.73m
2
 per year. 
This scatter plot is a graphic example of a patient with progressive CKD with multiple AKI 
events with partial recovery to a new baseline for a period of stability followed by a further 

























The number of AKI episodes in the Stable, Linear and Stepwise subgroups is shown in 
Table 6.2. Patients were further subdivided in those with no AKI events, 1 AKI event 
and multiple AKI events  ?A? ?</ĞǀĞŶƚƐ ? ?ZĞĐŽƌĚĞĚƐĞƌƵŵĐƌĞĂƚŝŶŝŶĞĚĂƚĂǀĂƌŝĞĚ
significantly in length of time from first test to date of referral and mean years of 
follow up for each group is also listed in Table 6.3 with a mean follow up period of 
5.94 years for each subject. 
 
There were 389 recorded episodes of AKI in total with 162 episodes occurring in the 
stable subjects and 146 episodes in the progressive CKD subjects. A total 55.9% of 
the study group did not have an episode of AKI, 30.2% had 1 episode of AKI and 
14.3% had 2 or more episodes of AKI. Of the 309 patients with stable CKD, 63.1% did 
not have a recorded episode of AKI whereas 43.1% of the 174 progressive subjects 
did not have an AKI episode. In the progressive CKD group, 35.1% had 1 AKI episode 
compared to 27.2% of the stable group. The presence of multiple AKI episodes were 
statistically associated with progression occurring in 20.7% of the progressive CKD 
group and only 10.7% of the stable group using the Chi-squared test. In the subgroup 
analysis of the progressive CKD group, there were fewer linear patients with an AKI 
episode with only 24.2% with 1 AKI event and 5.2% had multiple AKI events. In 
contrast, 40.9% of the stepwise group had 1 AKI episode and 28.7% had multiple AKI 
events. These results suggest that multiple AKI events are associated with CKD 
progression. 
 
The characteristics of patients grouped into less than two or two or more AKI 
episodes are shown in Table 6.4. There was no significant association of male gender 
with multiple AKI episodes and mean age was similar of the two groups. There was 
however, a significant difference in mean eGFR at referral with a mean of 36.9 
ml/min/1.73m
2
 in those with less than two AKI episodes and 31.8 ml/min/1.73m
2
 in 
those with two or more. This study suggests that lower eGFR at referral is associated 
with multiple AKI events.  
138 
 
Table 6.2 Table of the Number of AKI Events in Those with Stable CKD, Linear or 
Stepwise Progressive CKD 
 
 






Progressors, %   
   Total  
(n=174) 
Linear    
(n=58) 




































































Abbreviations: n, number; AKI, acute kidney injury; yr, year; FU, follow up; pt, patient.        
* Indicates reached statistical significance (p < 0.05) 
 
Table 6.2 
This table shows the number of AKI episodes in patients with stable and progressive CKD. 
Progressive CKD was defined as a decline in eGFR of > 10 ml/min/1.73m
2
 over 5 years or > 2 
ml/min/1.73m
2
 per year and this group were further subdivided into linear and stepwise 
sub-groups according to their pattern of eGFR decline. The remaining patients had stable 
CKD. An AKI episode was defined as a rise in serum creatinine > 26µmol or > 1.5 x above 
baseline creatinine. Baseline creatinine was calculated as the median creatinine over the 
prior 365 days. Any creatinine values measured during AKI events were excluded from 
baseline calculations. DƵůƚŝƉůĞ</ĞƉŝƐŽĚĞƐǁĞƌĞĚĞĨŝŶĞĚĂƐA? ?</ĞǀĞŶƚƐ ?Mean follow up 
periods for each category are shown. Multiple AKI events were compared between stable 
and progressive groups and between linear and stepwise subgroups using the Pearson Chi-
squared test and p values < 0.05 were considered to be statistically significant. No AKI events 
were associated with stable CKD however in the subgroup analysis there was an association 
with no AKI events and the linear progressors. Multiple AKI events were significantly more 





When comparing co-morbidity between those with less than two or two or more AKI 
events, hypertension was statistically more prevalent in those with less than two AKI 
events compared to those with two or more AKI events (80.2% vs 69.5%). Diabetes 
was more prevalent in those with multiple AKI episodes versus less than 2 AKI events 
(55.1% vs 36.2%) as was cardiovascular disease (63.8% vs 40.8%). This study found 
no association between malignancy and albuminuria categories with multiple AKI 
events. 
 
In the subgroup analysis of the progressive group, only 5.2% of linear progressors 
had multiple AKI episodes compared to 28.7% stepwise progressors which reached 
statistical signficance. Of the linear progressors, 70.7% had no AKI episodes 
compared to 29.6% of stepwise progressors. This study suggests that low eGFR at 
the time of referral, presence of diabetes and presence of cardiovascular disease are 
associated with multiple AKI events. 
 
All variables found to be significantly associated with CKD progression were then 
included in a logistic regression analysis to determine any potential non-linearity in 
the risk relationships to CKD progression. Presence of cardiovascular disease, 
diabetes, malignancy, multiple AKI events, albuminuria and eGFR at referral were 
included as variables in the nominal regression. The likelihood ratio showed that low 
eGFR at the time of referral, presence of diabetes and A3 albuminuria were 
independently associated with CKD progression whereas malignancy, cardiovascular 
co-morbidity and multiple AKI episodes were not independent variables. 
  
In summary, this study has demonstrated that in a selected population of people 
referred to nephrology services with CKD, a significant proportion progress. Of those 
who progress, the majority follow a stepwise pattern of decline compared to a linear 
decline. Low eGFR at presentation, diabetes, and severe albuminuria were 
independently associated with CKD progression. This study also found that multiple 
AKI events were also associated with CKD progression in particular the stepwise 




Table 6.3 Demographics of Patients With or Without Multiple AKI Episodes 
 
Demographics <2 AKI Episodes 
(n= 414  ) 
A? ?</ƉŝƐŽĚĞƐ 
(n= 69 ) 
Gender 
    Male, % 







Mean age at referral, years 
(SD) 
73.2 (10.8) 75.5 (11.1) 




36.9 (12.1) 31.8 (11.8)* 
Co-morbidity, n (%) 
    Hypertension 
    Diabetes 
    Cardiovascular 











Albuminuria category, % 
     
    A1 
    A2 
    A3 













Abbreviations: ACR, albumin to creatinine ratio; eGFR, estimated glomerular filtration rate; SD, 
standard deviation; n, number; min, minute; AKI, acute kidney injury. 
* indicates reached statistical significance (p < 0.05) 
 
Table 6.3 
This table shows the characteristics in patients with and without multiple AKI episodes. 
Multiple AKI events were ĚĞĨŝŶĞĚĂƐA? ?</ĞǀĞŶƚƐŝŶƚŚĞŽďƐĞƌǀĂƚŝŽŶƉĞƌŝŽĚ ?An AKI episode 
was defined as a rise in serum creatinine > 26µmol or > 1.5 x above baseline creatinine. 
Baseline creatinine was calculated as the median creatinine over the prior 365 days. Any 
creatinine values measured during AKI events were excluded from baseline calculations. Age 
at referral, albuminuria and malignancy were not associated with multiple AKI episodes 
whereas low eGFR at referral, diabetes and cardiovascular disease were associated with 
multiple AKI episodes using the Pearson Chi-squared test where p values of < 0.05 were 










This study examined the characteristics of a cohort of patients with CKD with a high 
proportion with progressive disease to determine which factors influence 
progression. A high proportion (36%) of the study patients were classified as having 
progressive CKD. This is not unexpected in this selected cohort of patients as all 
patients had CKD and had been referred to renal services. The study cohort was also 
relatively old with an average age of 73.2 years and fairly representative of the local 
population of Kent which has a high prevalence of elderly people. Epidemiological 
studies have shown an increased prevalence of reduced eGFR in older people (1, 2) 
partially due to co-morbidity and partly due to age-related glomerulosclerosis (23). 
The eGFR at referral of the cohort was low at 36.1 ml/min/1.73m
2
, which may 
explain the high proportion of subjects with progressive CKD in this study. Low eGFR 
at referral was found to be independently associated with progression. 
Epidemiological studies have shown an increased risk of progression in patients with 
more advanced CKD stages. In a prospective cohort study following 190 patients with 
CKD, 12 % reached ESRD and 6.5% died (187). Each 30% lower baseline eGFR was 
associated with a 3-fold higher ESRD rate and a 1.3-fold higher death rate.  
 
There was a high prevalence of hypertension, cardiovascular disease, diabetes and 
significant albuminuria in the study cohort which is not surprising given the fact that 
many of these co-morbidities are associated with CKD. This study supports the 
evidence that there is a strong association with CKD progression and presence of 
albuminuria. An analysis of trials in patients with and without hypertension or 
diabetic nephropathy showed that initial changes in albuminuria showed a roughly 
inverse relationship to the degree of long-term renal function decline (141). Every 
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50% reduction in albuminuria during the first six months of treatment angiotensin 
blocking agents was associated with a 45% reduction in risk for ESRD. The GISEN 
(Gruppo Italiano si Studi Epidemiologica in Nefrologia) group demonstrated that 
early proteinuria predicted the long-term rate of renal decline (137).  
 
Disappointingly, a high proportion (17%) of this study cohort lacked albuminuria data 
adding to the limitations of the analysis and highlights a need for more definitive 
assessment in primary care. The QOF renal indicators incentivising screening for 
albuminuria were introduced in 2006 which only came in shortly before the study 
period yet albuminuria recording remained at only 78-81% in patients registered 
with CKD stages 3-5 in 2008-2010 (190).  
 
Proteinuria is not only a risk factor for CKD progression but has also been shown to 
be an independent risk factor of the development of AKI but this study did not 
observe a statistical association with albuminuria and multiple AKI events.  
The Alberta Kidney Disease Network Study found that lower baseline eGFR and 
heavier proteinuria resulted in a significantly higher risk for hospitalisation with AKI 
(191). Proteinuria alone was associated with a 4.4 fold increased risk of AKI and 7.7 
fold increased risk of AKI requiring renal replacement therapy. The definition of 
proteinuria used in this study however was the presence of 2+ protein on urine 
dipstick i.e. equivalent to category A2 used in this study.  
 
Hypertension was not independently associated with CKD progression in this study. 
However, 78.7% of the total study cohort had hypertension resulting in a very small 
group without hypertension, limiting the ability to draw any conclusions from this 
result.  Diabetes and malignancy were both associated with progression although 
diabetes was the only independent co-morbid condition associated with CKD 
progression. This supports several studies that have shown diabetes is a well-
established risk factor that progression of CKD and is the leading cause of ESRD 
worldwide (14-15). Cardiovascular disease was highly prevalent in the study cohort 
(44.1%) however there was no association with progression of CKD. In contrast, 
other studies have shown associations between cardiovascular disease and 
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progression. Obemayr et al performed a large longitudinal cohort study with healthy 
volunteers from the general Viennese population (192). Their results showed that 
established cardiovascular risk factors predicted the development of new onset 
kidney disease.  In a pooled analysis of the Atherosclerosis Risk in Communities 
(ARIC) Study and Cardiovascular Health Studies (CHS) of over 13,000 subjects, people 
with baseline cardiovascular risk had a significantly increased risk of a decline in 
renal function compared to people without cardiovascular disease (34).  
 
Although cause of CKD was recorded in this study, the most common cause recorded 
ǁĂƐ ‘hŶŬŶŽǁŶĂĞƚŝŽůŽŐǇ ?ǁŚŝĐŚůŝŵŝƚƐŽƵƌƵƐĞŽĨŝŶĐůƵĚŝŶŐĐĂƵƐĞŽĨ<ŝŶƚŚĞ
analysis.  In clinical practice, CKD patients are often coded with an unknown 
aetiology as cases are often caused by a combination of multiple causes. In many 
cases the disease process is too advanced to obtain a true histological diagnosis or 
the risk of attaining a renal biopsy sample outweighs the potential benefits of a 
biopsy. This is particularly true for stable CKD but also true in some cases of 
progressive CKD. If a patient has CKD progressing in the way one would expect for 
example in a patient with diabetes, we would often not pursue a biopsy therefore 
cannot make the primary diagnosis diabetic glomerulosclerosis. Cause of CKD 
however is important in predicting risk for progression. The MDRD study 
demonstrated that polycystic kidney disease resulted in more rapid progression of 
CKD than other primary renal diseases. More recently the Study of Heart and Renal 
Protection (SHARP) study explored the relevance of cause of CKD to kidney 
progression in 6,245 non-dialysis participants and found cause had substantial 
prognostic implications not only in determining risk of progression but also in 
predicting risk of death prior to ESRD particularly in diabetics (48). 
 
Pre-existing CKD, diabetes and albuminuria as well as age and hypertension are all 
independent predictors of decline in GFR (134, 192-193) yet many CKD patients with 
these risk factors do not progress. There must be other risk factors that influence 
CKD progression and emerging evidence suggests that AKI may have a role to play. 
This study suggests that multiple AKI events that are managed in the community 
often of less severity may be a significant risk factor leading to progression of CKD. 
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AKI and CKD were thought be two different entities but it is evident there is a 
complex interplay between the two condition. Determination of the epidemiology of 
AKI and CKD and their interaction has been difficult due to the variation in 
definitions used and the different populations studied. What we do know is that CKD 
is a recognised independent risk factor for AKI (194) and AKI may lead to the 
development of CKD or progression of pre-existing CKD (195).  
 
What do we know about the relationship of AKI and CKD? AKI and CKD as separate 
entities are associated with high morbidity and mortality and one assumes that AKI 
in CKD has an even more significant effect on outcome but evidence in this area is 
debatable. This raises the question as to whether the outcome of AKI differs with the 
presence of background CKD. Some studies have shown AKI in the context of CKD 
show a lower mortality. /ƚŵĂǇďĞ ‘ĞĂƐŝĞƌ ?ƚŽŐĞƚ</ŝĨĂƉĂƚŝĞŶƚŚĂƐ<ƚŚĞƌĞĨŽƌĞ
people with AKI and no CKD may actually be more unwell thus conferring a greater 
mortality risk. Among critically ill patients with AKI, those with prior CKD experience 
a lower mortality rate but are more likely to be dialysis dependent at hospital 
discharge (196).  
 
Existing CKD is one the strongest predictors of developing AKI following contrast 
exposure, surgical procedures and after certain medical illnesses (96, 197-199). 
These studies have suggested that underlying CKD maybe the single most important 
risk factor for AKI. However the question remains as to whether it is possible to 
accurately correct for all confounding variables in these patients, and how much of 
this risk is an increased susceptibility of a kidney with pre-existing disease to develop 
an acute kidney injury. Part of the increased risk is the fact that this population of 
patients with CKD is heavily burdened with co-morbidity. This population is more 
likely to be subject to nephrotoxic insults such as exposure to contrast agents and 
certain nephrotoxic treatments for co-existing co-morbid conditions. This population 
is also more likely to be taking medications such as ACEIs or ARBs (200), which gives 
the patient increased susceptibility for developing AKI. These patients then 
experience an additional insult, such as ascending urinary tract infection or other 
inter-current illness, sustaining an overt AKI requiring admission, an event included 
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in the epidemiological analyses of AKI. A patient without pre-existing CKD, who is 
less likely to have these susceptibility factors, may well have an episode of AKI linked 
to their clinical episode, but of reduced severity, not requiring admission and 
possibly go unrecognised and may therefore not be captured.  
 
The difficulty in defining CKD as a risk factor for AKI is also confounded in studies by 
the actual definition of CKD and AKI used. These definitions also have substantially 
different effects at different levels of renal function. This study observed that lower 
eGFR at referral was associated with multiple AKI episodes. There have been few 
studies examining the relationship between the risk of AKI and severity of CKD and 
this is partly due to some AKI trials excluding patients with mild or moderately 
elevated baseline creatinine. A study by Hsu et al published in 2008, examined the 
risk of AKI in patients with chronic kidney disease, and how that risk varied with level 
of eGFR and hence stage of CKD (77). They assessed 1,746 hospitalized adults from 
the Kaiser Permanente integrated management care consortium in Northern 
California who developed dialysis-requiring AKI. Seventy-four per cent of these 
patients had CKD stage 3A or above at baseline. The 1,746 patients were then 
compared with 600,820 hospitalised members who did not develop AKI. The 
adjusted odds ratio for the development of dialysis-requiring AKI was 1.95 for stage 
3A, 3.54 for stage 3B, 28.50 for stage 4 and 40.07 for stage 5 patients not yet on 
maintenance dialysis compared to patients with stage 1 and 2. Similar associations 
were seen after controlling for inpatient risk factors, again highlighting the 
importance of CKD severity as a risk factor for the development of AKI. 
 
We are also unclear on how a large majority of patients develop CKD in the first 
place. An outcome of paramount interest is recovery of renal function and there is 
no agreed accurate and standardised definition of renal recovery. Patients with 
complete renal recovery following an AKI episode still have a higher incidence of CKD 
in the years following recovery (201). Patients without background CKD who develop 
AKI may already have an element of renal disease and reduced functional reserve, 
but have not yet manifested as a fall in GFR to define CKD. These patients are then 
more likely to develop CKD in the future following an episode of AKI and it may 
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speed up the process to development of overt CKD. This work has earlier 
demonstrated reduced accuracy of the MDRD equation at GFR > 60ml/min/1.73m
2
 
in the elderly with a tendency to overestimate GFR. As the MDRD study eGFR is less 
accurate at higher levels, should we be assessing rate of change in this group more 
closely or more accurately? The 2014 NICE CKD guidelines acknowledged this 
limitation and recommended that more accurate methods to estimate GFR such as 
Cystatin C or the CKD-EPI equation are used in patients with CKD stage 3a (57). This 
study suggests that a proportion of patients who have established CKD of uncertain 
aetiology may be attributed to a prior occurring AKI event.  
 
If AKI is a cause of CKD, it seems logical that AKI may occur before the onset of CKD. 
There are however difficulties in testing this hypothesis. A few studies have 
suggested that development of CKD occurs following an episode of AKI and in some 
cases can progress to requiring chronic dialysis treatment. Ishani et al reported that 
of the patients who had suffered an episode of AKI and did not have a background of 
CKD, 72.1% had CKD documented within 2 years of the occurrence of AKI (87). 
Triverio et al demonstrated that following AKI 50% of patients without background 
CKD progressed to CKD within 3 years (202). Previous follow-up studies in children 
have suggested that a significant proportion of patients successfully discharged from 
hospital following an episode of AKI went on to show features of CKD (203). More 
recently, Bucaloiu et al performed a longitudinal study of patients with no evidence 
of overt CKD and studied the effect of AKI on residual renal function (204). They 
found that despite fairly rapid recovery of renal function following an AKI episode, 
even a minor rise in creatinine was associated with a 90% increased risk of 
developing CKD. In addition to this, they found that those who subsequently 
developed CKD after a resolved AKI had a significant increased mortality rate. There 
is no doubt that the mortality from AKI is high, and of those that survive, there may 
be decline in renal function, in some cases leading to the development of ESRD, 
either at the time of AKI, or in the future. Mortality may well be a confounding factor 
in terms of progression. For example, a severe insult resulting in AKI may result in 




Studies suggest that approximately 40% of patients commencing dialysis for the first 
time start due to AKI (60, 205). These patients may however recover function with 
time so they are not reflective of the proportion of patients on chronic dialysis. From 
the annual report of the United States Renal Disease Survey 2006, approximately 6% 
of patients with an episode of AKI progressed to ESRD within 2 years, and two thirds 
of hospitalised patients who had an episode of AKI and progressed to ESRD, had a 
background of CKD (206). Thakkar et al looked at the effect of AKI on CKD in 
hospitalised patients with diabetes and found 23% reached CKD stage 4 at the time 
of discharge (207). 
 
Two studies, both prospective and observational, which were published in 2002, by 
Metcalfe et al and Robertson et al (60, 205), looked at patients starting dialysis for 
the first time, and split them into the following groups: CKD in which the patients 
started RRT in a planned manner for ESRD, AKI, and ACKD. The percentage of 
patients in each group was approximately, 40% due to CKD, 40% due to AKI and 20% 
due to ACKD. Importantly, though these patients started renal replacement therapy 
for the first time, this does not correspond to requiring on-going chronic dialysis. 
From the study by Metcalfe et al, 23.5% of the AKI group, and 16.5% of the ACKD 
group had recovered at 90 days (60). 
 
Wald et al looked at the outcomes of chronic dialysis and death in patients with 
acute kidney injury requiring dialysis (208). This was a ten year cohort study of adult 
patients in Canada who survived a hospital associated AKI requiring in-patient 
dialysis who were free of dialysis for at least 30 days after discharge. These patients 
with AKI were three times more likely to require chronic dialysis compared to those 
without AKI. They found that individuals with pre-existing CKD, who had an episode 
of AKI requiring dialysis, had a two-fold higher risk of requiring chronic dialysis 
compared to patients with CKD without an episode of AKI requiring dialysis. They 
also interestingly reported that in patients without pre-existing CKD, an episode of 
AKI requiring dialysis conferred a fifteen fold higher risk of chronic dialysis than 
patients with CKD without an episode of AKI. This comes as a surprise as one would 
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expect patients with pre-existing CKD to have an increased risk of developing ESRD 
following an episode of AKI, compared to patients without pre-existing CKD.  
In fact observational and database studies demonstrate that AKI on a background of 
CKD leads to ESRD at a higher frequency than does AKI alone. A study by Ishani et al 
looked at a random cohort of 233,803 patients hospitalised in the year 2000 based 
on Medicare claims, ĂŐĞĚA? ? ?ǇĞĂrs on discharge and with no previous ESRD or AKI 
(87). They reported that patients with concomitant AKI and CKD were far more likely 
to develop ESRD, indicating a strong causative effect of the interaction on ESRD 
development. In a population-based study by Ali et al, when comparing patients with 
ACKD to those with AKI alone, patients with ACKD were older and had less chance of 
renal recovery (62). These studies however again, all varied in definitions of both 
CKD and AKI.  
 
This study demonstrated an association of multiple AKI episodes with CKD 
progression and this has also been observed in other studies. Both frequency and 
duration of AKI have been found to be associated with CKD progression. In the study 
by Thakkar et al, which looked at the effect of AKI in a cohort of US veterans with 
diabetes, there was a 30% increased risk of recurrence of AKI after the first episode 
and they suggested that each episode of hospital-acquired AKI doubled the risk of 
their CKD progression (207). Studies have also demonstrated that severity of AKI is 
linked to CKD progression (209) and longer duration of AKI is associated increased 
mortality (210) but there has been no association with duration of AKI and CKD 
progression. Most studies on AKI outcomes have focused on mortality and 
subsequent development of ESRD following severe and hospital-based AKI, however 
little is known of these more minor episodes of AKI that occur in the community and 
the effect they have on progression of CKD.  
 
AKI frequently develops in the community and studies have shown that up to 60% of 
hospitalised-AKI is community-acquired (62), however, a substantial proportion of 
AKI events do not result in hospitalisation and are managed in the community. It is 
possible that some of these community-based AKI events may not have been 




group may have a significant effect on outcomes.  
 
Although this study demonstrated a clear relationship between multiple AKI events 
and CKD progression, this association was not independent of other variables. By 
experiencing an episode of AKI these patients are more likely to have risk factors for 
AKI and a large number of these risk factors are common for CKD. AKI also occurs 
more frequently in an older population group which has a greater burden of co-
morbidity, and in which there is a greater risk of progression of CKD anyway. AKI 
events however were also observed in patients with stable CKD, so what makes the 
progressive group more susceptible to non-recovery of function?  Not all AKI is the 
same and this study did not look at aetiology of AKI which may well be the key. 
Further studies need to determine what factors influence the outcomes of 
progression or full recovery.  
 
What this study does show is that CKD progression does not always follow a linear 
pattern. The slope in decline of GFR is a measure of progression rate and renal 
specialists often use this linear model of progression to predict when a patient will 
develop ESRD in order to initiate timely preparation for dialysis or transplantation. 
One advantage of this study was that the multitude of outpatient pathology results 
over several years follow up not only enabled a more accurate estimation of baseline 
kidney function but also enabled better interpretation of progression patterns. Most 
other studies in CKD progression have relied on follow-up data of less than five years 
and it is not always easy to interpret progression patterns in a short observation 
period with few GFR measurements.  
 
This study demonstrated that progression patterns can be either linear or stepwise 
in trajectory. While the familiar linear progressive pattern occurred in 34% of people 
whose GFR declined, stepwise progression was a far more commonly observed 
pattern in the progressive group in this study (66%). The stepwise subgroup were 
characterised by a decline in kidney function that deviated from a linear progression 
trajectory representing periods of deceleration or acceleration of disease 
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progression.  Periods of non-progression varied in length among individuals and in 
some subjects GFR increased with time. This study suggests that the determinants 
for progression of disease may vary over time within the same individual influencing 
their trajectory of decline in function. If we can identify these risk factors and 
intervene with the modifiable determinants, we may be able to slow CKD 
progression. The only significant variable differentiating the linear and stepwise 
subgroups were multiple AKI episodes suggesting an association of multiple AKI 
events and stepwise progressors. 
 
The potential effects of AKI events on CKD pattern progression is illustrated in 
Figures 7.1 which suggests the possible different outcomes following AKI. Complete 
recovery following an AKI would represent and initial insult leading to cellular injury 
and repair. A patient with non-progressive CKD may suffer an AKI leading to an acute 
drop from the prediction linear line. This may be followed by a new baseline GFR due 
to loss of functioning nephron mass subsequent to the AKI and the patient may have 
an altered pattern of decline in the future. In contrast, another individual may 
experience periods of rapid decline in GFR followed by prolonged periods of stability 
of varying length and that GFR trajectory pattern would represent stepwise 
progression. It is easy to see the potential to misinterpret CKD patterns if the GFR 
observations are limited to certain time periods during the deceleration phase or 
stable phase. Could it be that if rate of change was assessed over longer periods of 
observation, patterns of GFR decline would show a stepwise trajectory of decline 
ǁŚĞƌĞďǇĂŶĂĐĐĞůĞƌĂŶƚƉŚĂƐĞŝƐƉƌĞĐŝƉŝƚĂƚĞĚďǇĂ ‘ƉƌŽŵŽƚĞƌ ?ŽĨƉƌŽŐƌĞƐƐŝŽŶƐƵĐŚĂƐ
an AKI event? Many studies have investigated risk factors for progression to ESRD 
but little is known about predictors of change in renal function in the community 
(211).  
 
Many studies have not assessed risk factors for decline in renal function in 
populations without signs of kidney disease. The Tromso study was a prospective 
population study following individuals with no signs of kidney disease at baseline for 
7 years with a primary outcome of decline in GFR and predictors of change in GFR 
were assessed (193). They demonstrated both high systolic BP and high fibrinogen 
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levels contributed to a more rapid decline in GFR for men and women. Obermayr et 
al looked at 17,375 healthy volunteers over 7 years with an age range 20-89 years 
(192). The primary outcome was development of CKD and they showed that 
cardiovascular risk factors, pre-existing NKF-CKD stages 1 and 2, proteinuria and 
surprisingly, doing no sports, predicted new-onset kidney disease.  
 
ƌĞƚŚĞƐĞ ‘ƉƌŽŵŽƚĞƌƐ ?ŽĨƉƌŽŐƌĞƐƐŝŽŶŵŽĚŝĨŝĂďůĞĂŶĚĐĂŶǁĞŝĚĞŶƚŝĨǇĂŶĚ prevent 
those at risk from developing or acquiring this risk factor? Can we identify those at 
risk of AKI and intervene to reduce incidence of community-AKI? We need to 
investigate these AKI events that occur in the community in more depth and 
understand what factors influence renal recovery following an AKI and what 
characteristics differentiate them from those whose renal function declines 
following an AKI. Although the study has failed to disprove the null hypothesis of an 
independent association of multiple AKI events and CKD progression, it may be that 
the study was not adequately powered to demonstrate significance. The study does 
suggest that multiple community-</ŝƐĂŶŝŵƉŽƌƚĂŶƚ ‘ƉƌŽŵŽƚŽƌ ?ŝŶƚŚĞƉƌŽŐƌĞƐƐŝŽŶ
of CKD. It also suggests that GFR decline may not always follow a non-progressive or 






















Abbreviations: GFR, glomerular filtration rate; AKI, acute kidney injury; CKD, chronic kidney disease; 
ACKD, acute-on-chronic kidney disease; AKD, acute kidney disease or disorders. 
 
Figure 7.1. 
This model demonstrates the possible outcomes in GFR following an AKI event and 
illustrates the relationship between AKI, AKD, ACKD and CKD. Following an initial 
insult (AKI) renal function may either fully recover, partially recover and develop de 
novo CKD, progress in a linear inexorable decline towards ESRD or progress in a 
stepwise pattern with periods of stability followed by accelerated decline 
precipitated by a further insult. The phases of cellular injury in CKD are represented 
to temporally relate to disease patterns of progression.  







The results of this study need to be interpreted with caution as there are notable 
limitations. Firstly, demographic, clinical and pathology data collection was 
dependent on the quality of information provided on referral letters, hospital 
records and clinical information provided at the time of blood tests which may have 
led to missing data. The study subjects were selected from patients referred to 
nephrology services therefore not entirely representative of the general population 
with less co-morbid burden. Patients were recruited from a single county in the U.K. 
and the population demographics of East Kent is not entirely representative of the 
U.K. with more older patients with fewer ethnic minorities than the national 
average. A significant proportion of patients originally referred (24%) had to be 
excluded from the final cohort due to shorter follow-up time or lack of pathology 
data so interpretation of these results may not be truly representative of all those 
referred. All creatinine measurements however were measured at a single centre 
reducing the potential for GFR estimation error. 
 
One of the major limitations of this study is the definition used to determine an AKI 
event. Definitions of AKI, as I have described earlier, have rarely been consistent 
across studies. The definition of AKI has changed in recent years in line with the 
RIFLE criteria, then the AKIN criteria and more recently the KDIGO definition. This 
study was carried out prior to the publication of the 2012 KDIGO AKI clinical 
guidelines (70). Although the study design defined an AKI event as a rise in serum 
creatinine of 26 µmol above the baseline creatinine, the criteria does not truly meet 
the AKIN criteria as it was not possible to fulfil the time constraints for either the 
AKIN or RIFLE definitions of AKI. Also, the baseline creatinine was not derived from 
the median value of multiple creatinine measurements over a 365 day period as 
suggested by the KDIGO guidelines (and subsequently adopted by NHS England), but 
by the lowest serum creatinine in the 365 days prior to the event. Only results that 
deviated from the linear regression line applied to each graph were assessed as to 
the whether they were defined as an AKI event. Using the study definition of AKI, a 
rapidly declining linear progressor may have several creatinines over-called as AKI 
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episodes. Many AKI events in the study may well have been an overestimation and 
may well have not taken the biological and analytical variation of serum creatinine 
into account. It is unlikely that the approach to the definition of AKI would have 
dramatically altered the results of the study. Redesigning the study to use the 
methodology described by La France and Miller, which extends the time reference 
creatinine to 12 months (212) prior to the event as suggested by the NHS England 
AKI algorithm (71), would overcome this limitation. Only serum creatinine samples 
ǁĞƌĞĂŶĂůǇƐĞĚŝŶƚŚĞĂƐƐĞƐƐŵĞŶƚŽĨĂŶ</ĞƉŝƐŽĚĞĂŶĚƚŚŝƐƐƚƵĚǇ ?ƐŵĞƚŚŽĚŽůŽŐǇĚŝĚ
not assess AKI using urine output criteria to define AKI. Assessing AKI using urine 
output criteria is difficult in clinical practice and often involves invasive procedures 
to accurately monitor output which would be impractical in the assessment of 
community-based AKI. 
 
The study aimed to determine the effects of these minor community-managed AKI 
events however hospital admission records were not cross-referenced with the AKI 
events. Although the majority of the pathology tests at the time of the AKI events 
were requested from community healthcare, one cannot exclude that many of these 
AKI events did not lead to hospitalisation. We have limited data on how community-
managed AKI and hospital-managed AKI differ in terms of aetiology and outcomes. It 
is clear AKI is more prevalent in certain at risk populations but AKI is still a random 
event and whilst people may be at a higher risk of developing AKI, we still cannot 
always predict when they are going to have an episode of sepsis or require surgery 
or a contrast-scan which may then precipitate an AKI. The difficulty comes in 
capturing all these AKI events when they do occur in the community particularly as 
when they occur at random. It is far easy to identify AKI in hospitalised patients and 
in at risk populations when you are screening for it. It is possible that many of these 
random events also occur in the community and are not picked and these AKI events 
go undetected. This has important implications for physicians when counselling 
patients about their projected renal outcome. AKI events can also occurring in a non-
random fashion and are more likely to be picked up. For example, a patient is more 
likely to have renal function monitoring following initiation of a nephrotoxic agent. 
155 
 
One is more likely to detect an AKI event when susceptible individuals are screened. 
This highlights the difficulties in studying these events.  
 
Severity of AKI is known to increase risk for progression to ESRD (209) and a patient 
is more likely to be admitted to hospital with AKIN 2 or 3. Many AKI events are often 
acquired and managed in the community and are more likely to be AKIN 1. This study 
aimed to determine the renal outcomes of community-managed AKI however it did 
not assess severity of AKI according to the AKIN stages and, as mentioned earlier, 
one cannot assume all these AKI events were managed in the community. Severity 
was excluded from the study as the numbers of AKIN 2 or AKIN 3 events were 
considered to be too small to allow meaningful analysis. 
 
What is of significance is the lack of information regarding the aetiology, prescription 
data and management of these AKI events. AKI is multi-factorial and cause of AKI has 
a significant effect on outcome of AKI. Cause of AKI was not assessed as, although 
clinical information provided at the time of the blood request was extracted, 
information was not consistently provided or had little relevance to the AKI event so 
this was not included this in the analysis. Although prescription data was available on 
several patients at referral, prescription patterns at the time of the AKI event were 
not available hence analysis of the aetiology of AKI was not possible.  It would be 
interesting to determine whether recovery from certain AKI events is determined by 
aetiology of AKI. One would assume that drug-related AKI events would expect a 
better prognosis compared to, for example, a sepsis related AKI.  
 
Sepsis is a common problem with mortality rates as high as 36% even in those who 
reach intensive care (213).  A recent large NHS survey documented mortality rates of 
30-40% consistent across hospitals in the U.K. amongst severe AKI (AKIN 3) (214). 
Development of AKI during sepsis increases patient morbidity with significant effect 
on multiple organ functions, increases length of stay and predicts a higher mortality. 
Septic-AKI is the most common precipitating cause of AKI accounting for at least 50% 
of AKI in ICU patients. The combination of AKI and sepsis is associated with a 
mortality rate of up to 70% (215). The pathophysiology of septic-AKI is complex and 
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can be due to a combination of endothelial dysfunction, inflammatory cell activation 
and infiltration in the renal parenchyma (215), renal blood flow changes and tubular 
injury and necrosis.  
 
The Surviving Sepsis campaign was launched in 2004 and after several updates and 
simplification of recommendations combined with sepsis care bundles, there has 
been reduction in hospital mortality from 44.1% to 20.0% (217) demonstrated since 
its implementation. In 2010, NCEPOD (97) reported that only 50% of care of patients 
ǁŚŽĚŝĞĚĨƌŽŵ</ǁĂƐ ‘ŐŽŽĚ ?ĂŶĚƐƵďƐĞƋƵĞŶƚůǇ</'K ? ? ? ?and then NICE (72) 
published AKI guidelines, as clearly a strategy is required to improve the prevention 
and management of AKI. These guidelines and algorithms have the potential to 
reduce the morbidity and mortality associated with AKI as the Surviving Sepsis 
campaign has had for sepsis.  
 
The methodology of describing CKD progression pattern used the Delphi technique 
with a panel of experts assessing eGFR versus time trajectory graphs and came to 
high levels of agreement. Any graphs with disagreement were further discussed to 
form a unanimous decision of linear or stepwise decline. This method could be 
subject to bias particularly if the group were influenced by a strong individual 
opinion when assessing stepwise or linear patterns.  Interpreting progression 
patterns is more accurate with multiple eGFR measurements over a longer 
observation period and some individuals lacking in pathology data may not have 
been grouped appropriately. Differentiation between the linear and stepwise 
progressive subgroups using this methodology could also be open to criticism as 
interpretation of the different patterns was subjective and descriptive modelling was 
not applied to each pattern.  
 
Overcoming these limitations would be difficult particularly in a retrospective 
setting. Capturing these AKI events as they occur randomly in the community would 
be challenging and information regarding the events would be lacking. In order to 
better assess CKD progression patterns and the effect of promoters of progression 
such as AKI events have on eGFR decline, a long-term prospective follow-up study of 
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a large cohort with and without CKD is needed. In an ideal world, selecting a study 
cohort from patients undergoing regular blood test monitoring, such as those on 
immunosuppression requiring monthly bloods tests, would hopefully capture many 
more of these random events. Conversely, such a select cohort of patients would 
only represent a specific population.  
 
I would use the NHS England AKI algorithm defining AKI a serum creatinine A? 1.5 
times higher than the median of all creatinine measurements 8-365 days prior to the 
test to ensure a more accurate estimate of AKI incidence. Hospital admission data 
would need to be cross-referenced against these AKI events to identify community-
managed and hospital-managed. Each AKI episode would require extraction of 
clinical information at the time of the event in order to identify aetiology, duration, 
severity, prescription data and interventions.  This would allow comparison of 
outcomes between hospital-managed and community-managed AKI on CKD 




In conclusion, this study has suggested that the prevalence of progressive CKD may 
be higher than originally thought and the trajectory of GFR decline more commonly 
follows a non-linear stepwise pattern. Factors associated with progression were 
diabetes, malignancy, albuminuria and, although not an independent risk factor, 
multiple AKI episodes were significantly higher in those with progressive CKD 
particularly in the stepwise group. This suggests the incidence of community-AKI is 
more common than estimated and has a significant impact on progression of CKD.  
This observation has a significant implication both clinically and in research on CKD. 
Further analysis of these patterns could be used for predictive modelling to assess 
risk for CKD progression.  We also need to determine why some individuals recover 
from an AKI event whereas others do not. Most risk scores predicting risk of AKI in 
order to help improve outcomes have been developed where the timing of the AKI 
insult can be predicted, such as in the setting of cardiac surgery (218) or coronary 
angiography (219). Further knowledge of these community-managed AKI events and 
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how they differ from hospital-managed AKI in terms of outcome is necessary. 
Multiple AKI events, together with other known promoters of progression, could 









The NEOERICA project demonstrated that the UK prevalence of people with an eGFR 
< 60 ml/min/1.73m
2
 was 8.5% and observed an exponential increase with age with a 
prevalence of 25% in people aged > 70 years (2). Early identification of these patients 
with CKD 3-5 may allow implementation of multiple risk factor intervention 
strategies aimed at reducing morbidity, mortality and disease progression. KDOQI 
and NICE CKD guidelines highlight the importance of early identification of these 
patients with diagnosis and management recommendations to improve outcomes 
and improve appropriate referral to specialists (10, 67). The internationally adopted 
KDIGO CKD stages are defined by eGFR based on serum creatinine levels using the 
MDRD study equation. Not only do we base diagnosis and staging of CKD on eGFR 
but also drug dosing and important management decisions. The MDRD study 
equation was developed in a relatively young population with CKD and hence is 
inaccurate at higher GFR levels and in older populations. The CKD-EPI equation has 
been suggested to replace the MDRD study equation as it performs better 
particularly at higher GFRs which would have implications in population prevalence 
data. Neither equation has been validated in the elderly population.  
 
Although CKD prevalence is so high, only 1-2% of these patients with CKD 3-5 
progress to ESRD (15). Why is there such a disparity in numbers? Many patients with 
CKD 3-5 have increased risk of death particular from cardiovascular events but 
reported mortality rates do not account for the low rate of progression. The first of 
ƚŚŝƐƐƚƵĚǇ ?Ɛhypothesis was that the high population prevalence estimates of CKD 3-5 
are due to the inaccuracies of the MDRD study equation used to estimate GFR in 
older people. The hypothesis states that both equations underestimate GFR in older 
people and the MDRD study equation particularly underestimates GFR at higher 
levels where individuals are more likely to be misclassified as having CKD 3a when 
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ƚŚĞǇŚĂǀĞĂŵĞĂƐƵƌĞĚ'&ZA? ? ?ŵů ?ŵŝŶ ? ? ? ? ?ŵ2. This would have a significant effect 
on CKD prevalence data. 
 
This study assessed the performance of the two estimating equations compared to 
the measured GFR using iohexol GFR as the reference method in an elderly 
population. This study is the first study to endorse the validity of the current 
estimating GFR equations in an elderly population who have a high burden of CKD. 
Whilst falling short of the >90% P30 aspiration of the 2002 KDOQI guideline (10), the 
MDRD and CKD-EPI GFR estimating equations appear to work just as well in older 
compared to younger populations. There was no evidence that the MDRD equation 
underestimated GFR, irrespective of the level of GFR and this may reflect similar 
characteristics between this study cohort and the cohort the MDRD study equation 
was developed in. The CKD-EPI equation performed marginally better than the 
MDRD equation, particularly at '&ZA? 60 ml/min/1.73 m2 consistent with its 
performance in younger populations. This study has validated the accuracy and 
applicability of both the MDRD and CKD-EPI equations in estimating GFR in elderly 
caucasians and supports the KDIGO and NICE CKD guidelines recommending their 
use to assess renal function. These results will improve patient and physician 
confidence in the use of eGFR to accurately reflect renal function in older patients 
and its ensuing impact on CKD management and safer prescribing practice. 
 
This study has proved that the prevalence estimates of CKD are fairly accurate so this 
still leaves us with a question of what factors influence CKD progression. Although 
CKD is highly prevalent, it does not inexorably progress. Progression to ESRD in those 
with earlier stages of CKD is low whereas progression in those with stage 4 is much 
higher. There has been much debate around the definition of progression and rate of 
change of GFR is currently used. Albuminuria has emerged as an important predictor 
of progression along with cause of disease and the presence of diabetes, 
cardiovascular disease and poorly controlled hypertension (34-36, 192-193). The 
KGIDO guidelines have included the category of albuminuria in the CKD staging and 
have included guidelines on how to identify individuals at risk for progression (12). 
Although the presence of risk factors such as albuminuria and hypertension 
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increases the risk of progression to ESRD, many patients with these risk factors do 
not progress. Another question that arises is how patients develop CKD in the first 
place, one potential explanation is AKI. 
 
The incidence of AKI has dramatically increased over the past few decades. Pre-
existing CKD is one of the most important risk factors for developing AKI. AKI is 
becoming increasingly recognised as an important determinant in the development 
and progression of CKD and long-term mortality.  There has been a significant drive 
to improve the recognition and care of AKI patients particularly in hospitalised 
patients in order to improve survival. Several studies have helped our understanding 
of the complex relationship between AKI and CKD and the clinical consequences that 
occur with their co-existence, however, the majority of studies have focused on 
hospital based-AKI. We know that even minor AKI episodes in the hospital setting is 
becoming increasing common incurring a significant risk of progression to ESRD and 
reduced survival even after discharge. Community-acquired AKI is common, often 
less severe and most cases are not referred to nephrologists. Little is known about 
the effect that these community-based AKIs have on mortality and cardiovascular 
outcomes and on risk of progression to CKD. 
 
The second hypothesis was that multiple episodes of community-based AKI have an 
independent association with CKD progression, influencing the pattern of 
progression and the development of  ‘de novo ? CKD. The second study was a 
retrospective observational study of patients with CKD 3-5 referral to renal 
specialists assessing rate of decline of eGFR and what characteristics influence 
progression. The incidence of community-based AKI events were recorded and 
compared between stable and progressive CKD groups. This study suggests that a 
large majority of patients with progressive CKD experience a decline in GFR in a non-
linear pattern with variable periods of non-progression and accelerated progression 
resulting in a stepwise decline. This study found a significant association with 
multiple AKI and CKD progression particularly those following a stepwise decline but 
this association is not independent of other risk factors for CKD progression and AKI.  
It may be that the definitions used and methodology of this study was not 
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appropriate to demonstrate a significant association but it does suggest that AKI 
plays an important part as a promoter of CKD progression.  
 
This study suggests that the consequences of these small rises in serum creatinine 
occurring in primary care may have similar effects on disease progression as 
hospital-based AKI and merit further investigation for better understanding. It will 
be important to fully ascertain why the tests were requested at the time of the 
acute decline, whether these episodes of acute rise in serum creatinine are actually 
recognised with prompt appropriate management, or whether they go unrecognised 
by the healthcare system. Further studies are required to examine if there is a 
potential causal association between these events in primary care and poor 
outcomes other than CKD progression.  
 
There needs to be an increased awareness of the risk factors for AKI both in primary 
and secondary care with particular vigilance in subjects with CKD in order to develop 
strategies to prevent AKI occurrences and reduce risk of CKD progression. 
Interventions and identification of modifiable risk factors may lead to longer periods 
of non-progression in CKD patients and reduce progression risk in the future. This 
work suggests that further research is needed to assess the impact AKI events have 
in the progression of CKD and in particular analyse what time related risk factors 
ĚĞƚĞƌŵŝŶĞĂƉĂƚŝĞŶƚ ?ƐŶŽŶ-linear decline in GFR. This data can be used to develop a 
risk-model which could in turn be developed into a clinical tool used for determining 
an individual risk for patients at risk of both CKD progression and at risk of 
developing AKI. More recently studies have focused on the development of risk 
scores for identifying progressive decline in GFR and progressive increase in 
albuminuria. Some have studies have focussed on clinical risk factors including age, 
gender and blood pressure level and others have combined this with laboratory data 
such as eGFR level, albuminuria, C-reactive protein levels and serum albumin levels 
(220). These proposed predictive models have only been developed and validated in 
specific cohorts and further evaluation of these models is needed in different 
populations. The rationale for predicting risk of progression CKD is that it enables 
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determination of referral, care plans, frequency of monitoring and instituting 
appropriate treatment strategies.   
 
Both AKI and CKD confer a significant morbidity and mortality. With an ageing 
population and increasing co-morbidity burden, AKI and CKD will continue to have a 
significant impact on the healthcare economy across the world. We should aim to 
prevent susceptible patients developing AKI following an exposure that places them 
at increased risk and at the very least aim to prevent patients in whom AKI is 
apparent from developing the complications that may result in increased mortality, 
ESRD and development or progression of CKD. AKI in the community and the 
ĐŽŶĐĞƉƚŽĨ ‘ĚŝƐĐƌĞƚĞ ? AKIs require a prospective evaluation to establish the role of 
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